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Summary
Glioblastoma is the most common primary malignant brain tumour in the adult population. 
Despite multimodality treatment with surgery, radiotherapy and chemotherapy, outcomes are 
very poor, with less than 15% of patients alive after two years. Increasing evidence suggests 
that glioblastoma stem cells (GSCs) are likely to play an important role in the biology of this 
disease and are involved in treatment resistance and tumour recurrence following standard 
therapy. 
My thesis aims to address two main aspects of this research area: 1) optimization of methods 
to evaluate treatment responses of GSCs and their differentiated counterparts (non-GSCs), 
with a particular focus on a tissue culture model that resembles more closely the tumoral 
niche; 2) characterization of cell division and centrosome cycle of GSCs, investigating possible 
differences between these cells and non-GSCs, that would allow the identification of targets 
for new therapeutic strategies against glioblastomas.   
In the first part of my project, I optimized a clonogenic survival assay, to compare sensitivity of 
GSCs and non-GSCs to various treatments, and I developed the use of a 3-dimentional tissue 
culture system, that allows analysis of features and radiation responses of these two 
subpopulations in the presence of specific microenvironmental factors from the tumoral niche. 
In the second part, I show that GSCs display mitotic spindle abnormalities more frequently 
than non-GSCs and that they have distinctive features with regards to the centrosome cycle. I 
also demonstrate that GSCs are more sensitive than non-GSCs to subtle changes in Aurora 
kinase A activity, which result in a rapid increase in polyploidy and subsequently in senescence, 
with a consistent reduction in clonogenic survival. Based on these findings, I propose that 
kinases involved in the centrosome cycle need to be explored as a novel strategy to target 
GSCs effectively and improve outcomes of glioblastoma patients. 
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1Chapter 1 
Introduction
21.1 Glioblastoma: what impact does this disease have and how are we treating it? 
Glioblastoma is the most common primary malignant brain tumour in adults1. According to 
cancer registries in the UK and the US, the incidence of central nervous system tumours has 
increased in the last decades2, 3. Glioblastoma has reached an annual incidence rate of 
approximately 3 cases per 100.000 people1. Despite improvement in treatment outcome, the 
survival rates are still very poor, with only one third of patients alive after one year, less than 
15% and 5% after two and five years, respectively1. Glioblastomas are very challenging from a 
clinical point of view too, as they can induce not only focal neurological signs (paraesthesia, 
hemiparesis, aphasia, visual disturbances) and symptoms of increased intracranial pressure 
(headache, nausea, vomiting), but also fatigue, cognitive deficits (problems with memory and 
concentration) and mood and personality changes4. These clinical manifestations constitute a 
serious challenge for the quality of life (QoL) of patients and their significant others (SOs), 
when compared to healthy individuals as well as to patients with other malignancies with 
similar prognosis and their SOs: high grade glioma patients reported more severe social 
dysfunctioning than non-small cell lung cancer patients, while their SOs in addition to 
decreased social functioning presented also lower mental health scores than SOs of non-small 
cell lung cancer patients5, 6. The significant social impact of glioblastoma, together with its 
dismal prognosis, highlights the importance of finding more effective treatments to improve 
both prognosis and QoL of these patients. 
In recent years, investigation of molecular and genetic alterations has improved our 
understanding of the complex biology of these tumours, allowing identification of distinct 
genetic profiles associated with different subtypes of glioblastoma7. Glioblastomas are 
classified into the following classes 8-12:  
 Classical. These tumours exhibit the most common genomic alterations described in 
glioblastomas, i.e. chromosome 7 amplifications, chromosome 10 deletions, EGFR 
(epidermal growth factor receptor gene) amplification and CDKN2A (encoding for INK4A 
and ARF) deletion. 
 Mesenchymal. This subtype shows high expression of CHI3L1 (chitinase-3-like protein 1 
gene) and MET (c-Met or hepatocyte growth factor receptor gene), high frequency of NF1 
(neurofibromin 1 or neurofibromatosis-related protein NF-1 gene) mutation/deletion and 
more pronounced necrosis and inflammation, with expression of genes involved in wound 
healing and NF-KB signalling. 
 Proneural. These tumours are more common in younger patients and have a higher rate of 
PDGFRA (platelet-derived growth factor receptor alpha gene), IDH1 (isocitrate 
3dehydrogenase 1 gene) and TP53 (tumour protein p53 gene) abnormalities. All these 
characteristics have also been associated with secondary glioblastomas, i.e. glioblastomas 
derived from progression of lower-grade gliomas, as opposed to primary glioblastomas 
which arise de novo13. 
 Neural. This subtype is characterised by expression of GABRA1 (gamma-aminobutyric acid 
receptor subunit alpha-1 gene), NEFL (neurofilament light polypeptide gene), SLC12A5 
(potassium-chloride transporter member 5 gene) and SYT1 (synaptotagmin-1 gene), all 
neuron markers. 
Several studies analysed the correlation between specific genetic profiles and clinical outcome, 
suggesting their possible predictive role in terms of benefit from anticancer treatment12, 14-17. 
Though, their use to personalize therapy of glioblastomas, guiding selection of therapeutic 
options, is still premature18, 19. 
Current standard treatment primarily involves neurosurgical evaluation to assess feasibility of 
maximal safe resection. When appropriate, this procedure should always be performed, given 
that extent of surgery is associated with increased survival20, 21 and bulk reduction results in 
decompression of surrounding structures with improvement of symptoms. Approximately 20-
30% of patients are not eligible for surgery at all and simply undergo a diagnostic biopsy4. 
Following surgery or biopsy, patients are evaluated based on their performance status (PS) and 
age: 
- Karnofsky PS (KPS) ≥70 and age ≤70 years, fractionated external beam radiotherapy (EBRT) 
with concurrent and adjuvant temozolomide (TMZ)22; 
- KPS ≥70 and age >70 years, fractionated EBRT with concurrent and adjuvant TMZ (not 
licensed in all countries), fractionated EBRT or TMZ (evidence for different options 
reviewed in Laperriere et al 201323); 
- KPS <70, fractionated EBRT or TMZ or best supportive care24, 25. 
Following approval of the current standard regimen with temozolomide, other new 
therapeutic approaches have been shown to be active in patients with relapsed glioblastoma. 
Amongst these, two received approval by the US Food and Drug Administration (FDA)26, but 
not by the European Medicines Agency (EMEA):  
 Bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth 
factor (VEGF). This approach has a strong theoretical rationale in glioblastomas, given that: 
these tumours have a very high vasculature density27; glioblastoma cells express VEGF28; 
targeting blood vessels is likely to disrupt the perivascular niche of cancer stem cells29. The 
FDA licensed the use of bevacizumab for recurrent glioblastoma, based on the results of 
two phase ll clinical trials, which showed objective responses in pre-treated patients, with 
4a median survival of around 9 months30, 31. The EMEA refused approval because “validity of 
objective response rates as a surrogate endpoint for clinical benefit has not been 
established” and “due to the lack of a randomised concurrent control”32. Following the 
initial enthusiasm towards anti-angiogenic drugs, a phase lll trial, evaluating the use of 
bevacizumab as first line therapy in combination with current standard treatment, was 
conducted by the Radiation Therapy Oncology Group (RTOG): no overall survival 
improvement from the addition of bevacizumab was reported33. Several clinical trials are 
on-going and will likely address some of the controversies regarding the use of 
bevacizumab in glioblastomas, such as the optimal treatment schedule and dose, the most 
appropriate therapeutic agent for combination, the most reliable way to evaluate 
radiographic response34. 
 Tumour Treating Fields (TTF), consisting in low intensity, intermediate frequency, 
alternating electric fields, emitted by a portable device and administered via transducer 
arrays applied onto the scalp35. The anticancer effect is due to cell death of the 
proliferating tumour population, which some investigators interpret as a consequence of 
mitotic spindle disruption during the metaphase to anaphase transition and aggregation of 
macromolecules and organelles during telophase36, 37. The FDA approved the use of TTF for 
recurrent glioblastoma based on the results of a phase lll clinical trial comparing TTF alone 
to physician’s choice chemotherapy: overall survival did not differ in the two arms; 
responses were more frequent in the experimental arm, though not significantly; toxicity 
and quality of life were more favourable in patients treated with TTF38. Currently, a 
randomised phase III clinical trial is enrolling newly diagnosed patients who have 
undergone standard radiochemotherapy: TTF in combination with adjuvant temozolomide 
will be compared to temozolomide alone39. This trial will give an indication of whether this 
new treatment modality can be beneficial as first line therapy in glioblastoma patients. 
51.2 Current clinical research on glioblastomas: what are the targets and are these linked to 
cancer stem cells? 
Currently, there are numerous clinical trials exploring different approaches to improve 
outcome of patients with glioblastoma. In order to review these, I referred to the online 
database on the National Cancer Institute website 
(http://www.cancer.gov/clinicaltrials/search) and searched for relevant references, focusing 
on possible links with cancer stem cells (CSCs), which form the subject of my thesis. The main 
approaches grouped according to their target or therapy mode are summarized below, with a 
“CSC link” paragraph where relevant:  
 inhibitors of VEGF receptors (VEGFRs) and other protein kinases. These drugs are anti-
angiogenic agents but, differently to bevacizumab, which binds extracellular VEGF, they 
target intracellular pathways of VEGFRs and other receptors for angiogenic cytokines, such 
as platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF). Given that 
these are amongst the mechanisms involved in resistance to bevacizumab treatment40, 
multi-kinase inhibitors might have a stronger anti-tumoral effect, especially as some of 
these agents also inhibit other pathways that are dysregulated in cancer cells, such as 
mitogen-activated protein (MAP) kinase, c-kit and RET tyrosine kinase pathways.  
CSC link with VEGFRs. A recent study showed that glioblastoma stem cells (GSCs) 
preferentially express VEGFR2 and that they exhibit a persistent autocrine 
VEGFVEGFR2Neuropilin-1 loop which increases their viability, self-renewal and 
tumorigenicity41. The authors suggest that this signalling pathway contributes to 
bevacizumab resistance, which would in part be due to the formation of new blood 
vessels, following bevacizumab-induced disruption of the tumour vasculature, by cancer 
cells expressing high levels of VEGFR2. 
CSC link with PDGFRs. A recent study reported that GSCs have higher levels of PDGFRβ, 
compared to other cells, and that targeting PDGFRβ in GSCs reduces their CSC marker 
expression, self-renewal, migration and invasion ability and in vivo tumour growth42. The 
authors also report the results of a survival analysis of the Repository of Molecular Brain 
Neoplasia Data (REMBRANDT), which suggest that higher levels of PDGFRβ are associated 
with poorer prognosis in glioblastoma patients. 
CSC link with MAP kinases (also known as extracellular-signal-regulated kinases, ERKs). 
GSCs have been shown to undergo differentiation and become less tumorigenic following 
blockage of MEK/ERK activity by inhibitors or siRNA43. 
6 other anti-angiogenic drugs, inhibiting: 
o endoglin, a transforming growth factor beta (TGF-β) co-receptor expressed on 
proliferating tumour endothelial cells, which is involved in several mechanisms of 
vascularization: angiogenesis (formation of new blood vessels from pre-existing 
vessels), vasculogenesis (de novo generation of blood vessels through differentiation 
of circulating bone marrow-derived endothelial progenitor cells) and vascular mimicry 
(formation of new blood vessels through trans-differentiation of cancer cells into 
endothelial cells)44. The use of its inhibitor alone or in combination with bevacizumab 
is supported by the observation that its expression is up-regulated on tumour 
endothelial cells following inhibition of the VEGF pathway and generally in hypoxic 
areas45, 46. 
CSC link with endoglin. GSCs have been shown to be responsible for vascular mimicry 
in glioblastomas47-49. A study analysing the prognostic value and staining pattern of 
different vessel markers in paediatric high grade gliomas, found an association 
between endoglin and poor prognosis, and, most importantly in this context, showed 
that a proportion of endoglin positive blood vessels were also positive for the putative 
GSC marker CD13350. The authors suggest that this observation is an indication of 
vascular mimicry and that targeting endoglin might have a therapeutic advantage by 
disrupting the microenvironment where GSCs preferentially reside.   
o angiopoietins 1 and 2, two cytokines that are involved in angiogenesis and play a role 
in anti-angiogenic treatment resistance through various mechanisms, such as vessel 
co-option (use of pre-existent blood vessels which are hijacked by tumour cells that 
migrate along them) and recruitment of Tie2-expressing monocytes (TEMs), myeloid 
cells that have been shown to stimulate tumour angiogenesis40. 
CSC link with angiopoietin 1. GSCs have been shown to express the endothelial 
vascular receptor Tie2. Activation of Tie2 by angiopoietin 1 increases resistance of 
these cells to various chemotherapy agents, their adhesion to endothelial cells and 
invasion ability51, 52. Inhibition of the angiopoietin 1/Tie2 axis could potentially improve 
outcome by increasing chemosensitivity, disrupting the perivascular niche and 
reducing tumour invasiveness. 
o protein kinase C β (PKCβ), a protein kinase which has been implicated in various 
processes involved in cancer progression, such as VEGF-induced angiogenesis, 
proliferation, apoptosis and invasiveness of tumour cells53.  
o integrins αvβ3, αvβ5 and α5β1, heterodimeric receptors that mediate cell-cell and cell-
extracellular matrix (ECM) interactions and are involved in angiogenesis and invasion 
7of solid cancers54. These integrins are potentially promising targets in glioblastomas, 
given that: αvβ3 and αvβ5 are up-regulated not only in tumour blood vessels but also in 
glioma cells55; integrin α5β1, in addition to its pro-angiogenic role, is involved in TMZ 
resistance and expression levels of the α5 subunit are correlated with poorer prognosis 
in high grade gliomas56.  
 antibody-drug conjugate (ADC) against prostate-specific membrane antigen (PSMA), a 
transmembrane glycoprotein expressed in endothelial cells of glioblastoma blood vessels 
and absent in normal brain57. The potential advantage of this approach is that it targets 
directly the endothelium of the tumour vasculature, therefore avoiding two possible 
causes of treatment resistance, the blood-brain barrier protection and activation of 
alternative pro-angiogenic pathways. 
 molecules inhibiting the epidermal growth factor receptor (EGFR) only (Cetuximab and 
Erlotinib), EGFR and ErbB2 (Lapatinib) or EGFR, ErbB2 and ErbB4 (Dacomitinib). The 
rationale for targeting EGFR is based on the observation that it is amplified or mutated in 
over 40% of glioblastomas58, with up to 40% of the EGFR-amplified tumours harbouring 
the constitutively active EGFR variant III (EGFRvIII) mutation59, and that these genetic 
abnormalities are associated with increased proliferation and invasion of glioma cells60. 
Despite these promising findings, analysis of the impact of EGFR amplification and 
mutation on survival of glioblastoma patients has shown conflicting results, as have 
various clinical trials61. Approaches aimed at improving the efficacy of EGFR-targeting 
treatments include:   
o immunotherapy approaches with the aim of inducing specific immune responses 
against EGFRvlll-expressing cells. One involves the use of a cancer vaccine, 
consisting of the EGFRvlll peptide sequence conjugated to a carrier protein, given 
with GM-CSF62; the other consists of the administration of anti-EGFRvlll white 
blood cells, obtained by transducing peripheral lymphocytes from glioblastoma 
patients with vectors for anti-EGFRvlll chimeric antigen receptors (CAR)63.   
CSC link with EGFRvlll. During the development of the second approach, EGFRvlll 
expression was shown in all the tested GSC lines and these were efficiently 
targeted by the anti-EGFRvIII CAR-engineered T cells63.    
o inhibitors of multiple ErbB family members. The potential advantage of this 
approach is based on the observation that ErbB2 and ErbB3 harbour activating 
mutations in a subpopulation of glioblastoma patients58 and that they undergo in 
vitro compensatory activation following EGF deprivation64. 
8CSC link with ErbB family members. The latter study tested the effect of EGF 
withdrawal on GSCs and compared colony formation ability of these cells following 
inhibition of EGFR alone (cetuximab) to blockage of EGFR and ErbB2 (lapatinib)64. 
Dual inhibition gave a greater reduction in clonogenicity and decreased activation 
of downstream targets of the ErbB family, such as Erk 1 and 2 and Akt. Given these 
findings and that these pathways have been linked to CSC biology (see above for 
Erk43 and below for Akt), the authors suggest that inhibiting multiple ErbB family 
members is likely to target  more effectively the subpopulation of cells responsible 
for treatment resistance.  
 multi-tyrosine kinase inhibitors. These drugs mainly target the Src family, c-Kit and/or 
Eph/ephrin signalling.  
o Src and Src-family kinases are downstream effectors of several growth factor 
receptors and, therefore, regulate various processes involved in tumour 
progression. Their relevance as targets in glioblastomas is suggested by their 
frequent activation in glioblastoma cell lines and patient specimens65, 66, and their 
role in mediating the oncogenic effect of EGFR and EGFRvIII in an in vivo model67.  
o c-Kit (also known as stem cell factor receptor, SCFR) is a tyrosine kinase receptor 
that following binding with its ligand, the stem cell factor (SCF), activates several 
signalling cascades, including Src, MAPK and phosphatidylinositol 3-kinase (PI3K) 
signalling, and therefore induces proliferation, survival, migration and 
angiogenesis68. Several studies have reported amplification of its gene in 
glioblastomas, although the percentage of tumours harbouring this varies 
considerably amongst different patient series (between 4% and 47%), as does its 
prognostic significance69-72. 
o the Eph receptors are the largest family of tyrosine kinases, and together with 
their ligands, the ephrins, they are involved in regulation of glioma cell growth, 
migration and invasion, and angiogenesis. Given that these proteins have both 
tumour growth promoter and suppressor potentials, their role in glioma 
progression is complex and probably results from an imbalance in their function73. 
Also, Ephs and ephrins frequently show altered expression in glioblastomas, with a 
significant correlation to patient outcome. All these findings suggest that targeting 
Eph/ephrin signalling could be a potentially effective anti-cancer strategy.  
CSC link with Eph/ephrin signalling. Two recent studies showed that GSC express 
EphA2 and that knockdown or downregulation of EphA2 causes reduction of GSC 
9stemness, with decreased self-renewal, stem marker expression and 
tumorigenicity74, 75. 
 molecules inhibiting the PI3K-AKT-mTOR pathway. This signalling pathway is often 
deregulated in glioblastomas. The Cancer Genome Atlas project showed that 15% of 
patients had amplification or activating mutations of PIK3CA, the gene encoding the p110a 
subunit of PI3K, or PIK3R1, the gene encoding the p85 regulatory subunit of PI3K58. The 
same study reported that in 36% of cases there was an inactivating genetic alteration of 
phosphatase and tensin homolog (PTEN), a tumour suppressor that antagonizes PI3K 
activity. Furthermore, given that PI3K is activated by EGFR, the amplifications and 
activating mutations of this receptor’s gene mentioned above also have a positive effect 
on PI3K signalling. These data suggest that the PI3K-AKT-mTOR pathway could be a 
promising target for glioblastomas. 
CSC link with the PI3K-AKT-mTOR pathway. Several studies have shown a role of PI3K 
signalling in GSC biology. Treatment with PI3K inhibitors was shown to give a reduction of 
GSCs identified with two different approaches, the side population method and CD133 
expression76, 77. The study using CD133 expression to enrich for GSC also showed a 
reduction in sphere formation ability and tumour growth in vivo, following treatment with 
NVP-BEZ235, a dual PI3K/mTOR inhibitor. This effect was potentiated by combining this 
drug with MEK/ERK inhibition43. Another study investigating the positive impact of hypoxia 
on expansion of CD133+ cells, showed that this effect could be reversed by inhibiting PI3K 
or mTOR78. More recently, the interaction between CD133 and PI3K was analysed, showing 
that CD133 directly regulates PI3K/Akt signalling: CD133+ cells had higher levels of PI3K 
activity than CD133- cells; also, following CD133 knockdown the PI3K/Akt pathway was 
inhibited, with a concomitant reduction in sphere formation and tumorigenicity of GSCs79. 
The effect of PI3K/Akt/mTOR pathway inhibition on radiosensitivity of GSCs was 
investigated in two studies, with partially conflicting results: despite the common 
observation of autophagy induction, one paper reported no effect on radiosensitivity or 
even a tendency to reduce it, the other showed an increase80, 81. These data highlight the 
importance of the PI3K-AKT-mTOR pathway in GSC biology and the need for a better 
understanding of its interactions in order to design more effective combination 
approaches82. 
 molecules inhibiting hepatocyte growth factor (HGF)/MET signalling. A vast body of 
evidence supports the rationale for targeting HGF (also known as scatter factor) and its 
receptor, MET, in glioblastoma patients. MET amplification and overexpression have been 
reported in 4% and 29% of patients, respectively58, 83. Higher levels of MET expression are 
10
associated with poorer prognosis83-85. One study also demonstrated a significant 
correlation between MET overexpression in glioblastoma patient specimens and increased 
tumour invasiveness both radiologically and on the molecular level83. This finding is 
consistent with the well-known role of HGF/MET signalling in promoting ‘invasive growth’ 
of cancer cells86. MET has also been implicated in treatment resistance to EGFR and VEGF 
inhibitors: both types of anticancer agents caused an increase of MET activity in glioma 
cells, in vitro and in vivo, with the induction of a pro-survival and invasive response87-89. 
Based on these data, one of the proposed uses of HGF/MET signalling inhibitors is in 
combination with EGFR or VEGF inhibitors. Another promising approach is combining MET 
pathway inhibition with radiotherapy, given that blocking MET signalling radiosensitizes 
glioma cells, both in vitro and in vivo, through impairment of DNA damage repair90-92.  
CSC link with HGF/MET signalling. Several studies demonstrated the role of MET in 
regulating the GSC phenotype. The first, which used glioblastoma-derived neurosphere 
cultures, showed that HGF treatment increased their self-renewal ability and impaired 
their capacity to differentiate in response to differentiating stimuli, via the induction of 
transcription factors known to regulate the expression of stem-like features, such as 
Nanog, Sox2, c-Myc, Oct4 and Klf4. MET inhibition gave the opposite effect93. Another 
study analysing glioblastoma patient specimens showed that MET-positive cells were 
closer to blood vessels compared to MET-negative cells, a feature known to be 
characteristic of GSCs29. These authors also reported that tumour-derived METhigh cells 
formed neurospheres and generated tumours in vivo more efficiently than their matched 
METlow/negative cells94. Two recent studies using in vivo models further confirmed the role of 
MET in regulating stemness of GSCs through a process of cellular reprogramming95, 96. 
 histone deacetylase (HDAC) inhibitors. An imbalance in acetylation of histones and other 
proteins, due to increased activity of HDACs or inactivity of histone acetyltransferases 
(HATs), results in epigenetic changes that are now recognized to play an important role in 
tumourigenesis and treatment resistance97. Both pre-clinical and clinical data indicate that 
HDAC inhibitors could potentially be an effective treatment against glioblastomas. Pre-
clinical studies have shown that these drugs have several anticancer mechanisms, 
including: induction of cell death via apoptosis, mitotic failure, accumulation of reactive 
oxygen species and autophagy; inhibition of angiogenesis; increase in natural killer cell-
mediated anticancer immune response97, 98. Promising clinical data come not only from 
early phase clinical trials with vorinostat, a small-molecule inhibitor of most HDACs, but 
also from retrospective analyses of the effects of valproic acid on outcomes of 
glioblastoma patients99-102. Valproic acid, which was used for its antiepileptic properties, 
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gave a benefit in terms of overall survival in newly diagnosed patients treated with 
radiation with or without temozolomide. This positive effect supports the development of 
HDAC inhibitors in the clinic, given that it is mainly explained by the HDAC inhibitory 
properties of valproic acid, which confer to this drug not only antitumoral activity, but also 
radiosensitizing action103, 104.  
CSC link with HDAC. HDAC inhibitors have been shown to inhibit neurosphere formation, 
induce differentiation and reduce tumorigenicity of GSCs. This effect was linked to up-
regulation of the noncanonical Notch ligand Delta/Notch-like epidermal growth factor 
(EGF)-related receptor (DNER) in one study105, to decreased expression of the histone 
methyltransferase Enhancer of Zeste 2 (EZH2) in another106. These findings confirm the 
complexity of the mechanism of action of HDAC inhibitors and highlight the need for a 
better understanding of its antitumoral effect in order to maximize its benefits in the clinic. 
 poly ADP-ribose polymerases (PARP) inhibitors. The rationale for the use of these drugs in 
glioblastoma patients is mainly based on enhancing the cytotoxic effect of DNA lesions 
caused by standard therapy107. TMZ and ionizing radiation cause various types of damage 
to DNA, some of which are recognized and processed by the base excision repair (BER) 
pathway. Given that PARP is implicated in BER, several studies have tested the effect of 
combining PARP inhibitors with TMZ and/or radiotherapy. Early studies showed that PARP 
inhibition increased sensitivity of glioblastoma cells to TMZ both in vitro and in vivo108, 109. 
Subsequent research demonstrated that PARP inhibitors also induce radiosensitization of 
glioma cells and that this effect is replication dependent110, 111. This feature is potentially 
very promising for increasing the therapeutic index of radiotherapy in glioblastomas given 
that these tumours are highly proliferative while their surrounding normal tissue is 
virtually non-dividing.  
CSC link with PARP. A recent study suggested that GSCs rely on PARP to tolerate the effects 
of the increase in reactive oxygen species observed in these cells, i.e. single strand DNA 
breaks and oxidative base damage. PARP inhibition reduced self-renewal of GSCs in vitro
and, in combination with radiotherapy in vivo, it decreased the radiation-induced 
enrichment of GSCs112.  
 microtubule inhibitors. These drugs stabilize microtubules during cell division and 
therefore induce blockage of cells in G2/M phase and apoptosis. Hence, they target 
dividing cells and have a radiosensitizing effect, as G2 and M are phases during which cells 
are more sensitive to radiation. This mechanism of action supports their use in 
glioblastomas given that these tumours have a high percentage of proliferating cells and 
that they are treated with radiotherapy. Amongst microtubule inhibitors, a first generation 
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taxane, paclitaxel, was tested with or without radiotherapy and yielded modest results in 
terms of response and survival in phase II clinical trials113-115. This disappointing outcome 
has been attributed to the low concentration of drug in the central nervous system (CNS), 
despite its highly lipophilic nature. It has been suggested that this feature is partly due to 
the fact that Paclitaxel is a substrate of the transporter P-glycoprotein 1 (p-gp), a multidrug 
resistance (MDR) protein116. Consequently, microtubule inhibitors with an increased CNS 
penetration and not affected by MDR mechanisms were developed and are being tested in 
the clinic117-120. 
 hypoxia modifying techniques. Two modalities are currently being tested to increase 
oxygen concentration in glioblastoma patients:  
o hyperbaric oxygen (HBO) therapy. HBO modifies the partial pressure of oxygen 
(pO2) in the tumour by increasing plasma pO2 and this effect is maintained for 
minutes following the end of each treatment session121. A phase II clinical trial 
showed the safety of HBO when combined to chemo-radiation and suggested its 
efficacy in terms of survival122.  
o cervical spinal cord stimulation (SCS). SCS increases tumour pO2 by augmenting 
the regional blood flow. The mechanism underlying this vascular effect remains 
uncertain and the biological consequences of this microenvironment modification 
need to be evaluated123.  
Both techniques are likely to increase radiosensitivity of tumour cells in hypoxic areas, 
while SCS also has the potential of improving regional drug delivery based on its positive 
effect on blood flow. 
CSC link with hypoxia. The role of hypoxia in GSC biology is well established and is 
reviewed in section 1.4. Treatments that increase tumour pO2 could potentially reduce 
growth and stemness of glioblastoma cells, though it is not known whether the transient 
modifications in pO2 caused by HBO and SCS are capable of reversing the hypoxia-induced 
changes in GSCs. 
 proteasome inhibitors. The 26S proteasome is involved in regulating several processes, 
such as cell cycle progression, apoptosis, cell adhesion and migration, angiogenesis. 
Altered proteasomal activity that results in deregulation of these functions is associated 
with carcinogenesis124. In vitro experiments showed that proteasome inhibitors induce 
apoptosis and reduce proliferation of glioblastoma cell lines and explants125, 126. These 
drugs also exhibited an inhibitory effect on O6-methylguanine–DNA methyltransferase 
(MGMT), a DNA repair protein involved in TMZ resistance, supporting the rationale for a 
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therapeutic approach combining proteasome inhibitors to current standard treatment127, 
128. A phase I clinical trial showed the feasibility and safety of this strategy129.  
CSC link with proteasome. The role of proteasomes in GSC biology is difficult to interpret 
based on the current literature, as various studies have used different approaches and 
have given partially conflicting results. One of the main groups researching this area 
published several papers showing that:  
o lower proteasomal activity is associated with GSC phenotype, i.e. neurosphere 
formation, CSC markers expression, tumorigenicity130. 
o patients with glioblastomas with lower proteasomal activity have a significantly 
shorter overall survival131.  
o GSCs have a different metabolic state compared to more differentiated tumour cells, 
as they rely less on glycolysis, they consume less glucose, produce less lactate and 
have higher ATP levels; these features were associated with lower proteasomal 
activity131. These findings are consistent with recent data suggesting a metabolic 
regulation of proteasomes132. 
o proteasomal activity in GSCs is downregulated by Musashi-1, an mRNA-binding protein 
overexpressed in CSCs; this contributes to maintenance of the stem cell phenotype133. 
Based on these data, the authors suggest that proteasome inhibition might not be an 
effective approach to target GSCs133. Though, a study comparing toxicity of various 
chemotherapy agents in GSCs and neural stem cells found that proteasome inhibition with 
bortezomib induced apoptosis in GSCs while sparing normal cells and that this effect was 
inversely correlated with baseline proteasome expression and activity134. Also in favour of 
the possible efficacy of proteasome inhibitors in targeting GSCs is a comparative 
expression microarray analysis of GSCs that survived radiochemotherapy, showing that 
these cells have: reduction in glucose uptake, increase in lipid catabolism, activation of 
oxidative stress responses, blockage of proliferation and differentiation, and intensification 
of cellular maintenance and repair activities. Amongst various genes upregulated to 
mediate these effects are those involved in ubiquitin-proteasomal pathways135. These 
findings are consistent with those above concerning the metabolic state of GSCs, but 
appear to be in contrast with regards to proteasomal activity. This inconsistency could be 
due to the use of different populations in the two studies, as the latter focused on selected 
GSCs obtained from the expansion of few cells surviving ionizing radiation and TMZ in 
vitro. 
Finally, several studies testing the efficacy in glioblastomas of another proteasome 
inhibitor, disulfiram, showed that this drug reduced proliferation and self-renewal of GSCs 
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both in vitro and in vivo136, 137. Disulfiram also targets aldehyde dehydrogenase (ALDH), a 
putative GSC marker, but in vitro data suggest that the cytotoxic effect on GSCs is due to 
inhibition of proteasomal activity138.  
Given these findings, the use of proteasome inhibitors in glioblastoma patients appears 
promising, especially in combination with chemoradiation. 
This brief review of the main approaches that are currently being tested in clinical trials 
demonstrates the complexity of glioblastomas and highlights how relevant and topical the 
cancer stem cell theory is in this disease. I will now introduce, in the next section, this theory 
and review the main findings regarding the role of GSCs in treatment resistance. 
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1.3 Cancer stem cell theory: what is the evidence for the existence and the clinical 
significance of these cells in glioblastomas?  
The cancer stem cell theory postulates that tumours are composed by a heterogeneous 
population of cells with a specific hierarchy; only those cells that are at the top of that 
hierarchy, i.e. CSCs, are able to self-renew and propagate tumours, and therefore are 
responsible for clinical recurrence139. The traditional model also recognizes the heterogeneity 
of cell populations within a cancer, but holds any of the cells composing the tumour bulk 
responsible for recurrence. According to the cancer stem cell model only treatments that 
target CSCs can effectively eradicate cancers and result in a positive long term outcome for 
patients. 
GSCs are characterised by the following features: 
o capacity to generate a continuously growing tumour. This characteristic is tested 
evaluating induction of invasive tumoral masses following intracranial injection of 106, 105, 
104, 103 or even 102 selected cells in mice. 
o self-renewal ability. Self-renewal is a process by which cells divide to generate one or two 
daughter cells that retain self-renewal capacity140. A self-renewing cell division can be:  
- symmetrical, which results in two identical daughter stem cells with the same 
developmental potential as the mother cell; 
- asymmetrical, which gives one stem cell and one more differentiated progenitor 
cell. 
This feature is of paramount importance as its regulation under various stimuli allows GSCs 
to regenerate differentiating daughter cells, which form the tumour bulk, while 
maintaining a pool of self-renewing stem cells141.  
Self-renewal is evaluated in vitro testing the ability of single cells to form neurospheres 
when cultured in the appropriate conditions. 
CSC division and the rationale for targeting this process to eradicate GSCs will be reviewed 
in detail in the last section of this introduction. 
o potential to differentiate into the heterogeneous lineages of cancer cells that make up 
glioblastomas, i.e. astroglial, neuronal and oligodendroglial cells. This feature is tested 
evaluating expression levels of stem cell and differentiation markers in cells exposed to 
differentiating stimuli, such as serum-containing medium. 
Enhancement of this attribute has been investigated as an anticancer approach in 
differentiation therapies, at first with retinoids and more recently with bone 
morphogenetic proteins (BMPs). Despite the preliminary encouraging findings on the use 
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of retinoic acid in glioblastomas, a phase II clinical trial in newly diagnosed patients did not 
suggest an advantage in adding this drug to radiation and/or chemotherapy, and therefore 
did not justify phase III testing142. Research on the use of BMPs in glioblastomas is mostly 
preclinical, but it has already highlighted many complexities. On the one hand, BMP4 and 
BMP7 have been proposed as potential therapeutic agents following in vitro and in vivo
studies showing that they are capable of inducing CSC differentiation and prolonging 
survival of mice injected with GSCs143, 144. On the other hand, a study testing the effect of 
BMP2 on several GSC lines demonstrated that treatment with this protein induced 
differentiation or proliferation depending on the status of BMP receptor 1B in these 
cells145. Also, a recent study showed that GSCs overexpress Gremlin 1, a BMP antagonist, 
and that this allows them to maintain their stemness despite high levels of BMPs in the 
tumour146. Given these findings, a better understanding of the BMP signalling pathway and 
its regulation is needed to design treatments that can effectively induce terminal 
differentiation of CSCs in glioblastoma patients and therefore yield the desired therapeutic 
outcome.   
The first in vitro evidence for the existence of CSCs in brain tumours was published in 2002, 
when Ignatova et al. reported the isolation from high grade gliomas of cells that could form 
clones under culture conditions used in neural stem cell research, i.e. these cells could grow as 
neurospheres in serum free medium supplemented with epidermal growth factor (EGF), 
fibroblast growth factor (FGF) and insulin147. These “neural stem-like cells” were also shown to 
differentiate and express astroglial and neuronal markers following serum stimulation. Soon 
after, Singh et al. confirmed these findings in vitro and developed an intracranial xenograft 
assay, showing that a subpopulation of cells isolated from glioblastoma specimens was capable 
of inducing tumours phenotypically resembling the patient’s original specimen148, 149. These 
cells, selected for CD133 expression, gave tumours at a very high frequency (100 cells were 
sufficient) and could be serially transplanted, while the rest of the population, i.e. CD133-
negative cells, was not tumorigenic, following the injection of up to 105 cells. 
Thereafter, a vast number of studies reported the isolation of CSCs from glioblastoma patient 
specimens, using various techniques and yielding a wide range of results in terms of 
tumorigenicity of selected cells. Anthony Chalmers and I summarised these findings in a review 
at the beginning of my doctoral studies (see Appendix)150. At the time, two main methods were 
used to enrich populations for stem cells:  
1) expression of putative stem cell markers, such as CD133, A2B5, SEEA-1 and integrin α6149, 151-
159. 
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2) growth in serum free medium supplemented with growth factors, as spheres (in uncoated 
flasks) or adherent cultures (in extracellular matrix or laminin coated flasks)154, 160-165.  
Since then, the variety of methods has not diminished, but it is now widely accepted that a 
single marker is unlikely to define GSCs derived from all patient specimens166. Identification of 
GSCs based on analysis of CD133 staining, for example, can be misleading given that: 
expression levels of this marker fluctuate throughout the cell cycle167-169; recognition of the 
cell-surface epitope by specific antibodies is influenced by posttranslational modifications170.  
Also unchanged is the lack of standardization of the culture conditions, despite their well-
known strong impact on CSC biology171. Even the nomenclature to define these cells is still not 
clear, as different names (cancer stem cells, stem-like cancer cells, tumour-initiating cells) are 
used in various studies and often not in the same way172, 173. This impossibility to identify a 
universal technique for the isolation of GSCs in vitro and the lack of standardization in the CSC 
methodology probably constitute the main arguments against the cancer stem cell theory. 
However, these controversies are outweighed by the consistency of clinical data regarding the 
prognostic value of GSC features, summarized in table 1. The vast majority of studies showed a 
statistically significant correlation between various GSC features in glioblastoma patient 
specimens and poorer outcome. A few reported no difference and a couple a positive effects 
on overall survival. Limitations of these data are that: 1) most studies were retrospective; 2) 
multivariate analysis was not always performed and in most cases did not include all the 
established prognostic factors; 3) a wide range of cut-offs in GSC marker expression were used 
to define subgroups, for example for CD133 the cut-off ranged from 1% to 50% in different 
studies; 4) studies on putative GSC markers focused only on one or two proteins. The 
weakness of the latter approach in this setting was highlighted by a very interesting study 
analysing CD133 expression in paired glioblastoma patient specimens, comprising a sample 
from the primary tumour and one from the recurrence after adjuvant chemoradiation174. 
Following the observation that a more pronounced increase in CD133 expression in recurrent 
tumours was associated with a significantly longer survival after recurrence, CD133 positive 
cells were characterized more in detail to verify their nature. Co-labelling with CD34 and CD45 
was used to quantify the fraction of CD133-positive cells of endothelial and hematopoietic 
origin, respectively. Analysis of tumour-specific chromosomal aberrations and in vivo
tumorigenicity assays allowed the identification of normal neural stem cells amongst the 
CD133-positive population. Surprisingly, these experiments showed that a minority of the 
CD133-positive population was of tumoral origin and that the percentage of normal neural 
stem cells was associated with a significantly longer patient survival after recurrence. These 
findings demonstrate the need for more extensive approaches when identifying GSCs and 
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analysing their clinical significance. Amongst those used in the studies summarized in table 1, 
analysis of multiple gene expression profiles and ability to grow as neurospheres in specific 
culture conditions probably constitute the most reliable methods.  
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Table 1. Clinical studies analysing the correlation between GSC features and patient outcome. 
Study Type of 
analysis
Number of patient 
specimens
Analysed factors Multivariate 
analysis factors
Statistics for endpoint
Strojnik et al 
2007175
Retrospective 87 gliomas 
(54 glioblastomas)
A) Nestin expression 
B) Musashi expression
Patient age and 
gender, cathepsins 
B and L. 
A) Shorter OS: p < 0.001.
B) OS: no significant difference.
Mangiola et al 
2007176
Retrospective 20 glioblastomas Nestin and JNK expression OS: no significant difference.
Zhang et al. 
2008177
Retrospective 125 gliomas Co-expression of Nestin and 
CD133
Tumour grade Shorter OS: p < 0.01
Pallini et al. 
2008178
Prospective 44 glioblastomas A) CD133 expression 
(≥2% vs <2%) 
B) in vitro neurosphere 
formation ability 
(present vs absent)
Symptom duration, 
extent of resection, 
patient age, 
MGMT status and 
p53 status.
Higher risk of death  
A) HR 2.22 (p =0.03)
B) HR 2.92 (p =0.005)
Zeppernick et al 
2008179
Retrospective 95 gliomas 
(47 glioblastomas)
A) CD133 expression 
(>1% vs ≤1%) 
B) organization of these cells 
(cluster vs single cells)
Histological grade, 
patient age and 
extent of resection
Shorter OS:
A) HR 17.46 (p <0.001)
B) HR 5.62 (p <0.001).
Murat et al 
2008180
Retrospective 80 glioblastomas from 
two prospective 
clinical trials 
comparing RT+TMZ (A) 
to RT alone (B)
Hox genes, comprising 
CD133 gene
Patient age, MGMT 
status and EGFR 
expression.
(A) Shorter OS: HR 3.32 (p =0.001).
(B) OS: no significant difference.
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Chinnaiyan et al 
2008181
Retrospective 153 glioblastomas 
from RTOG 
prospective clinical 
trials
Nestin expression (high, 
intermediate and low, based 
on intensity and positive 
area)
OS and PFS: no significant difference.
Laks et al 2009182 Retrospective 15 glioblastomas “Renewable neurosphere 
formation”
Ki67 staining. Shorter OS: HR 17 (p =0.49)
Shorter PFS: HR 4.7 (p =0.034)
Sihto et al 
2009183
Retrospective 43 glioblastomas SCF (high vs low) Shorter OS: p =0.034
Colman et al 
2010184
Retrospective 4 glioblastoma 
microarray data sets 
(MDA, MGH, UCLA, 
UCSF) for 
identification + 2 FFPE 
sample sets (68 and 
101 glioblastomas) for 
validation
9-gene set including CD133 
and nestin
Age and KPS. Shorter OS: HR 2.7 (p =0.0003)
Rossi et al 
2011185
Prospective 106 glioblastomas β-catenin and Gli1 
expression
OS: r ≤ -0.65
Metellus et al 
2011186
Prospective 48 glioblastomas CD133 expression (high vs 
low, with mean level as 
cutoff)
Age, extent of 
surgery and MGMT 
gene promoter 
methylation.
Shorter OS: HR, 1.91 (p =0.007).
Kim et al 2011187 Retrospective 88 glioblastomas Nestin expression [high 
(<50% positive cells) vs low]
CD133 expression (positive 
vs negative)
CD15 (positive vs negative)
OS: no significant difference.
21
He et al 2011188 Prospective 59 HGGs 
(33 glioblastomas)
CD133 expression (positive 
vs negative)
Shorter PFS: HR 2.838 (p =0.001)
Adam et al 
2012189
Retrospective 1. 93 glioblastomas 
(own institution)
2. 177 glioblastomas 
(REMBRANDT 
dataset)
ALDH1A1 expression [high 
(>7% positive cells)  vs low 
(≤7%)]
1. Age and MGMT 
gene promoter 
methylation.
Shorter OS:
1. HR 0.483 (p <0.01)*
2. trend towards longer OS 
(p = 0.071)*. 
Nakata et al 
2013190
Prospective 179 glioblastomas LGR5 expression [high (>10% 
positive cells) vs low (≤10%)]
Age and gender Shorter OS: p =0.002
Sandberg et al 
2013191
Retrospective 
bioinformatics 
analysis
1) 77 HGGs (Phillips 
dataset)
2) 85 HGGs (Freije 
dataset)
30-gene signature 
expression (high vs low)
Shorter OS:
1) p =0.00859
2) p =0.00325
Shibahara et al 
2013192
Retrospective 112 glioblastomas CD133 expression (high vs 
low)
TTD: Ki67, 9p 
deletion and 10q 
loss.
TTL: extent of 
surgical resection, 
Ki67 and MGMT 
gene promoter 
methylation.
Shorter TTD: HR 2.9 (p =0.038).
Shorter TTL: HR 0.44 (p =0.0056)*. 
OS: no significant difference.
Kase et al 2013193 Retrospective 42 glioblastomas CD133 expression [< median 
(28%) vs ≥ median)
Radiotherapy dose, 
chemotherapy and 
KPS.
Shorter OS: HR 1.99 (p =0.04)*
Binder et al 
2013194
Retrospective 
bioinformatics 
analysis
181 glioblastomas 
(REMBRANDT dataset)
PODXL expression (high vs 
intermediate)
Shorter OS: HR 1.67 (p =0.001)
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Shin et al 2013195 Retrospective 67 glioblastomas CD133 expression (positive 
cells <50 % vs ≥50 %)
Age, gender, extent 
of surgery, 
treatment (TMZ, 
chemoradiation), 
expression levels of 
CD34, VEGF and 
IDH1.
Longer OS: HR 2.49 (p=0.037)
Dahlrot et al 
2013196
Retrospective 187 glioblastomas Musashi-1 expression OS: no significant difference.
Lathia et al 
2014197
Retrospective 
bioinformatics 
analysis
1) 76 HGGs (Phillips 
dataset)
2) 180 glioblastomas 
(REMBRANDT 
dataset)
3) 185 glioblastomas 
(Odense dataset) 
JAM-A expression OS:
1) JAM-A low longer OS than JAM-A 
medium and high (p < 0.05)
2) JAM-A low longer OS than JAM-A 
high (p < 0.05)
3) JAM-A low longer OS than JAM-A 
high (p < 0.05)
Hale et al 2014198 CD36 expression (high vs 
low)
Poorer prognosis
OS, overall survival. JNK, c-Jun NH2-terminal kinase. MGMT, O6-methylguanine–DNA methyltransferase. HR, hazard ratio. RT, radiotherapy. TMZ, 
temozolomide. EGFR, epidermal growth factor receptor. RTOG, Radiation Therapy Oncology Group. PFS, progression free survival. SCF, stem cell factor. 
MDA, MD Anderson. MGH, Massachusetts General Hospital. UCLA, University of California-Los Angeles. UCSF, University of California-San Francisco. FFPE, 
formalin-fixed paraffin embedded. KPS, Karnofsky performance status. HGG, high grade glioma. ALDH1A1, aldehyde dehydrogenase 1 family member A1. 
LGR5, leucine-rich repeat containing G protein-coupled receptor 5. TTD, time to distant recurrence. TTL, time to local recurrence. PODXL, podocalyxin-like 
protein. VEGF, vascular endothelial growth factor. IDH1, isocitrate dehydrogenase 1. JAM-A, junctional adhesion molecule A. 
*positive prognostic effect. 
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Further evidence for the existence of GSCs comes from two studies using in vivo lineage 
tracing. The first consisted in the observation of matched cell populations, stem and non-stem 
(GSC-enrichment based on CD133 expression), derived from a glioblastoma patient specimen, 
labelled with two fluorescent proteins and injected into a xenograft model with a ratio of 
1:9199. Cells were then monitored with serial in vivo intravital microscopy to measure the 
respective growth and test their relative tumorigenic potential. Analysis of sequential time 
points showed that GSCs were responsible for tumour formation and that their volume 
increased by 52 fold, while non-stem cells remained relatively unchanged (0.92 fold increase). 
Based on expression patterns of another putative CSC marker, SOX2, the authors also suggest 
that the cell population derived from GSCs is heterogeneous in terms of differentiation, i.e. it 
displays a hierarchy. This study is definitely more informative than standard 
xenotransplantation models with regards to the contribution of CSCs to cancer formation, 
though it does not explore their role in treatment resistance and tumour recurrence, which are 
the most relevant questions in the clinical setting. These were addressed by another study 
using in vivo lineage tracing in a genetically engineered mouse model of glioma200. The authors 
introduced a Nestin-ΔTK-IRES-GFP transgene into glioma prone mice, obtaining tumours with a 
relatively quiescent GFP+ subpopulation and a proliferating GFP- one. To test the role of these 
cells in treatment resistance, they treated mice with TMZ and observed that most of the GFP- 
cells were killed, while the quiescent GFP+ population survived. Pulse chase labelling with 
bromodeoxyuridine analogues demonstrated that, following TMZ treatment, GFP+ cells 
started to proliferate and at 7 days post-chemotherapy the proliferating population was 
mostly GFP-. To confirm that the originally GFP+ cells were responsible of recreating a 
heterogeneous population of cells and therefore giving rise to tumour recurrence, the mice 
were also treated with ganciclovir, which would selectively kill GFP+ cells thanks to the 
inclusion of a herpes simplex thymidine kinase ‘suicide gene’ in the GFP construct. Sequential 
treatment with TMZ and ganciclovir resulted in a significant reduction in maximal tumour cell 
density and a prolonged survival compared to TMZ only, suggesting that the relatively 
quiescent GFP+ subpopulation was indeed responsible for post-chemotherapy tumour growth. 
These findings constitute a very important chapter in the story of the CSC theory and are 
viewed by many experts in the field as a clear demonstration of the importance of targeting 
these cells to eradicate tumours and improve patient outcome201, 202. 
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1.4 Glioblastoma stem cell features: what is the role of the microenvironment in maintaining 
these? 
A large body of evidence is also accumulating on the pivotal role of the microenvironment in 
regulating stemness and treatment resistance of glioblastoma cells. The first indication of the 
importance of microenvironmental factors in GSC biology came from studies analysing the 
distribution of tumour cells expressing CSC markers. A comparative analysis of the distance 
from tumour capillaries of Nestin+ and Nestin- cells in glioblastoma patient specimens showed 
that cells expressing the putative stem cell marker were significantly closer to the vascular 
structures and were in direct contact with endothelial cells29. The perivascular location of GSCs 
was confirmed by another study investigating the distribution of CD133+ cells in glioblastoma 
specimens: these cells were observed in perivascular niches, in pseudopalisade formations 
surrounding necrotic areas and as dispersed single cells203. In these tumour sections, there 
were also many CD133+ blood vessels. This observation found an explanation in the findings of 
two studies, which demonstrated that CD133+ glioblastoma cells are able to differentiate into 
endothelial cells, both in vitro and in vivo47, 48. A study analysing the role of hypoxia inducible 
factor (HIF) 2α in GSC showed that up to 10% of tumour cells adjacent to blood vessels and 
necrotic areas expressed HIF2α and most of these co-expressed CD133204. Taken together, 
these data suggest an association between GSCs and perivascular and necrotic niches. Several 
in vitro and in vivo studies confirmed and elucidated the mechanisms underlying these 
interactions. The main findings of these studies are summarised below. 
Perivascular niche. A study using a 3-dimentional organotypic ‘explant’ system derived from 
glioblastoma specimens, showed that selective elimination of endothelial cells via a toxin 
conjugate results in a reduction in neurosphere formation ability, hence a decrease in self-
renewal of GSCs205. Another study, which used a genetically engineered mouse model of PDGF-
induced glioma, observed a spatial relationship between endothelial cells expressing 
endothelial nitric oxide synthase (eNOS) and Nestin+ tumour cells expressing soluble guanylyl 
cyclase (the main receptor for nitric oxide, NO)206. Based on this observation and on in vitro
experiments, the authors suggested that the effect of endothelial cells on stemness of glioma 
cells is mediated by NO through the Notch pathway. The link between endothelial cells, Notch 
signalling and GSCs, was confirmed by a study analysing the distribution of Notch ligands in 
glioblastoma patient specimens: Notch ligands were found in cells adjacent to Nestin+ cells, 
often in endothelial cells207. Also, in vitro experiments co-culturing GSCs with human brain 
microvascular endothelial cells (hBMEC) demonstrated an increase in self-renewal ability and 
in CSC marker expression, which was reversed following knockdown of Notch ligands in 
25
hBMECs. Hence, the authors suggested that endothelial cells create a ‘Notch signalling 
activating environment’ that promotes stemness. Another study testing the effect of 
endothelial cell-conditioned medium on neurosphere formation, showed that self-renewal 
ability of GSCs was partially retained and that this culture condition was able to maintain 
activation of mTOR downstream targets, suggesting that endothelial cells sustain GSC self-
renewal by secreting mTOR activating factors208. A study using a porous, polymeric scaffold as 
a system to evaluate the impact of paracrine endothelial cell signalling on GSCs, demonstrated 
that co-transplantation of human brain endothelial cells (hCMECs) with GSCs grown in the 3D 
model increased tumour growth relative to GSCs alone209. Also in vitro exposure of GSCs to 
conditioned medium from hCMEC 3D cultures induced a higher expression level of putative 
stem cell markers, Nestin and SOX2. 
Data from other studies suggest that GSC maintenance induced by endothelial cells is also 
mediated by laminins and by their receptors, integrins. One showed that, in glioblastoma 
patient specimens, laminin α2 is expressed by tumour associated endothelial cells in integrin 
α6+ areas and that tumour formation in vivo is delayed when GSCs are injected with 
endothelial cells with laminin α2 knockdown210. A previous study from the same group 
demonstrated that integrin α6 is co-expressed with CD133 in glioblastoma patient specimens 
and that targeting this protein in GSCs reduces neurospheres formation and tumour growth in 
vivo159. Another integrin that might be involved in the link between the perivascular niche and 
GSCs is integrin α3, given that it has been shown to be preferentially expressed in tumour cells 
localized around blood vessels and in the invading front and that its levels are significantly 
higher in CD133+ cells211. 
On the one hand, these findings reveal how important the perivascular niche is for GSC 
biology, providing a strong rationale for targeting its elements as a therapeutic approach. On 
the other, they highlight how multifaceted the interaction between endothelial cells and GSCs 
is, suggesting that treatments aimed at perturbing this relationship need to take into account 
these complexities to avoid the failure experienced with previous drugs targeting blood 
vessels.    
Perinecrotic niche. Necrotic areas in glioblastomas are the result of lack of oxygen and 
nutrients. Several studies have demonstrated that hypoxia increases CSC features in 
glioblastoma cell lines. This effect was attributed to activation of HIF1α in an in vitro study 
which showed that culturing GSC populations at 1% oxygen increased their self-renewal ability 
and positivity for CD133, while it reduced expression of differentiation markers78. The above 
mentioned analysis on the role of HIFs in GSCs demonstrated that targeting HIF1α or HIF2α in 
GSCs inhibited their self-renewal ability in vitro and tumorigenicity in vivo204. Though, the 
26
authors suggested that HIF2α, not HIF1α, is the specific mediator of the effects of low oxygen 
levels on GSCs, based on co-expression of HIF2α and CD133 in glioblastoma patient specimens 
and on different mRNA levels of HIF1α and HIF2α in GSCs grown in hypoxia. Similar results 
were reported by another group, that demonstrated: increase in self-renewal and CD133 
expression in cells incubated at 1% oxygen; up-regulation of both HIF1α and HIF2α in GSCs
grown in hypoxic conditions; abrogation of the effect of hypoxia on self-renewal following 
knockdown of HIF1α or HIF2α; reduction of the hypoxia-induced up-regulation of CD133 in 
HIF2α knockdown cells but not in those with HIF1α knockdown212. These three studies 
consistently suggest a role of hypoxia in GSC biology, even though they show partially 
conflicting results with regards to the impact of low oxygen levels on HIF1α and HIF2α
expression in GSCs and the effect of HIF knockdowns on CSC features. This inconsistency is 
probably due to differences in experimental procedures and, most importantly, to the use of 
different cell lines in the three studies, as suggested indirectly by the results included in 
another publication from the group proposing a specific role of HIF2α213. In this study they 
used a different cell line and showed a response of non-stem cells to hypoxia with regards to 
HIF2α mRNA levels, which was not seen in the other cell lines included in their previous 
publication.  
Other investigators tested the effect of hypoxia on GSCs focusing on two aspects of cancer 
biology: cellular metabolism and immunosuppression. 
Metabolism. Cancer cell metabolism differs from that of normal cells as it relies mainly on 
glycolysis for ATP production, even in the presence of sufficient oxygen levels214. This 
phenomenon, known as ‘Warburg effect’, translates in increased glucose uptake and lactate 
production. Adaptive responses to the hypoxic tumour microenvironment, together with 
altered signalling due to oncogene activation, are proposed as the main causes of this 
metabolic difference215. Several compounds that target glycolysis have been developed to 
exploit this phenomenon therapeutically. A study testing the effects of 2-deoxyglucose (2DG), 
a glucose analogue, on primary glioblastoma cell lines, showed that it forced them into 
mitochondrial metabolism and reduced CD133 and nestin expression inducing neuronal 
differentiation; 2DG also induced apoptosis, although this effect was reduced in hypoxic 
conditions216. While these findings suggest a possible role of glycolysis inhibitors in targeting 
GSCs, data from other two studies do not support this approach. One study evaluated in GSCs 
the effect on ATP production, i.e. energy production, of 2DG, used to target glycolysis 
specifically, and oligomycin, an inhibitor of mitochondrial ATP synthase, used to disrupt 
oxidative phosphorylation131. Both drugs given as a single agent reduced ATP levels marginally, 
while the combination had a substantial effect (40-50% decrease), suggesting that GSCs are 
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able to satisfy their energetic needs by using oxidative phosphorylation as well as glycolysis. 
Furthermore, analysis of glucose uptake and lactate production showed that GSCs consume 
less glucose and generate less lactate compared to more differentiated tumour cells, 
suggesting they rely less on glycolysis. Based on these findings, the authors concluded that 
therapeutic approaches aimed at disrupting glycolysis, or more generally a single metabolic 
pathway, are unlikely to be effective in killing GSCs131. Another study characterized metabolism 
of GSCs after dividing them into treatment sensitive and resistant clones, based on their 
clonogenic survival following ionizing radiation alone or in combination with TMZ. The two CSC 
subpopulations differed with regards to glucose uptake and response to inhibition of glycolysis 
(with 2DG) or fatty acid oxidation (with Etomoxir):  treatment resistant GSC clones had lower 
glucose uptake; treatment sensitive clones showed a reduction in ATP production following 
exposure to either 2DG or Etomoxir, while treatment resistant clones had a decrease in ATP 
levels only after inhibition of fatty acid oxidation. Based on these findings and on results of a 
microarray analysis performed on the two subpopulations, the authors suggested that 
glioblastoma recurrence is driven by GSCs with a glucose restriction-like phenotype, that use 
fatty acid oxidation, rather than glycolysis, as their preferential energy source for ATP 
production135.  
Immunosuppression. Hypoxia was also shown to increase another feature attributed to GSCs, 
immunosuppression, given that in vitro experiments demonstrated the following: GSC 
populations produced more immunosuppressive cytokines when cultured in hypoxic 
conditions; exposure to GSC-conditioned medium resulted in reduction of T cell proliferation, 
interferon γ production by CD3+ T cells and phagocytosis in monocytes; these effects were 
augmented if GSCs were grown at low oxygen levels217.  
The interaction between GSCs and cells of the immune system is another important 
component of the CSC-microenvironment cross-talk, which is receiving increasing attention 
due to the development and clinical testing of several glioblastoma vaccines. This research 
field still has significant limitations with regards to experimental systems, given that generally 
used in vivo xenografts are unlikely to be truly representative models for tumour-immune 
system interactions. Indirect proof is provided by the inconsistency in the results of flow 
cytometry analyses characterizing inflammatory cell infiltrates in rat gliomas and in 
glioblastoma human specimens. In animal models, there was marked microglia infiltration in 
the tumours, their periphery and in the tumour-free brain; macrophages were less present 
within the tumours and their periphery, and rare in the tumour-free tissue; lymphocytes were 
more common than macrophages, but their number and distribution differed considerably 
amongst tumour models218. In glioblastoma patient specimens, macrophages were the most 
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common cell type in the tumoral mass; in the samples from the ‘overlying normal cortex’ the 
inflammatory cell infiltrates were quite scarce219. As suggested by the authors of the latter 
study, the observed differences might be partly due to the inherent immunogenicity of rat 
models, as suggested by the higher amount of lymphocytes found in the experimental tumours 
and the more pronounced inflammatory infiltrate present in the normal brain of the animals. 
Despite these limitations, these studies have highlighted the presence of monocyte lineage 
cells in gliomas. Increasing evidence suggests that these cells induce immunosuppression and 
promote glioblastoma growth and invasion220. Some findings also indicate a crosstalk between 
microglia/macrophages and GSCs. A study evaluating this interaction showed that: in 
glioblastoma patient specimens, there was a positive correlation between localization of 
microglia/macrophages and CD133+ cells; in an in vitro migration assay, GSC-conditioned 
medium attracted microglia/macrophages more efficiently than medium from more 
differentiated tumour cells221. Consistently with these results, another group reported a 
positive correlation in the localization of microglia/macrophages and CD133+ cells in the 
invasive front of glioma patient specimens, suggesting a pro-invasive effect of the immune 
system cells on GSCs222. 
These findings on the role of the tumoral niche in GSC biology have contributed to a more 
complex view of the cancer stem cell theory, which does not simplistically hold GSCs per se
responsible for tumour recurrence, but rather identifies the origin of treatment resistance in 
the plasticity of GSCs modulated by microenvironmental factors.   
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1.5 Glioblastoma stem cells and treatment responses: what is the role of the 
microenvironment in regulating these? 
The majority of studies analysing the effects of the microenvironment on treatment resistance 
of GSCs focused on ionizing radiation. Before analysing the findings regarding intrinsic and 
microenvironment-regulated radiosensitivity of CSCs in glioblastomas, I will review the existing 
data on resistance of GSCs to standard chemotherapy, i.e. TMZ, starting with a brief 
introduction on its mechanism of action.  
1.5.1 Temozolomide resistance.
TMZ is an alkylating agent, which causes three main lesions: O6-Methyl-Guanine (O6-Me-G, 
6%), N7-Methyl-Guanine (N7-Me-G, 70%) and N3-Methyl-Alanine (N3-Me-A, 9%)223. N7-Me-G 
and N3-Me-A are promptly repaired by the DNA base excision repair (BER) pathway, and 
therefore generally do not result in a cytotoxic effect. O6-Me-G is repaired by MGMT, which 
restores guanine by removing the methyl group. If levels of MGMT are insufficient, O6-MeG 
persists and during S phase it mispairs with thymine, instead of cytosine. This error is detected 
by the DNA mismatch repair (MMR) system, which is only able to recognise and excise the 
mispaired thymine on the daughter strand, leaving O6-MeG in the template strand. This 
results in cycles of thymine reinsertion and excision, with persistent DNA strand breaks and 
consequent replication fork collapse, which triggers G2/M cell cycle arrest via ATR/CHK1-
dependent signalling. Given this mechanism of action, intrinsic cellular sensitivity to TMZ is 
dependent on the functionality of repair proteins involved in processing DNA damage, i.e. TMZ 
resistance is associated with high levels of MGMT and functional MMR. The clinical relevance 
of MGMT levels is fairly well established, based on several clinical studies showing that MGMT 
gene silencing, mostly due to methylation of its promoter, is associated with longer survival 
following TMZ treatment224. The data on MGMT and TMZ resistance in GSCs is rather complex. 
The association between MGMT methylation and protein expression is not clear in in vitro
studies. The largest published analysis, including twenty GSC enriched cell lines, did not find a 
correlation between methylation status and protein expression; sensitivity to TMZ was 
correlated to MGMT levels, but not to its methylation225. Similarly, another study comparing 
TMZ response in CD133+ and CD133- cells, showed that cellular sensitivity to TMZ was 
inversely correlated to MGMT protein levels, but not to methylation status; surprisingly, the 
most sensitive population of cells was expressing the CSC marker226 . In contrast with these 
findings are those from a study showing that CD133+ cells had higher levels of MGMT mRNA 
expression and were more resistant to TMZ, compared to CD133- cells227. Another group 
reported yet contrasting findings from analysing patient-matched GSC and non-GSC early 
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passage cultures: no difference in MGMT methylation status or expression levels in the two 
populations; TMZ sensitivity was not influenced by in vitro enrichment for CSCs, as it was 
patient specific and similar in matched populations228. In conflict with these results are those 
from two studies analysing the association between differentiation status, MGMT and GSC 
sensitivity to TMZ. In vitro differentiation of GSC populations, induced by BMP2 treatment or 
by changing the culture conditions, sensitized cells to TMZ and this effect was correlated to 
MGMT expression and methylation status, respectively229, 230. The variability of these findings is 
probably due to several factors: lack of standardization of the tested dose levels of TMZ, which 
can strongly impact the output of sensitivity assays; small number of cell lines used in most 
studies; characterization of cell lines rarely done for other factors associated with TMZ 
resistance, such as MMR functionality and p53 status. 
Besides intrinsic cellular mechanisms, determinants of TMZ resistance in glioblastoma patients 
are represented by microenvironmental factors responsible for intratumoral drug 
concentration. TMZ concentration is influenced locally by structure and functionality of 
tumour vasculature and by blood flow. The importance of these factors was demonstrated 
with two different approaches. One used an MRI technique to analyse changes in tumour 
blood flow in newly diagnosed glioblastomas treated with a pan-VEGF receptor tyrosine kinase 
inhibitor, in combination with chemoradiation: the antiangiogenic drug increased tumour 
perfusion in a subset of patients, probably due to induction of a transient period of vessel 
normalization, and this was associated with improved overall survival231. Another showed that 
it was possible to predict the fraction of glioblastoma cells killed with chemotherapy in 
individual patients, by using a mathematical model based on three parameters: fraction of 
blood volume within the tumour, distribution of vessel diameters and drug diffusion distance 
through cancer tissue232.  
To my knowledge, the effect of increasing tumour blood flow on GSC response to TMZ has not 
been analysed specifically. Though, given that the perivascular niche is one of the preferential 
locations of GSCs, it is likely that these cells would be amongst the first to be exposed to higher 
TMZ concentrations, following treatments which increase perfusion and normalize the 
structure of blood vessels. 
With regards to other microenvironmental factors, some evidence suggests the possible role of 
hypoxia in influencing TMZ sensitivity of GSCs. A study analysing distribution of cells expressing 
hypoxia-induced factors, CD133, differentiation markers and MGMT, in glioblastoma patient 
specimens, showed a link between hypoxic conditions, GSCs and TMZ resistance: there was a 
gradient from the core to the periphery, consisting in higher levels of CD133 and MGMT in the 
hypoxic core, which gradually decreased towards the outer layers; also, cell lines derived from 
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the core and intermediate areas were more resistant to TMZ in vitro, compared to those 
derived from the periphery233.  
This brief review summarizing the literature on sensitivity of GSCs to TMZ again highlights 
many complexities in the mechanisms underlying response of CSCs to standard treatment in 
glioblastomas, suggesting the need for a more standardized and comprehensive approach 
when analysing the impact of intrinsic and extrinsic factors on treatment resistance.  
1.5.2 Radioresistance.  
I will now discuss the data regarding radiosensitivity of GSCs, starting with a critical analysis of 
the landmark paper which was the first to claim that GSCs are the radioresistant entity in 
glioblastomas, based on the following findings152:  
 CD133+ cells are more clonogenic than CD133- cells after irradiation. Although clonogenic 
survival is the ‘gold standard’ method to test clinically relevant radiosensitivity, there were 
two important limitations in the way this assay was performed: only one dose level was 
tested (5 Gy); no quantification of colony formation was shown (only images with photos 
of representative plates). 
 tumorigenicity of CD133+ cells is not affected by in vitro irradiation with 2 Gy and 
decreased slightly with 5 Gy. Even though these results show that single doses of ionizing 
radiation have limited effect on the tumorigenic potential of CD133+ cells, they cannot be 
interpreted as an indication of the relative radioresistance of these cells, given that a 
comparison with CD133- cells was not possible due to the inability of these cells to form 
tumours in this study. 
 CD133+ cells have a higher repopulation potential than CD133- cells, both in vitro and in 
vivo, following irradiation. This was demonstrated performing an experiment in which the 
two subpopulations were differentially labelled, mixed, treated (or not) with ionizing 
radiation, implanted in the brains of athymic nude mice (only for the in vivo setting) and 
quantified after a set period of time. Enrichment in the CD133+ fraction was observed in 
untreated as well as treated samples, but was more pronounced in the latter, suggesting 
that CD133+ cells not only proliferate more in the experimental conditions, but also have 
higher survival ability following radiation. Consistent with these findings are those from 
two subsequent studies, mentioned above, using in vivo lineage tracing, which 
demonstrated that a subpopulation of glioblastoma cells expressing putative stem cell 
markers have an advantage in terms of growth in xenograft models and post-treatment 
repopulation of the tumour199, 200. Indirect confirmation also came from a small clinical 
study analysing the percentage of CD133+ cells in matched pre- and post-treatment high 
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grade glioma specimens from ten patients undergoing high-dose irradiation: CD133 
expression was significantly higher in the post-radiotherapy specimens234.  
 CD133+ cells exhibit more pronounced activation of the DNA damage checkpoint than 
CD133- cells. This was suggested by the results of western blots showing higher levels of 
phosphorylated ATM, Rad17, Chk1 and Chk2 following irradiation in the CD133+ 
subpopulation. A subsequent publication from the same group proposed that this 
response is regulated by the surface protein L1CAM through up-regulation of NBS1, a 
component of the MRE11–RAD50–NBS1 (MRN) complex that activates ATM and early 
checkpoint responses235. Though, the absence of experiments with non-GSCs in the latter 
study precludes the possibility of interpreting this mechanism as a GSC-specific one.  
 CD133+ cells are more efficient at repairing ionizing radiation induced DNA damage than 
CD133- cells. Kinetics and efficiency of single and double strand break repair were 
evaluated with alkaline comet assays and immunofluorescence quantification of cells 
positive for phosphorylated histone 2AX, respectively.  
Following this paper, several other studies analysed radiosensitivity of GSCs, mostly focusing 
on DNA damage responses of these cells. Despite the abundance of publications, only the 
following three studies performed a comparative analysis of radiosensitivity of GSCs and non-
GSCs using clonogenic survival assays: 
 one compared clonogenicity of CD133+ and CD133- subpopulations from two cell lines, 
following 0, 1, 2, 3 and 4 Gy. While CD133+ cells from one cell line were more 
radioresistant than the CD133- counterpart, there was no difference in radiosensitivity of 
the two subpopulations from the other cell line236. 
 one compared clonogenicity of CD133+ and CD133- cells from seven cell lines, following 2 
Gy. CD133+ cells from all cell lines were more clonogenic than their CD133- counterpart 
after irradiation237. 
 one compared clonogenicity of subpopulations enriched or depleted for stemness, using 
different culture conditions, from three cell lines, following 0, 1, 2, 3, 4 and 5 Gy. GSCs 
from all cell lines were more radioresistant238. 
Apart from the dishomogeneity in CSC-enrichment methods and tested dose levels amongst 
the four studies, there were also important differences in the conditions used for the 
clonogenic assays: 
 Bao et al. plated both subpopulations in serum-free medium without growth factors for 24 
hours post-treatment followed by transfer to medium with serum152; 
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 Mc Cord et al. plated both subpopulations on poly-L-lysine coated wells in serum-free 
medium236; 
 Yang et al. plated both subpopulations in soft agar237;  
 Carruthers et al. seeded both subpopulations in Matrigel-coated wells, maintaining GSCs in 
serum-free medium and non-GSCs in serum-containing medium238. 
The importance of the experimental conditions chosen for clonogenic assays is highlighted by 
the latter study, which also performed neurosphere formation assays on GSCs from two of the 
three cell lines: in both cell lines 2 Gy caused a more pronounced reduction in neurosphere 
formation than in colonies grown in Matrigel-coated wells238. Despite the limitations related to 
the lack of standardization of clonogenic assays for CSCs, on the whole these findings suggest 
that cells with GSC features are more resistant to ionizing radiation. The variety of 
experimental conditions used to measure clonogenicity of GSCs and non-GSCs reflects one of 
the main issues in the cancer stem cell field, i.e. designing methods for comparative analyses 
of sensitivity to ionizing radiation and chemotherapy between the two subpopulations of cells. 
Given the pivotal role of clonogenic survival assays in in vitro cancer research, I decided to 
dedicate part of my doctoral studies to optimizing this method. 
Two of the four studies also evaluated DNA damage responses236, 238. Though only the more 
recent one made a comparative analysis between GSCs and non-GSCs, showing that: 1) GSCs 
have a more pronounced activation of the G2/M checkpoint after ionizing radiation (5 Gy) than 
their differentiated counterpart, as indicated by the lower percentage of GSCs positive for 
phosphorylated histone H3, a mitotic marker, 3 and 6 hours post-treatment; 2) GSCs exhibited 
a lower number of phosphorylated histone 2AX foci per cell 24 hours after ionizing radiation (1 
Gy)238. The authors suggested that these responses were mediated by different levels of ATM 
activation following ionizing radiation, though these were not seen in all cell lines and no 
quantification was shown of the western blots. Also, they reported a potent, yet similar, 
radiosensitizing effect of ATM inhibition on both subpopulations, suggesting that other 
mechanisms are responsible for the observed relative radioresistance of GSCs in their study. 
Even if not specific to GSCs, ATM inhibition appears to be a promising strategy to kill these 
cells, given that other studies have shown a marked effect of ATM inhibitors in combination 
with ionizing radiation on GSC survival, using both in vitro and in vivo models239, 240.  
Another recent study made a comparative analysis of single strand DNA breaks (SSBs) and 
oxidative base damage in matched CD133+ and CD133- cells, following the observation that 
the former population had higher levels of reactive oxygen species (ROS): both DNA lesions 
were increased in CD133+ cells112. Consistently, PARP activity was higher in this population and 
treatment with a PARP inhibitor reduced colony formation in CD133+ cells, while having no 
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significant effect on the CD133- counterpart. Combination of ionizing radiation and PARP 
inhibition in both subpopulations was evaluated with viability assays, caspase 3/7 activity at 
three days post-treatment (as a measure of apoptosis) and quantification of phosphorylated 
histone 2AX foci: all experiments showed that PARP inhibition increased the effect of radiation 
on CD133+ cells, whereas had negligible or no impact on CD133- cells. These findings have two 
important limitations: lack of clonogenic survival analysis; inconsistency of data on constitutive 
levels of SSBs with that reported for other cell lines in previous publication from the same 
group152. Nevertheless, the authors suggested that PARP inhibitors could be a promising 
approach to target GSCs, based on the hypothesis that these cells rely on PARP to tolerate the 
observed enhanced constitutive DNA damage. Ongoing clinical trials will likely give indications 
of the veracity of this hypothesis (see section 1.2). 
In contrast with the theory that radioresistance of GSCs is due to enhanced DNA repair 
responses is a paper which made a comparative analysis of double and single strand break 
repair in matched CD133+ and CD133- cells, showing no difference between the two 
subpopulations241. The authors proposed that resistance of GSCs to ionizing radiation was 
correlated with their longer cell cycle duration and increased basal activation of checkpoint 
proteins. Though this hypothesis was not supported by their data, given that: GSCs had a 
longer potential doubling time (PDT) compared to established cell lines; while, when matched 
CD133+ and CD133- cells were analysed, the former subpopulation had a shorter PDT, hence a 
shorter cell cycle. Also, the checkpoint activation data consisted only in a representative image 
of a western blot, with no quantification shown.    
In order to determine whether radiation induced DNA damage responses of GSCs to ionizing 
radiation could be influenced by factors other than intrinsic to the cells, a study quantified 
phosphorylated histone 2AX and 53BP1 foci in CD133+ and CD133- cells grown in vitro and in 
orthotopic xenografts242. While there was no difference in DNA double strand break induction 
and repair between the two subpopulations from two cell lines cultured in vitro, both types of 
foci were reduced in CD133+ cells compared to CD133− cells in the in vivo setting. 
Quantification of CD133+ cells in untreated and irradiated mice showed that the latter group 
had a higher percentage of cells expressing the putative stem cell marker. Based on these 
findings, the authors suggested that the brain microenvironment specifically increases 
radioresistance of GSCs. 
More evidence for the influence of microenvironmental factors on radiation responses comes 
from two studies mentioned above, in the “Perivascular niche” section: 
 one evaluated responses of GSCs to ionizing radiation by comparing their neurosphere 
formation rate following treatment of cells grown in a 3-dimentional organotypic ‘explant’ 
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system or in neurosphere cultures: a single dose of 10 Gy reduced their self-renewal ability 
more dramatically in the latter condition, suggesting that radiosensitivity of GSCs is 
influenced by microenvironmental factors present in the explants205. Surprisingly, the 
effect of radiation on the percentage of CD133+ cells in the two conditions was the 
opposite, i.e. neurosphere cultures maintained a higher proportion of cells expressing the 
putative stem cell marker following treatment with 10 Gy. Apart from this partial 
contradiction, another limitation of the study is the use of a high single dose, whose effect 
should be correlated with caution to that of clinically relevant doses.   
 the other analysed the impact of laminin α2 on radiation responses of CD133+ cells, 
showing that in the presence of this integrin, compared to the control condition (BSA), 
these cells had: 1) increased survival, measured in terms of viability 48 and 72 hours after 
1, 3 and 6 Gy; 2) reduced phosphorylated histone 2AX, quantified as the number of cells 
with > 10 foci 24 hours after ionizing radiation (3 Gy)210. Although these findings suggest 
that radioresistance of GSCs might be influenced by the presence of specific integrins in 
the tumoral niche, they need to be confirmed with clonogenic survival assays and a more 
rigorous analysis of DNA damage responses, given that short-term viability and the use of a 
cut-off of 10 foci per cell are not recognised methods to test radiosensitivity in a clinically 
relevant manner.  
Despite their limitations, on the whole, these findings suggest that microenvironmental 
factors, together with intrinsic cellular features, are determinants of radioresistance, 
highlighting the need for studies that analyse responses of GSCs to ionizing radiation in 
experimental models that allow inclusion of elements from the tumoral niche.  
Based on the data above regarding the tumoral niche, I decided to dedicate part of my 
doctoral studies to developing the use of a tissue culture system that allows analysis of 
features and radiation responses of GSCs and non-GSCs in the presence of specific 
microenvironmental factors.  
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1.6 Aims of my research on glioblastoma cancer stem cells. 
The aims of my project are: 
 optimization of the following methods for cancer stem cells:  
o a clonogenic survival assay, to compare sensitivity of GSCs and non-GSCs to 
cytotoxic therapies; 
o a 3 dimentional culture system, to grow GSCs and non-GSCs in the presence of 
microenvironmental factors and evaluate their features and treatment responses 
in a model that resembles in vivo conditions more closely than the traditional 
tissue culture plastics.     
 characterization of mitosis in GSCs and non-GSCs, with the intention to elucidate possible 
differences between the two subpopulations, that would allow us to identify targets for an 
effective therapeutic strategy to improve outcomes of patients with glioblastoma.   
I decided to optimize methods for GSCs and non-GSCs to address the need for the 
development of laboratory techniques that allow comparative analyses of the two 
subpopulations, as mentioned in the previous section (1.5.2), but also as a preparatory step for 
the part of my project investigating cell division of CSCs. 
My interest in mitosis originated from the following: 
- cell division is one the identifying properties of CSCs, as its regulation enables them to 
divide both symmetrically and asymmetrically, giving rise to differentiating daughter cells, 
which form the tumour bulk,  as well as maintaining a pool of self-renewing stem cells. 
- one of the studies, mentioned above, using in vivo lineage tracing in a genetically 
engineered mouse model of glioma, showed that post-treatment cancer growth is due to a 
relatively quiescent subpopulation of cells, which, following chemotherapy, produces 
transient subsets of highly proliferating cells repopulating the tumour200.  
Confirmation of the strength of this approach comes from findings on the role of mitotic 
kinases in GSCs. A study, which combined the results of a functional genetic approach with a 
bionetwork created from glioblastoma patient molecular signatures as a strategy to identify 
targets differentially required for expansion of GSCs, generated a mitotic checkpoint kinase, 
BUB1B, as a top-scoring hit243. This output was validated by knockdown experiments, 
demonstrating that targeting BUB1B reduced neurosphere formation and differentially 
blocked growth, both in vitro and in vivo, of GSCs from several primary cell lines, while having 
no significant effect on neural stem cells. Based on these findings and on results of mechanistic 
studies, the authors suggest that GSCs have an added requirement for BUB1B and propose 
targeting this protein as a therapeutic strategy against glioblastomas. Another target linked to 
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mitosis was proposed by a study analysing the interaction of the transcription factor FOXM1 
and the mitotic kinase MELK (maternal embryonic leucine-zipper kinase) in GSCs, based on the 
following data: FOXM1 and MELK had higher expression levels in CD133+ cells compared to 
CD133- cells; immunofluorescence analysis showed that FOXM1 co-stained with the putative 
CSC markers SOX2 and nestin; disruption of MELK-mediated FOXM1 signalling, using the 
antibiotic Siomycin A, reduced neurosphere formation ability of GSCs and delayed growth of 
GSC-induces xenograft models244. Based on these findings, the authors suggest targeting the 
FOXM1-MELK interaction as a therapeutic strategy against glioblastomas. A previous 
publication suggested polo-like kinase 1 (Plk1), a mitotic kinase, as a target to kill GSCs and 
improve treatment outcome of glioblastoma patients, based on the following findings: analysis 
of microarray data from 467 patients showed that Plk1 was highly expressed in these tumours 
and was correlated to poor survival; treatment with BI2536, a Plk1 inhibitor, reduced self-
renewal of GSCs; targeting Plk1, with siRNA or BI2536, induced differentiation of GSCs, 
demonstrated by down-regulation of the putative CSC marker SOX2 and up-regulation of a glial 
differentiation marker245. 
The main hypothesis of my project originates from these data as I propose that GSCs have 
distinctive mitotic features, compared to non-GSCs, and that these represent effective targets 
to kill this subpopulation of cells. 
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Chapter 2 
Materials and Methods 
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2.1 Materials
2.1.1 Cell lines 
G7, E2, S2 and G1 primary glioblastoma cell lines were a generous gift of Colin Watts 
(Cambridge).  
Human glioblastoma established cell line U87-MG was obtained from the European Collection 
of Animal Cell Cultures (ECACC). 
2.1.2 Ionizing radiation 
Cells were irradiated with 250 kVp X-rays (dose rate 0.5 Gray/min). 
2.1.3 Drugs 
 Aurora kinase A inhibitor: MLN8237, Millenium.   
 Nocodazole, Sigma. 
 PARP inhibitor: AZD2281, a gift of Kudos Pharmaceuticals/AstraZeneca. 
 Polo-like kinase I: BI2536, Axon Medchem. 
 Paclitaxel, Sigma. 
2.1.4 Antibodies 
Primary antibodies are listed in table 2.1. 
Secondary antibodies were Alexa Fluor, Invitrogen (dilution 1:1500). 
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Table 2.1 Primary antibodies 
Antigen Source (catalogue number) Species Dilution (assay)
53BP1 Bethyl Laboratories (A300-272A) Rabbit 1:1000 (IF)
Acetylated α-tubulin Sigma (clone 6-11B-1) Mouse 1:1000 (IF)
ARL13B Abcam (ab83879) Rabbit 1:200 (IF)
Aurora A Epitomics (1800-1) Rabbit 1:1000 (WB)
Caspase 3 Abcam (ab4051)
Cell Signaling (9668)
Rabbit
Mouse
1:200 (IF)
1:1000 (WB)
CENP-F Abcam (ab5) Rabbit 1:800 (IF)
Centrin-2 Gift from Elmar Schiebel Rabbit 1:500 (IF)
Fibronectin Abcam (ab26245) Mouse 1:800 (IF)
γH2AX Millipore (05-636) Mouse 1:1600 (IF)
Histone H3 Millipore (05-499) Mouse 1:1000 (WB)
1:100 (FACS)
Nestin Abcam (ab6320) Mouse 1:200 (IF)
Total p53 Cell Signaling (9282) Rabbit 1:1000 (WB)
Phosphorylated p53 Cell Signaling (9286) Mouse 1:1000 (WB)
Phosphorylated Aurora A Cell Signaling (3079) Rabbit 1:100 (IF)
Phosphorylated histone H3 Cell Signaling (3465) Rabbit 1:200 (IF)
1:50 (WB)
Polo-like kinase 1 Abcam (ab14210) Mouse 1:400 (WB)
SOX2 Abcam (ab75485) Mouse 1:50 (IF)
α-tubulin Abcam (ab7291) 
Abcam (ab18251)
Mouse
Rabbit
1:1000 (IF)
1:1000 (IF)
γ-tubulin Abcam (ab11316) Mouse 1:250 (IF)
IF, immunofluorescence; WB, western blot; FACS, Fluorescence Activated Cell Sorting.
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2.1.5 Other reagents 
 AccutaseTM. 
 B-27, Invitrogen. 
 CellTracker Green CMFDA (5-Chloromethylfluorescein Diacetate), Molecular Probes. 
 CellTracker Blue CMAC (7-Amino-4-Chloromethylcoumarin), Molecular Probes. 
 Click-iT® EdU Alexa Fluor® 647 Imaging Kit, Life Technologies C10340. 
 Collagen type IV, Sigma C5533. 
 Concanavalin A, Sigma. 
 Epidermal growth factor, Invitrogen PHG0313. 
 Fibronectin, Sigma F0556. 
 Fibroblast growth factor, Invitrogen PHG0263. 
 Fluoromount, Sigma. 
 HyClone, Thermo Scientific HyClone, 12822966. 
 Immobilon Western Chemiluminescent HRP Substrate, Merck Millipore WBKLS0500.  
 Laminin, Sigma L4544. 
 MaxGelTM ECM Matrix, Sigma E0282. 
 Neurobasal-A medium, Invitrogen. 
 Phalloidin, Invitrogen. 
 ProLong Gold mounting solution containing DAPI, Molecular Probes. 
 Senescence detection kit, Abcam ab65351. 
 Vitronectin, Sigma V8379. 
 Western blot lysis buffer: 20mM Tris pH 7.5, 137mM NaCl, 10% glycerol, 1% triton, 2mM 
EDTA, 0.05% b-mercaptoethanol, protease and phosphatase inhibitors.
 Western blot sample buffer: 0.01% bromophenol blue, 62.5mM Tris-HCl pH 6.8, 7% SDS, 
20% sucrose and β-mercaptoethanol. 
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2.2 Methods 
2.2.1 Generation of GSC and non-GSC populations and cell culture 
G7, E2, S2 and G1 primary glioblastoma cell lines were derived from freshly resected 
glioblastoma patient specimens as described in Fael Al-Mayhani et al. Protocols for tissue 
collection were compliant with the UK Human Tissue Act 2004 (HTA Licence ref 12315) and 
approved by the local regional Ethics Committee (LREC ref 04/Q0108/60). Each patient gave 
their informed consent prior to undergoing surgery. In summary, anonymised patient 
specimens were minced, digested, filtrated and washed. Cells were then seeded in serum-free 
media and allowed to form primary aggregates, which were then plated onto extracellular 
matrix (ECM)-coated flasks (ECM 1:10 dilution, Sigma, UK) and allowed to form a monolayer.  
To obtain cancer stem cell enriched populations (referred to as ‘GSCs’ in the text), cell lines 
were cultured in Neurobasal-A medium supplemented with B-27, epidermal growth factor (20 
ng/ml), fibroblast growth factor (20ng/ml), glutamine and penicillin/streptomycin (referred to 
as ‘GSC medium’ in the text). All cell lines grew as neurospheres in these culture conditions. 
To induce differentiation, hence obtain matched differentiated populations (referred to as 
‘non-GSCs’), cell lines were cultured in MEM supplemented with HyClone, NEAA, L-glutamine, 
sodium pyruvate and penicillin/streptomycin (referred to as ‘non-GSC medium’). All cell lines 
formed adherent colonies in these conditions. 
In order to test whether the primary glioblastoma cells grown as neurospheres were enriched 
for GSCs, in comparison to those cultured as adherent colonies, the two subpopulations were 
characterized for key features that distinguish GSCs from their differentatiated counterparts 
(see section 1.3). These experiments were performed by other members of the Anthony 
Chalmers Laboratory. G7 and E2 cell lines were analysed for expression of stem cell and 
differentiation markers, using western blotting and fluorescence activated cell sorting: 
neurosphere cultures exhibited higher levels of CD133, nestin and Sox2, while they had lower 
levels of the astrocytic differentiation marker GFAP, compared to adherent cultures (view data 
in Mannino et al. 2014 in the appendix). The two cell lines were also tested for their ability to 
form tumours in CD1 nude mice. Intracranial injection of 105 G7 neurospehere cells generated 
highly invasive tumours in 100% of cases; injection of 105 G7 cells from adherent cultures also 
formed tumours but these had well defined edges and did not exhibit an invasive pattern. 
Following intracranial transplantation of 105 E2 neurosphere cells, pathology analysis showed 
the presence of a highly invasive mass in the injection site and of infiltrative cells in both 
hemispheres in 100% of mice; in contrast, injection of 105 E2 cells from adherent cultures did 
not generate tumour masses (view data in Mannino et al. 2014 in the appendix). These 
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findings confirm that the use of different culture conditions is a legitimate method to obtain 
subpopulations of cells enriched for GSCs or non-GSCs, i.e. they validate the approach I chose 
for my project.The majority of experiments in my doctoral studies are carried out with the G7 
cell line. This choice was based on the availability of a relatively large stock of G7 cells with low 
passage number and the higher growth rate of these cells, compared to E2 and S2 cells. These 
aspects made this cell line the most suitable one for optimizing various methodologies and 
performing experiments in triplicates.  
Detailed characterization, with gene sequencing and methylation analysis, of GSCs and non-
GSCs of the primary cell lines is not part of my project and is being performed by other 
members of the Anthony Chalmers laboratory. Available data is cited were relevant in the 
results chapters.   
When cell lines are split or prepared for experiments, they are incubated with Accutase™ to 
induce detachment between cells in GSCs and from flasks in non-GSCs, obtaining a single cell 
suspension.  
To culture cells on Alvetex®, GSCs and non-GSCs are seeded onto the polystyrene disks as 
single cell suspensions in their respective medium, which is changed every four days at first 
and then more frequently, depending on changes in the colour of the medium indicating a 
reduction in pH due to increase in cell number and waste products. 
2.2.2 Neurosphere formation assay
Cells are retrieved from flasks to obtain a single cell suspension, counted and diluted serially to 
achieve a final concentration of 1 cell/200 µl. The cell suspension is seeded in 96 well plates 
with a multichannel pipette, plating 200 µl/well. Plates are incubated for at least two weeks. 
EGF and FGF are added every 5 days. Spheres are counted with the Gel Count (Oxford 
Optronix). 
2.2.3 Clonogenic survival assays 
The following is the protocol that I used for all clonogenic survival assays. I optimized it as an 
adapted version of the neurosphere formation assay (see above). For the protocol 
development see chapter three. 
Cells are retrieved from flasks to obtain a single cell suspension, counted and diluted serially to 
achieve a final concentration of 1 cell/100 µl for drug sensitivity tests, 1 cell/200 µl for 
radiosensitivity assays. The cell suspension is seeded in 96 well plates with a multichannel 
pipette, plating 100 µl/well for drug sensitivity tests, 200 µl for radiosensitivity assays. Plates 
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are then treated: drugs are added to the plates six to twelve hours after seeding and left for 
the whole duration of the experiment; ionizing radiation (IR) is delivered six hours after 
seeding; in the combined treatment with MLN8237 and IR, the drug was added as usual and 
plates were irradiated 24 hours later. Plates are incubated for at least two weeks. EGF and FGF 
are added every 5 days to the plates with GSCs. Colonies are counted after at least 15 or 21 
days (depending on the cell line), using the Gel Count for GSCs and methylene blue staining for 
non-GSCs. To prepare plates for Gel Count scanning, two simple steps are performed: 1) wells 
are filled up completely with PBS, making sure not to create any air bubbles; 2) the bottom of 
the plate is wiped with IMS (industrial methylated spirit) to remove dust. For methylene blue 
staining, a standard protocol adapted to the 96-well format is used, as follows: the medium is 
removed with a sharp downward movement holding the plate upside down; 70% ethanol is 
added with a multichannel pipette to fix the cells and left for ten minutes; after ethanol is 
removed (with the same vigorous movement as before!), methylene blue is added with a 
multichannel pipette and left for at least 30 minutes; plates are then rinsed with water and left 
to dry.  
2.2.4 Cell sorting with Fluorescence Activated Cell Sorting using FACSAria™ I
Cells are retrieved from flasks to obtain a single cell suspension, counted and resuspended in 
PBS, containing 1mM Na2EDTA (to reduce clumping and clogging), at a concentration of 1x106
cells/ml. The cell suspension is filtered using 40µm cell strainers prior to sorting, again to 
reduce clumping and clogging. To minimize mechanical stress on cells, a 100μm nozzle and low 
pressure mode is used.  
2.2.5 Coating Alvetex® with extracellular matrix (ECM) components 
2.2.5.1 MaxGelTM human ECM  
ECM is thawed on ice and then diluted with medium (tips are cooled in the freezer prior to 
pipetting ECM). The diluted ECM is applied gently and slowly on the scaffold, which is 
transferred onto a mesh for a few minutes. The scaffold disk is inserted in the well and 
incubated for 30 minutes at 37°C. The single cell suspension is added slowly moving the tip 
around the well.  
2.2.5.2 Customized ECM mixture 
The customized ECM mixture contains collagen, fibronectin, laminin and vitronectin. First of 
all, collagen and vitronectin are reconstituted in acetic acid and water, respectively. Then, each 
solution is diluted in HBSS to obtain the desired concentration, as follows: collagen 1mg/ml, 
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fibronectin 5µg/ml, laminin 10µg/ml, vitronectin 0.5µg/ml. The solutions are mixed and 
applied gently and slowly on the scaffold, which is transferred onto a mesh for a few minutes. 
The scaffold disk is inserted in the well and incubated for 2 hours at 37°C. The disks are then 
rinsed twice with medium and the single cell suspension is added slowly moving the tip around 
the well.  
2.2.6 Preparation of frozen samples of scaffold  
The scaffold disk is removed from the well, quickly rinsed three times with PBS and cut into 
small pieces (approximately 6 x 4 mm). A drop of optimal cutting temperature (OCT) 
compound is placed on a cork disk and a scaffold piece is immersed in it, taking care to orient it 
standing or lying. The sample is transferred into an isopentane bath first and then into a liquid 
nitrogen bath. The samples are retrieved from the liquid nitrogen bath and stored at -80°C in a 
plastic bag. Samples are cut with a cryostat and placed on polylysine coated slides.  
2.2.7 Immunofluorescence 
2.2.7.1 2D culture system.  
For experiments evaluating centrosome maturation, mitotic spindle phenotype and cell cycle 
distribution, cells are retrieved from flasks to obtain a single cell suspension and pipetted on 
Concanavalin A coated coverslips. They are then fixed with 70% methanol for 5 minutes. 
For phosphorylated Aurora kinase A analysis, cells are retrieved from flasks to obtain a single 
cell suspension, cytospun on Concanavalin A coated coverslips and fixed with 4% 
paraformaldehyde (PFA) and 70% methanol, sequentially for 5 minutes each.  
For all the above experiments, cells are permeabilized in PBS 0.3% Triton for 5 minutes, 
blocked in 3% BSA for 30 minutes and incubated with primary antibodies for one hour at 37°C. 
Slides are then washed and probed with the appropriate secondary antibody for one hour at 
room temperature. Coverslips are mounted using ProLong Gold mounting solution containing 
DAPI. 
Images are acquired on DeltaVision microscope equipped with a UPLS Apochromat NA 1.40, 
60x oil immersion objective (Olympus), standard filter sets (excitation 360/40, 490/20, 555/28; 
emission 457/50, 528/38, 617/40) and a CoolSNAP HQ2 camera (Photometrics). Z series are 
acquired using softWoRx software (version 4.0.0; Applied Precision). When applied, 
deconvolution is performed using SVI Huygens Professional Deconvolution Software (Version 
3.5). For 3D view and quantitative analysis of γH2AX foci, DAPI volume, γ tubulin and 
phosphorylated AurA centrosomal accumulation, DeltaVision files are imported into Imaris 
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software (version 6.3.0; Bitplane) and processed with the relevant algorithm. Measurements 
are exported to Excel (Microsoft) and plotted. The γ tubulin and phosphorylated AurA data was 
further analysed using Mann-Whitney U test. 
2.2.7.2 3D culture system (Alvetex®).  
Medium is removed from the well, PFA is added and left for 10 minutes. The scaffold disk or 
piece is immersed in PBS and stored in a well at 4°C until staining. Reagents and incubation 
times are as for coverslips. The difference in the protocol is that the cells are within the 
scaffold, rather than on a coverslip; hence, the various solutions (diluted primary antibody, 
PBS, diluted secondary antibody, etc.) are placed in adjacent wells in a plate and the scaffold 
piece is moved from one well to another using appropriate tweezers. For mounting, the 
scaffold piece is placed on top of a drop of mounting medium on a slide and then covered with 
a coverslip. 
Confocal images are acquired using LSM Zeiss Axiovert 200M-LSM 510 META COMBI Confocal 
Microscope with Coherent Enterprise II 693 UV laser, equipped with the following objectives: 
63x and 40x water immersion, 20x. 
2.2.8 Chromosome spreads 
Cells are treated with nocodazole for 6 hours, collected, spun down and incubated in KCl 
(75mM) for 10 minutes. KCl is removed and fixative (methanol:glacial acetic acid, 3:1) is added 
slowly and left for 10 minutes. Cells are spun down, resuspended with fixative, spun down 
again and resuspended in fixative. A drop of cell suspension is then pipetted onto a pre-wet 
(50% ethanol) slide from at least 20 cm high. Slides are left to dry and are mounted with 
ProLong Gold mounting solution containing DAPI. 
Images are acquired as described in section 2.2.7.1. 
2.2.9 Ploidy analysis 
Cells are retrieved from flasks to obtain a single cell suspension, pipetted on Concanavalin A 
coated coverslips and fixed with 4% paraformaldehyde for 10 minutes. Cells are permeabilized, 
blocked and probed with phalloidin for 30 minutes. Coverslips are mounted using ProLong 
Gold mounting solution containing DAPI. 
Random images are acquired as described in section 2.2.7.1. 
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2.2.10 Fluorescence Activated Cell Sorting (FACS) analysis  
Cells are retrieved from flasks to obtain a single cell suspension, washed with PBS, fixed with 
70% ethanol (it is important to vortex cells gently while adding ethanol to avoid clumping of 
GSCs) and stored in fridge. They are then centrifuged at 1500 rpm for 3 minutes, rinsed twice 
with 3%BSA/PBS (with addition of EDTA for all steps to avoid clumping) and re-suspended in 
500µl of 3%BSA/PBS solution containing 250μg/ml of RNase A and 5μg/ml of propidium iodide 
(PI). After at least I hour incubation in the dark at room temperature, analysis of DNA content 
of cells is performed using the FACSCanto (BD). Plots of PI area versus cell counts are done 
with FACSDiva software (BD). 
For mitotic index analysis, after the cells are rinsed twice with 3%BSA/PBS, they are incubated 
for 1 hour at room temperature in 50µl of anti-phosphorylated histone H3 antibody diluted in 
3%BSA/PBS, washed once with 500µl of 3%BSA/PBS and incubated for 1 hour at room 
temperature in 50µl of secondary antibody diluted in 3%BSA/PBS. Cells are then rinsed once 
and re-suspended in 500µl of 3%BSA/PBS solution containing 250μg/ml of RNase A and 5μg/ml 
of PI.
2.2.11 Western blot 
Cells are retrieved from flasks to obtain a single cell suspension, counted and washed once 
with PBS. To prepare cell lysates, cells are re-suspended in 40 µl IP lysis buffer and 10 µl 5x 
sample buffer and then incubated on ice for 20 min, before sonication. Cell lysates are boiled 
for 5 minutes at 95°C and loaded to electrophoresis in SDS polyacrylamide gel. Gels are then 
transferred with a semi-dry technique to nitrocellulose membranes, which are blocked for 30 
minutes with 5% milk/PBS/0.1% NP-40. Membranes are incubated overnight at 4°C with 
primary antibody diluted in the blocking buffer, washed three times for 5 minutes with PBS 
and incubated with the appropriate horseradish peroxidase (HRP) conjugated secondary 
antibody for 1 hour at room temperature. Three washing steps with PBS are done before 
chemiluminescent detection is performed. Emission is captured with radiograph films using 
the Xograph compact 4 automatic X-ray film processor.  
2.2.12 Cell tracking  
Cells are retrieved from flasks to obtain a single cell suspension, divided into two parts and 
incubated separately with 1μM CellTracker Green CMFDA and 1μM CellTracker Blue CMAC for 
45 minutes. Medium with dyes is removed, cells are incubated in fresh medium for 24 hours 
50 nM MLN8237. Cells are collected from flasks, spun down, re-suspended, pipetted on 
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Concanavalin A coated coverslips and fixed with 4% paraformaldehyde for 10 minutes. They 
are then stained with phalloidin (as in ploidy analysis). Coverslips are mounted using 
Fluoromount. 
Random images are acquired as described in section 2.2.7.1. 
2.2.13 -galactosidase staining
Cells are treated with 0 and 50 nM MLN8237. After 2 and 7 days they are stained according to 
an adapted version of the manufacturer’s protocol. Cells are retrieved from flasks to obtain a 
single cell suspension and transferred to plastic tubes (polypropylene plastic tubes only for 
whole experiment). Cells are incubated with the fixative solution for 10-15 minutes at room 
temperature, washed twice with PBS and incubated with the staining solution mix. Cells are 
then incubated at 37°C for 1 hour and cytospun on slides. Coverslips are mounted using 
Fluoromount. 
Random images are acquired on microscope Axio Lb A1 (Zeiss) equipped with an AxioCam ERc 
5s and a 40x objective. -galactosidase positive and negative cells are counted on a computer 
monitor and percentages of -galactosidase positive cells are calculated and blotted. 
2.2.14 Edu labelling 
GSCs and non-GSCs are treated with 0, 2 and 4 nM of BI2536. After 24 hours of incubation, 
they are stained according to an adapted version of the manufacturer’s protocol. Following 23 
hours of treatment, they are incubated with EdU solution for 1 hour, retrieved from flasks, 
cytospun on coverslips and fixed with 4% PFA for 10 minutes. Cells are then rinsed twice with 
3% BSA/PBS solution, permeabilized with 0.5% Triton for 20 minutes and, after other two 
rinsing steps, they are incubated with the Click-iT® reaction cocktail for 30 minutes at room 
temperature in the dark. Cells are rinsed once and incubated with the primary antibody for 1 
hour, washed three times and incubated with the secondary antibody for one hour at room 
temperature in the dark. Coverslips are mounted using ProLong Gold mounting solution 
containing DAPI. 
Random images are acquired as described in section 2.2.7.1.  
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2.3 Statistics 
Experiments are performed in triplicate, unless otherwise stated. In the graphs, data are 
generally presented as means with standard deviations.  
Statistical significance is evaluated with the two-tailed Student’s t-test or the Mann-Whitney U 
test and a P value < 0.05 is considered statistically significant. 
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Chapter 3 
Optimization of methods for cancer stem cells 
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3.1 Introduction 
Starting with the first isolation of cells with CSC features from glioblastoma patient specimens, 
which applied cell culture techniques developed for neural stem cells, the methodology used 
in GSC research has often found inspiration in the normal stem cell field. Due to the 
heterogeneous nature of cancer and given the completely different aims of research 
investigating GSCs and neural stem cells, application and adaptation of methods from the 
latter field has important limitations. An example is represented by the variable results 
obtained with neural stem cell markers when used to identify GSCs166. Also, non-adherent 
sphere culture, a valuable technique exploiting a recognised feature of GSCs, generates some 
important issues, such as: increased heterogeneity of cellular populations compared to 2D 
cultures164, 165; difficulties in designing experiments for comparative analysis of sensitivity to 
chemotherapy and ionizing radiation between GSC enriched populations and their 
differentiated counterparts. Various groups have addressed these issues in different ways, 
introducing distinct possible biases. Although the non-adherent sphere culture technique is 
one of the sources of the lack of standardization that characterizes the GSC field, the following 
findings suggest the value of this method in glioblastoma research: 1) the ability of cancer cells 
to grow as neurospheres is correlated with poorer patient outcome (see general introduction 
for detailed data); 2) a study, comparing efficacy of various TMZ dosing schemes against GSC 
lines, showed good correlation between in vitro findings and data from clinical trials246; 3) 
serum-free medium supplemented with growth factors, i.e. medium for non-adherent sphere 
cultures, was demonstrated to preserve more closely glioblastoma genotype and 
phenotype247-249. While the latter data question the value of comparative analyses with cellular 
populations grown in serum-containing medium, a recent proteomic study characterizing 
primary cell lines, derived from patient specimens as adherent or as sphere cultures, 
demonstrated that each subpopulation type displayed distinct features of glioblastomas, 
suggesting that both culture conditions are potentially useful tools to improve our 
understanding of this disease250. Furthermore, most of our knowledge of cancer biology is 
based on studies analysing adherent cells grown in serum-containing medium and many assays 
were developed and validated using these culture conditions.  
In conformity with this evidence, the first aim of my project was to optimize a clonogenic 
survival assay to compare sensitivity of GSCs and non-GSCs to various treatments, the former 
grown as neurospheres, the latter as adherent cultures. As described in detail in the first part 
of this chapter, my approach consisted in optimizing the neurosphere formation assay, in 
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terms of plating accuracy and time consumption, and then creating an adapted version of the 
standard clonogenic survival assay. 
The normal stem cell field has also produced exciting advances in 3-dimensional (3D) cell 
culture models, which need to be implemented as fundamental tools to investigate CSC 
behaviour and treatment-response in conditions that resemble more closely their tumoral 
niche, given the data, discussed in the general introduction, regarding the emerging role of the 
microenvironment in GSC biology. The second part of this chapter illustrates the experiments 
that I carried out to optimize the use of a 3D model to analyse features of GSCs and non-GSCs 
in the presence of various elements of their tumoral niche and to evaluate whether these 
factors influence response of the two subpopulations to cytotoxic treatments, particularly to 
ionizing radiation. 
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3.2 Optimizing the clonogenic survival assay  
The first aim of my project was to optimize a clonogenic survival assay to compare sensitivity 
of GSCs and non-GSCs to ionizing radiation and cytotoxic agents. For the initial steps in the 
optimization process, I used U87 MG cells that had been cultured in ‘GSC-medium’ (see section 
2.2.1) and formed neurospheres.  
I started by seeding increasing numbers (25, 50, 100, 250, 500 and 1000) of cells in a 24-well 
plate and observed them daily: sphere-looking aggregates were seen as soon as day 1; by day 
7, wells plated with 1000 cells contained up to 40 spheres; from day 9, the number of sphere-
looking aggregates started to decrease due to merging of various aggregates. I could not 
identify any differences in the appearance between sphere-looking aggregates formed at day 1 
and those formed later on. 
I then selected U87 cells cultured in ‘GSC-medium’ for CD133 expression using magnetic 
sorting and seeded increasing numbers (100, 250 and 500) of CD133+ and CD133- cells in a 24-
well plate. Again sphere-looking aggregates were present very early, at day 3; by day 5, there 
were up to 26 sphere-looking aggregates in wells plated with 500 CD133+ cells; from day 7, the 
number of sphere-looking aggregates in the CD133+ plate started to decrease due to merging 
of various aggregates. There was no difference in the maximum number of sphere-looking 
aggregates per well counted in CD133+ and CD133- plates. 
Given that U87 cells have a cell cycle of about 24 hours, I concluded that spheres observed at 
days 1 and 3 and part of those observed at later time points were due to cell clumping. The 
decrease in the number of spheres after day 7 was consistent with this interpretation. Hence, 
to completely exclude this phenomenon, I decided to perform all clonogenic survival assays in 
96-well plates by seeding cells at a density of one cell per well. I also chose to abandon CD133 
magnetic sorting to select for stemness, following the interpretation of the above lack of 
difference in the light of published data showing that CD133- cells, as well as CD133+ cells, 
displayed GSC features153. Based on increasing evidence that specific culture conditions enrich 
or deplete cellular populations for stemness, I decided to use this method to obtain matched 
GSC and non-GSC subpopulations162, 163.   
I tested two methods to seed one cell per well, using mostly G7 GSCs: serial dilution and cell-
sorting with FACSAria I. I evaluated precision of serial dilution, by seeding cell populations in 
multiple flasks at different times and observing the cells down the microscope in the following 
days. The percentage of wells with cells had a variation of less than 5% within each sample and 
more than 95% of positive wells had single cells when observed on the same day. Given that 
other studies had reported the use of FACSAria to seed GSC populations as single cells in 96-
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well plates, I tested the effect on neurosphere formation rate of sorting G7 GSCs through this 
flow-cytometer: there was a reduction of at least 25% in the number of neurospheres when 
cells were seeded with FACSAria, compared to manual plating based on serial dilution, even 
when the 100 μm nozzle and low pressure mode were used to sort cells. Based on these 
findings and on published data, suggesting that hydrodynamic forces generated in flow 
cytometers cause significant cell damage and apoptosis, I decided to use serial dilution to seed 
one cell per well251. 
The next step was to optimize the assay in terms of time consumption of the colony counting 
step, which until then was performed by scoring the presence of neurospheres under the 
microscope. To achieve this, I tested the feasibility of using a colony counter, GelCountTM, to 
quantify the number of neurospheres. This system identifies colonies based on several 
parameters, such as shape, density and size. Once the optimal settings to identify G7 
neurospheres were determined, all plates were scored with GelCountTM. A representative 
image of the bitmap generated by the software is shown in figure 3.1. The only necessary 
procedure, prior to counting, was filling the wells with PBS, making sure no bubbles formed. 
This was to avoid artefacts that could hamper colony detection, such as those shown in figure 
3.2. 
Given that my aim was to optimise a method to compare sensitivity of GSCs and non-GSCs to 
ionizing radiation and cytotoxic agents, I then tested whether a clonogenic assay with one cell 
per well in 96-well plates was also feasible with non-GSCs, which formed adherent colonies. As 
shown in figure 3.3, colonies were visible and easily identifiable following methylene blue 
staining. 
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Figure 3.1 Representative image of bitmap created by GelcountTM.
Above is the image of the entire 96-well plate, while below are enlargements showing two wells, each 
one containing a colony identified by the counter and marked with a red triangle. 
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Figure 3.2 Representative images of artefacts created by suboptimal filling of the wells and the 
presence of large or small air bubbles.  
Incomplete filling of wells results in the presence of a dark meniscus on the periphery of the well, which 
can hamper detection of colonies in that area (red arrow in the top image indicates a colony which had 
been missed by the software and was subsequently identified by me while viewing the images on the 
monitor). Two examples of meniscus are shown in the top and central images.  
Artefacts created by large and few small air bubbles are shown in the central and bottom images, 
respectively.
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 Figure 3.3 Representative images of 96-well plates with adherent colonies stained with methylene blue. 
 Plates were seeded with G7 non GSCs, treated with 0, 2, 3 and 5 Gy, incubated for 15 days and stained with methylene blue. Red arrows indicate colonies. 
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3.3 Preliminary evaluation of sensitivity to ionizing radiation and DNA repair inhibitors. 
I performed clonogenic assays with G7 and E2 matched GSCs and non-GSCs to compare their 
intrinsic radiosensitivity. I observed no difference in survival between the two subpopulations 
of G7 cells, while, amongst E2 cells, non-GSCs were more radioresistant (see figure 3.4). 
Keeping in mind that only G7 cells’ data represent results of three independent experiments, 
they are consistent with findings from a study which reported no difference in clonogenicity in 
one of the two tested cell lines, but in contrast with the other studies which showed that GSCs 
are more radioresistant than non-GSCs152, 236-238. This inconsistency is probably due to 
variations in experimental procedures, given that one of the above studies used the same cell 
lines, i.e. G7 and E2, though cultured in different medium, and performed clonogenic survival 
assays with another protocol238.  
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Figure 3.4 Preliminary clonogenic survival assays comparing radiosensitivity of G7 and E2 matched 
GSCs and non-GSCs.  
G7 GSCs and non-GSCs showed no difference in survival (A), while E2 GSCs were more sensitive than 
matched non-GSCs (B). A. Results for G7 cells are representative of three independent experiments. 
Error bars indicate means ± SD. B. Each data point for E2 cells is derived from the mean of the number 
of colonies counted in two 96-well plates.
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I also performed preliminary clonogenic assays with G7 matched GSCs and non-GSCs 
comparing their sensitivity to a PARP inhibitor, AZD2281. GSCs were more resistant compared 
to non-GSCs, which showed a dramatic decrease in survival. Again, keeping in mind that these 
results are preliminary and that they need to be confirmed and tested in other cell lines, they 
are in contrast with published data showing that GSCs are more sensitive to PARP inhibition112. 
Though, this inconsistency is likely to be cell line dependent, given that G7 non-GSCs were very 
sensitive to relatively low doses of the PARP inhibitor AZD2281.  
Detailed analysis of intrinsic cellular radiosensitivity and radiation responses of GSCs, as well as 
exploring the possible role of DNA repair inhibitors as radiosensitizers, was not the scope of 
my project. This field was and is being investigated further by other members of the Anthony 
Chalmers laboratory.  
Figure 3.5 Preliminary clonogenic survival assays comparing sensitivity of G7 matched GSCs and non-
GSCs to PARP inhibition.  
G7 non-GSCs were more sensitive to AZD2281 than GSCs, showing a marked reduction in survival. Each 
data point is derived from the mean of the number of colonies counted in two 96-well plates.
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3.4 Optimizing the use of a 3D culture system for GSCs and non-GSCs. 
The second part of this chapter covers optimization of the use of a 3D system to culture GSCs 
and non-GSCs in the presence of microenvironmental factors from the tumoral niche and test 
the effect of these on responses of the two subpopulations to ionizing radiation and cytotoxic 
agents.  
Amongst the various 3D culture systems, Anthony Chalmers (my supervisor at the time) and I 
chose to test the use of a 200 µm thick polystyrene scaffold, named Alvetex® (see figure 3.6), 
for numerous reasons. A) It allows several molecular and cellular techniques to be carried out 
on cells grown on it, such as: tissue processing, fixation, embedding and sectioning; histological 
staining; cryostat sectioning; immunocytochemistry; bright-field, fluorescence, confocal and 
electron microscopy; isolation of viable cells for passaging; isolation of cells for FACS, 
extraction of nucleic acid and total protein. B) Its composition, i.e. polystyrene, is inert and is 
the same as that of flasks used in tissue culture; hence, it is unlikely to introduce unknown 
effects on cells from other materials. C) It does not require specific medium or culture 
conditions, allowing us to continue growing GSCs and non-GSCs in their respective media. D) It 
is extremely user-friendly.  
The choice of Alvetex® for our project, whose ultimate aim was to create a 3D model that 
would allow us to measure toxicity of various treatments on GSCs in a more reliable and 
clinically relevant system, was also supported by data (published at the time) reporting its use 
for hepatotoxicity studies, showing the superiority of this 3D system in terms of maintenance 
of cell structure, function and viability, compared to 2D cultures252. Since I started optimizing 
its use for our purpose, several other investigators employed Alvetex® to study various aspects 
of normal and cancer cells, suggesting that it is a very flexible system that could be used 
routinely to investigate cellular responses in a 3D tissue culture model, possibly replacing 
xenografts in some experiments253.  
The first step was to verify whether G7 GSCs were able to grow within the scaffold. I stained 
with Draq5 G7 GSCs that I’d previously seeded onto the scaffold and left to grow in the 
incubator for 7 days. As shown in figure 3.7, G7 GSCs were present deep in the scaffold. I then 
confirmed that the cells had grown in the whole thickness of the scaffold by analysing the 
distribution of G7 GSCs in frozen sections (see figure 3.8).  
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Figure 3.6 Images showing the 3D culture system Alvetex®. 
On the left is a scanning electron microscope (SEM) image, showing the architecture of the scaffold. On 
the right is a photo of the 12-well plate format. Both images are taken from the Reinnervate brochure.
Figure 3.7 G7 GSCs are able to grow within the scaffold. 
On the left, confocal microscope images taken with brightfield and fluorescence mode of G7 GSCs grown 
within the scaffold (fresh sample); red circle indicates cells stained with Draq 5™, shown in red. On the 
right, z-stack of same set of images; red and green lines indicate corresponding points in the orthogonal 
planes, showing localization of stained cells within the pictured scaffold (20x).
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Figure 3.8 G7 GSCs are able to grow through the whole thickness of the scaffold. 
Confocal microscope images of G7 GSCs grown within the scaffold (sections of frozen sample), taken 
with bright-field and fluorescence mode. Sections of frozen samples were cut along the width of the 
scaffold, with increasing thickness, as indicated in lower left corner of z-stack images (A bottom right, B 
and C). Nuclei of cells are stained with Hoechst (shown in red). In z-stack images, red and green lines 
indicate corresponding points in the orthogonal planes, showing localization of stained cells within the 
pictured scaffold. 
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The second step was to verify the feasibility of coating the scaffold with ECM components. I 
tested a commercially available ECM mixture first, and then a specific combination of some of 
the ECM components which have been shown to compose the vascular basement membrane 
in glioblastomas, i.e. collagen, fibronectin, laminin and vitronectin254. Figures 3.9 and 3.11.A 
demonstrate the ubiquitous distribution of fibronectin in fresh portions and in sections of 
frozen samples of the scaffold, while figure 3.10 shows the specificity of the anti-fibronectin 
antibody binding. I then seeded G7 GSCs on scaffolds coated with the specific mixture, 
showing that they were able to grow within the scaffold in the presence of the ECM 
components (see figure 3.11.B).  
Coating the scaffold with customized mixtures of ECM components is valuable as it allows 
analysis of specific interactions of GSCs and non-GSCSs with one or more of these 
microenvironmental factors in a 3D culture system. This is particularly intriguing following 
recently published data, suggesting that these interactions need to be studied from two 
different perspectives. 1) How ECM components, present in the tumoral niche, influence GSC 
behaviour; an example of this is the role of laminin α2 expressed on tumour-associated 
endothelial cells in maintenance of GSCs (see perivascular niche section)210. 2) How GSCs 
modulate the microenvironment. This is suggested by a study, analysing mRNA and protein 
expression in GSCs as they differentiate: following exposure to serum in vitro, there was an 
increase in cell adhesion molecules, such as integrin α2 and αV, and ECM components, such as 
collagen IV, fibronectin and laminin; also, a treatment schedule combining TMZ with RGD 
peptide, which inhibits the interaction between integrins and fibronectin, resulted in 
prolonged survival of xenograft models obtained by injecting GSCs intracranially255. Based on 
these findings, the authors suggested that, by inducing an increase in certain ECM 
components, GSCs create a specific “differentiation niche”, which promotes tumour 
recurrences; they propose targeting the interaction between GSCs and ECM as a therapeutic 
strategy against glioblastomas. Given that in this and in many other studies GSCs are simply 
seeded onto uncoated or ECM-coated dishes to mimic interactions in the tumoral niche, it 
follows that a 3D system, like Alvetex®, in which cancer cells are able to grow up to several 
weeks in the presence of exogenous or secreted ECM components, is likely to improve the 
methodology and produce more reliable and clinically relevant results.   
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Figure 3.9 The scaffold is coated homogenously and ubiquitously with ECM mixture. 
The sequence of images displays rotation of the 3D reconstruction of a z-stack of fluorescence confocal microscope images, showing distribution of anti-fibronectin 
antibody (green) on ECM-coated scaffold.
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Figure 3.10 Binding of anti-fibronectin antibody is specific. 
On the left, fluorescence confocal microscope image showing distribution of anti-fibronectin antibody 
(green) on ECM-coated scaffold. On the right, isotype control (40x). 
Figure 3.11 ECM-coating is present in the whole thickness of the scaffold and G7 GSCs are able to grow 
within the coated scaffold. 
A. Fluorescence confocal microscope image of section of frozen sample, showing distribution of anti-
fibronectin antibody (green) in the whole thickness of scaffold; nuclei of cells are stained with DAPI, 
shown in blue (20x). B. Fluorescence confocal microscope z-stack image of fresh sample, showing nuclei 
of G7 GSCs (stained with DAPI, blue) grown within a scaffold coated with an ECM mixture containing 
fibronectin, detected with an anti-fibronectin antibody, shown in green (40x).  
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The next step was to verify whether cells grown on the scaffold could be characterized for 
expression of stem cell markers. I stained GSCs and non-GSCs grown within the scaffold for 
Nestin and SOX2. As seen in figure 3.12, this experiment confirmed that characterization was 
possible and, most importantly, that GSCs had higher levels of stem cell markers than non-
GSCs, i.e. cells grown on the scaffold exhibited patterns of stem cell marker expression 
consistent with their differentiation status. 
Figure 3.12 G7 GSCs grown within the scaffold express higher levels of SOX2 and Nestin compared to 
G7 non-GSCs. 
Fluorescence confocal microscope images of G7 GSCs (A and C) and non-GSCs (B and D), showing 
expression of SOX2 (A and B) and Nestin (C and D). Both markers are shown in green, nuclei of cells were 
stained with DAPI, shown in blue (40x). 
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For the rest of my immunofluorescence experiments with cells grown within the scaffold, I 
decided to stop using sections of frozen samples and continued working only with fresh ones, 
given that: 1) confocal microscopy allowed me to image groups of cells within the scaffold 
without having to section it; 2) avoiding all the steps involved in freezing and sectioning was 
likely to result in more accurate images; 3) fresh samples were less time consuming. However, 
testing the feasibility of imaging our populations of cells within sections of frozen and paraffin 
embedded (data not shown) samples was an important step in the preparation of another 
project that is being pursued by other members of the Anthony Chalmers laboratory at the 
University of Glasgow, using this 3D in vitro culture system in conjunction with frozen or 
paraffin embedded glioblastoma patient specimens to further characterize GSCs and their 
interaction with microenvironmental factors. Figure 3.13 shows images of the preliminary 
experiments I contributed to, in which we used the same antibodies as for the scaffold to 
analyse distribution of fibronectin, nestin and SOX2, in patient samples.  
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Figure 3.13 Fibronectin, nestin and SOX2 distribution in glioblastoma patient specimens. 
Representative light microscope images of sections of paraffin embedded patient specimens stained 
with immunohistochemistry, using HRP detection (brown), for fibronectin (A), nestin (B) and SOX2 (C), 
followed by counterstaining with haematoxylin (light blue). The images on the right show enlarged 
views of selected areas (indicated by black rectangles) from each image on the left. Red arrows indicate 
examples of blood vessels.  
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3.5 Optimizing the use of Alvetex® to study radiation responses of GSCs and non-GSCs. 
Once I demonstrated that GSCs and non-GSCs could be cultured on the scaffold in the 
presence of microenvironmental factors, I started testing whether studying radiation 
responses in the same model was feasible. Besides clonogenic survival assays, which represent 
the gold standard method, radiosensitivity of cancer cells is measured by quantifying induction 
and resolution of phosphorylated histone H2A (gamma H2AX), as a surrogate marker of DNA 
double strand break repair, and evaluating percentage of apoptotic cells following ionizing 
radiation. Hence, I tested whether quantifying gamma H2AX foci in cells grown and irradiated 
within the scaffold was possible. Figure 3.14 shows representative images of G7 GSCs cultured 
on Alvetex® and analysed for gamma H2AX at 1, 4 and 24 hours, following treatment with 3 
Gy. 
Figure 3.14 G7 GSCs grown and irradiated within the scaffold can be evaluated for formation and 
resolution of gamma H2AX foci. 
Fluorescence confocal microscope images of G7 GSCs, showing gamma H2AX (in green) and CENP-F (in 
red) staining, at 0, 1, 4 and 24 hours (from left to right) after treatment with 3 Gy; nuclei of cells were 
stained with DAPI, shown in blue (40x). 
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In order to optimize this assay, first I used deconvolution to improve the contrast and 
resolution of gamma H2AX foci and then the 3D view on the Imaris (version 6.3.0; Bitplane) 
software, which allows an interactive visualization of the entire z-stack. As seen in figure 3.15, 
with this processing technique, foci appeared clearer and more distinct.  
Figure 3.15 Use of deconvolution and Imaris software 3D view to optimize gamma H2AX foci counting 
in cells grown and irradiated within the scaffold. 
3D view on Imaris software of deconvolved fluorescence confocal microscope images of G7 non-GSCs, 
showing gamma H2AX (in green) and CENP-F (in red) staining, at 0, 1, 4 and 24 hours (from left to right) 
after treatment with 2 Gy; nuclei of cells were stained with DAPI, shown in blue (63x). 
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Then, in order to reduce the variability in foci counting related to the state (i.e. tiredness) of 
the operator, I evaluated the feasibility of quantifying gamma H2AX foci by using the Imaris 
software, and specifically the ‘spot function’. In figure 3.16, an example of a deconvolved 
image of G7 GSCs viewed and processed with Imaris shows how foci are identified and marked 
with the ‘spot function’, demonstrating that this is feasible and accurate, especially as the 
operator can easily check the results on the computer monitor.  
Figure 3.16 Use of the ‘spot function’ on the Imaris software to identify gamma H2AX foci in cells 
grown and irradiated within the scaffold. 
3D view on Imaris software of deconvolved fluorescence confocal microscope images of G7 GSCs, 
showing gamma H2AX (in green) and CENP-F (in red) staining 1 hour after treatment with 3 Gy; nuclei of 
cells were stained with DAPI, shown in blue (63x). Each identified focus is marked with a white sphere. 
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Given that the output of the software in terms of number of spots (i.e. foci) is referred to the 
entire image, the next step was to establish the most accurate and user-friendly way to obtain 
a quantification of the spots per cell. I tested whether the ‘area of interest function’ was an 
appropriate tool to identify each cell in the images, but found that it was extremely time-
consuming and was not suitable for my purpose, given the shape and spatial distribution of the 
cells in the various planes. Furthermore, data from the mitotic kinase project indicated that it 
was not accurate to estimate the DNA content of GSCs simply by performing DAPI probing 
without co-staining with markers for cell cortex, as GSCs have a slightly higher percentage of 
polynucleated cells and often present nuclei of irregular shapes (see section 4.3). Given these 
findings, I tested whether the volume rendering algorithm in the Imaris software was an 
appropriate tool to obtain a reproducible quantification of nuclear volume, which could be 
used as a denominator to normalize the number of foci. Figure 3.17 shows a representative 
image of the view of the volume rendering, together with the ‘spot function’, on the monitor 
of the Imaris workstation. Figure 3.18 displays the data from one of the experiments that I 
carried out during the optimization process, comparing induction and resolution of radiation 
induced gamma-H2AX foci in cells grown and irradiated within the scaffold and on coverslips. 
Differently to other studies that quantified radiation-induced gamma-H2AX foci per cell, 
showing no difference between GSCs and non-GSCs at early time points238, 242, these 
preliminary results suggest that the two subpopulations differ in their DNA repair ability 1 hour 
post-irradiation. Though, interpretation of these findings with regards to DNA damage 
induction and resolution in GSCs and non-GSCs needs to be cautious as further testing and 
validation is warrented.  
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Figure 3.17 Use of the ‘spot function’ and the volume rendering algorithm on the Imaris software to 
quantify nuclear volume of cells grown within the scaffold. 
3D view on Imaris software of deconvolved fluorescence confocal microscope images of G7 GSCs, 
showing gamma H2AX (in green) staining 1 hour after treatment with 3 Gy; nuclei of cells were stained 
with DAPI, shown in blue (63x). Each identified focus is marked with a white sphere (central image). On 
the right, example of visualization of volume rendering of DAPI staining.  
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Samples and treatment DAPI Volume (μm
3
) Number of foci Foci/volume ratio
GSCs (3D)
0 Gy
3 Gy 1h
3 Gy 4hh
3 Gy 24hh
72862
182136
79705
86144
410
4862
880
426
0.006
0.027
0.011
0.005
Non-GSCs (3D)
0 Gy
3 Gy 1h
3 Gy 4hh
3 Gy 24hh
51612
53168
39064
42422
85
767
512
103
0.002
0.014
0.013
0.002
2D non-GSCs
0 Gy
3 Gy 1h
3 Gy 4hh
3 Gy 24hh
84062
103820
88474
67483
250
2219
1365
442
0.003
0.021
0.015
0.007
Figure 3.18 Use of the ‘spot function’ and the volume rendering algorithm on the Imaris software to 
quantify induction and resolution of radiation induced gamma-H2AX foci in cells grown and irradiated 
within the scaffold and on coverslips. 
In the table above, output data obtained by processing deconvolved fluorescence confocal microscope 
images with the ‘spot function’ and the volume rendering algorithm on the Imaris software. Images of 
cells stained for gamma H2AX were taken at 0, 1, 4 and 24 hours after treatment with 3 Gy. The 
foci/volume ratios are plotted in the graphs at the bottom, as raw data on the left, as normalised to 
untreated on the right. 
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One of the potential benefits of normalizing the number of foci to the DAPI content with the 
volume rendering algorithm is that it addresses possible variations in DNA content between 
two populations, i.e. it reduces the known inaccuracies due to differences in cell cycle 
distribution256.  Other studies, that developed the use of computer software modules to 
automatically interpret and/or count foci on microscopy images, validated them by comparing 
their output with the most commonly used method, i.e. manual counting either directly 
viewing the samples with a microscope or subsequently looking at previously captured images 
on a monitor257. I did not perform correlation analysis with manual foci quantification, because 
I routinely carefully inspected all images processed with the ‘spot function’ to correct any 
misinterpretations. In fact, the above experiments were not designed to develop a fully 
automated interpretation tool for counting foci, but rather a semi-automated one with the aim 
of improving the accuracy of simple visual interpretation, while reducing time-consumption. 
Other evaluations of the accuracy of this approach, such as correlation with clonogenic survival 
data, would be difficult to interpret, given that previous studies have not found positive 
results258. 
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Finally, I tested whether I could evaluate apoptosis in cells grown and irradiated within the 
scaffold by quantifying the number of cleaved caspase 3 positive cells. As seen in figure 3.19, 
GSCs stained for cleaved caspase 3 are easily identified and quantified. 
Treatment
Cleaved caspase 3 + 
cells/total number of 
cells
Normoxia Hypoxia
0 Gy 6/353 3/196
3 Gy 12 hh 7/526 1/198
3 Gy 18 hh 36/691 8/326
3 Gy 48 hh 10/407 7/429
Figure 3.19 G7 GSCs grown and irradiated within the scaffold can be evaluated for apoptosis rates. 
A and B. Fluorescence confocal microscope images of G7 GSCs, showing cleaved caspase 3 (in green) 
staining, at 0 and 18 hours (from left to right) after treatment with 3 Gy; nuclei of cells were stained 
with DAPI, shown in blue (40x). Red arrows indicate apoptotic cells. C. Data obtained by quantifying 
cleaved caspase 3 positive cells in fluorescence confocal microscope images viewed on the Imaris 
software. Images of G7 GSCs, grown within the scaffold in incubators with 21% (normoxia) and 3% 
(hypoxia) pO2, were taken at 0, 12, 18 and 48 hours after treatment with 3 Gy. D. The percentages of 
cleaved caspase 3 positive cells are plotted in the graph.  
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3.6 Discussion 
In this chapter, I describe optimization of methods to study both GSCs and non-GSCs. These 
tools allow analysis of treatment responses related to intrinsic cellular characteristics as well as 
those induced by microenvironmental factors. 
For the clonogenic survival assay, I adopted a different approach to those used in the 
published studies comparing radiosensitivity in GSCs and non-GSCs. Bao et al. chose to expose 
both subpopulations to serum-free medium without growth factors for 24 hours post-
treatment and then changed to serum-containing medium to induce attachment and allow 
colony visualization with the standard methylene blue staining method152. Mc Cord et al. used 
poly-L-lysine coated wells with serum-free medium for both subpopulations236. These studies 
selected GSCs and non-GSCs based on CD133 expression and applied the same growth 
conditions to all the cells. Their approach has the advantage of evaluating radiosensitivity by 
quantifying the same type of colony grown in the same conditions, but it has the limitation of 
using pro-attachment methods (addition of serum to medium, withdrawal of growth factors, 
exposure to poly-L-lysine) that are likely to induce pro-differentiation signals in GSCs. 
Carruthers et al. plated GSCs in serum-free medium and non-GSCs in serum-containing 
medium, seeding both subpopulations in Matrigel™-coated 6 wells dishes238. Therefore, they 
used the culture condition to select for stemness and induced growth of GSCs as adherent 
monolayer cultures by plating them on Matrigel™, a technique routinely used in several of 
their experiments, including the tumorigenicity assay. This approach has the advantage of 
analysing radiosensitivity maintaining the two subpopulations in their culture conditions and, 
at the same time, evaluating similar types of colonies. As briefly mentioned in the introduction 
to this chapter, I chose a strategy that combined the neurosphere formation assay with an 
adapted version of the standard clonogenic survival assay, given that both in vitro techniques 
have been correlated to clinical outcome of cancer patients259, 260. It is not possible to predict 
which approach is the most clinically relevant one based on published data. This evaluation 
would need a comparative study of the various methods analysing radiosensitivity of several 
patient derived primary cell lines and calculating the correlation of each set of results with 
clinical outcome.  
Concerning the 3D model, I have already analysed the rationale for choosing and optimizing 
the use of Alvetex® to culture GSCs and non-GSCs. Comparing my experience to published data 
regarding the use of 3D systems to culture glioblastoma cells, my work gives additional 
contributions to this field, given that other studies have simply grown cells within the chosen 
3D model, without introducing elements of the tumoral niche261, 262. The only exception is a 
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pre-implantation co-culture with endothelial cells for a tumorigenicity assay in a study 
analysing regulation of GSCs by IL-8; no other evaluation of the effects of this interaction on 
the 3D system was reported by the authors209. Not only I have shown that GSCs and non-GSCs 
can grow on the scaffold in the presence of several microenvironmental factors, I have also 
demonstrated that these cells can be interrogated in these conditions with regards to their 
response to treatment, quantifying DNA damage surrogate markers and apoptosis. The next 
step will be to assess how this 3D culture system compares to in vivo models in terms of 
clinical relevance, evaluating the possibility of replacing animals for a portion of the pre-clinical 
investigational studies. I was not able to start this work due to the lack of facilities to create 
intracranial xenografts at University of Sussex. Other members of Anthony Chalmers 
laboratory in Glasgow generated these in vivo models using G7 and E2 cell lines and are 
currently developing this research area. 
In conclusion, I propose that the techniques I have optimized are useful tools that are likely to 
allow a more comprehensive approach in glioblastoma research and a better selection of 
therapeutic agents for in vivo pre-clinical experiments. 
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Chapter 4 
Glioblastoma stem cells are highly sensitive to subtle changes  
in Aurora kinase A activity 
81
4.1 Introduction 
Processes involved in mitosis are targeted by two main treatment modalities that are currently 
under investigation in clinical trials in glioblastoma patients (discussed in the first section of 
the general introduction): 
- the tumour treating fields (TTF), consisting in alternating electric fields, which cause cell 
death of the proliferating tumour population; although the mechanism underlying their 
cytotoxic effect is not fully clarified, proposed modes of action mainly involve cell division, 
with disruption of mitotic spindles during the metaphase to anaphase transition and 
aggregation of macromolecules and organelles during telophase36;  
- microtubule inhibitors, which cause cell death through stabilization of microtubules, 
disrupting intracellular transport during interphase and spindle assembly during mitosis263.  
Given that these therapeutic strategies have quite a broad mechanism of action and based on 
the increasing evidence associating specific mitotic kinases with GSC biology, I decided to 
adopt a focused approach, investigating mitotic phenotypes and characterizing cellular factors 
involved in asymmetric cell division, one of the key features of CSCs141. 
I will now give a brief introduction on general concepts related to mitosis, starting with a 
review of the literature on asymmetric cell division. 
Most of the current knowledge on asymmetric cell division is based on studies using 
Drosophila melanogaster and Caenorhabditis elegans, i.e. fly and worm models. Four main 
steps are involved in asymmetric cell division: 1) symmetry is broken; 2) polarity is established; 
3) fate determinants are segregated in specific regions; 4) mitotic spindle is positioned so that 
the fate determinants are correctly distributed in the two daughter cells264. A major role in 
these steps is played by the centrosome, the main microtubule organising centre in 
proliferating mammalian cells, which coordinates mitosis, cell polarity and motility265. Each 
centrosome is formed by two centrioles, composed of tubulin polymers and surrounded by a 
matrix of proteins, known as the pericentriolar material (PCM), comprising mainly pericentrin 
and γ-tubulin. During the cell cycle, centrosomes undergo the following changes: in G1, the 
pair of centrioles is surrounded by a relatively small amount of PCM; during S phase, centrioles 
duplicate; in G2, more abundant PCM accumulates around the centrioles, allowing them to 
organize the microtubules that form the mitotic spindle during M phase266. This process by 
which centrosomes form the two poles of the mitotic spindle in a dividing cell is regulated by 
several proteins, such as Plk1, Plk4, Aurora kinase A (AurA), Cyclin dependent kinase 1 
(Cdk1)267. Given that the general principle and several genes encoding for symmetry regulators 
are conserved through species, findings from these studies have formed the bases of our 
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understanding of asymmetric cell division in normal stem cells. Though, whether and how 
these mechanisms apply to CSCs is still mostly unknown, suggesting the need for studies 
investigating mitotic phenotypes and characterizing structural and functional features of 
centrosomes and their regulatory proteins in GSCs and non-GSCs. These studies are also 
supported by data showing that: centrosome abnormalities are implicated in tumour 
initiation268; altered centrosomes are present in brain tumour patient specimens269; 
centrosome regulatory kinases, such as Plk1 and AurA, are overexpressed in glioblastomas and 
their expression levels are correlated to patient outcome245, 270-274.  
In this chapter, I report the results of my analysis of mitotic spindle and centrosome 
morphology in GSCs and non-GSCs. Based on the observation of a higher level of spindle 
abnormalities and a more pronounced maturation of centrosomes preceding cell division in 
GSCs, I explore whether these cells have an increased requirement for AurA activity, 
investigating the effects of the selective AurA inhibitor MLN8237 on the two subpopulations. 
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4.2 Glioblastoma stem cells have higher levels of mitotic spindle abnormalities
Cell division of GSCs remains poorly characterized. To my knowledge, the only publication 
analysing this process focused on examining the modes of cell division, i.e. symmetric or 
asymmetric, used to maintain a pool of GSCs141. Given the lack of data on GSC mitosis, I 
decided to start with analysing mitotic spindle phenotypes in GSCs and non-GSCs, using 
immunofluorescence and staining the two subpopulations for α-tubulin and γ-tubulin, as a 
method to visualize spindle microtubules and the PCM, respectively. I observed that there 
were significantly more abnormal mitotic spindles (monopolar and multipolar) in GSCs than in 
non-GSCs: in the G7 cell line, the percentages were 14% vs 4%, respectively (see figure 4.1.A). 
Figures 4.1.B-D show representative images of bipolar, monopolar and multipolar spindles. I 
then verified whether the difference in mitotic spindle abnormalities was a consequence of 
growth in suspension. I cultured non-GSCs as non-adherent aggregates by using tissue culture 
plastics that would not allow attachment. All randomly imaged mitotic cells had bipolar 
spindles, suggesting that growth conditions are not a confounding factor for the observed 
mitotic defects.  
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Figure 4.1 GSCs have a higher percentage of abnormal mitotic spindles than non-GSCs. 
GSCs and non-GSCs were stained for α tubulin (green), γ tubulin (red) and DAPI (blue), to visualize 
mitotic spindle morphology. A. A graph displays the percentages of normal and abnormal spindles in G7 
GSCs and non-GSCs. An average of 26 mitotic cells/condition/experiment were randomly imaged and 
scored. Results are representative of three independent experiments. Error bars indicate means ± SD 
(*p=0.0232, two tailed t-test). B-D. Representative images of mitotic phenotypes observed in G7 GSCs: 
bipolar (B), monopolar (C) and multipolar (D). Scale bar 2µm.  
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4.3 Glioblastoma stem cells have higher percentages of polyploid cells 
In order to evaluate the consequences of the observed mitotic abnormalities in terms of 
aneuploidy, I analysed metaphase chromosome spreads. As seen in figure 4.2, examination of 
GSCs showed the presence of cells with large numbers of chromosomes. Given that cells in 
suspension tend to form aggregates and that, while evaluating mitotic spindles, I often noted, 
in the GSC subpopulation, two or more nuclei in close vicinity (see figure 4.3), I speculated that 
the difference in chromosome numbers between the two populations could be a consequence 
of cell clumping as well as a sign of polyploidy resulting from mitotic failure. In order to 
distinguish clumps from polyploid cells, I analysed both subpopulations following staining with 
phalloidin, a dye that allows visualization of the cell cortex. I found that, amongst GSCs, 
polyploid cells were much more frequent than in the non-GSC subpopulation: in the G7 cell 
line, the percentages were 25% vs 6%, respectively (see figure 4.4.A). Figures 4.4.B-C show 
representative images of GSCs and non-GSCs stained with phalloidin. These findings suggest 
that the higher percentage of mitotic spindle abnormalities results in higher levels of 
aneuploidy in GSCs. 
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Figure 4.2 Chromosome spreads of GSCs show considerable numerical abnormalities.  
Representative images of chromosome spreads of G7 GSCs (A-C) and non-GSCs (D). 
Figure 4.3 Observation of the GSC subpopulation shows several cellular images with two or more 
nuclei in close vicinity.   
GSCs were stained for α tubulin (green), γ tubulin (red) and DAPI (blue). Representative images of G7 
GSCs, with one nucleus undergoing mitosis and the other in interphase. Scale bar 2µm.  
A B
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Figure 4.4 GSCs have a higher frequency of polyploid cells. 
GSCs and non-GSCs were stained with phalloidin (red) and DAPI (blue) to visualize the cell cortex and 
nucleus. A. A graph shows the percentages of polynucleated cells in GSCs and non-GSCs. An average of 
251 cells/condition/experiment were randomly imaged and scored. Results are representative of three 
independent experiments. Error bars indicate means ± SD (*p=0.000275, two tailed t-test). B-C.
Representative images of GSCs (B) and non-GSCs (C). Arrows show polyploid cells. Scale bar 10µm.  
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4.4 Glioblastoma stem cells show a distinct centrosome cycle 
Given that centrosomes have a pivotal role in mitotic spindle assembly, I investigated whether 
there were any distinctive features in the centrosome cycle of GSCs and non-GSCs. As a 
measure of centrosome maturation, i.e. the process by which PCM proteins accumulate 
around the centrioles in preparation for mitosis, I analysed distribution of γ-tubulin, one of the 
main PCM proteins, during the cell cycle. I quantified the size of centrosomal γ-tubulin 
staining, obtained with immunofluorescence, in interphase and mitotic cells from the two 
subpopulations. I then calculated the ratio between centrosomal γ-tubulin in mitotic and 
interphase cells to obtain a numerical estimate of accumulation of this protein at the 
centrosomes. GSCs exhibited a more pronounced accumulation of γ-tubulin at the 
centrosomes, with a ratio more than twofold higher than that of non-GSCs in the G7 cell line 
(see figure 4.5.A). Representative images from the two subpopulations are shown in figures 
4.5.B-C.  
In order to verify that the observed γ-tubulin staining was centrosomal, I tested whether it co-
localized with centrin, a protein present in centrioles and PCM. As seen in figure 4.6, the 
centrosomal specificity of γ-tubulin staining was confirmed. Furthermore, a preliminary 
analysis of centrin distribution in interphase cells of the two subpopulations showed that 
amongst GSCs there were higher percentages of cells with increased centrosome staining 
compared to non-GSCs, suggesting more frequent centriole numerical abnormalities: 32% vs 
17% in G7 GSCs and non-GSCs, respectively.  
Taken together, these findings support the hypothesis that there are structural and/or 
functional differences between GSCs and non-GSCs with regards to centrosomes, suggesting 
the importance of investigating in detail regulatory proteins involved in the centrosome cycle, 
as a strategy to find specific therapeutic targets to kill GSCs. Amongst the various mitotic 
kinases, I decided to focus on AurA, a member of the Aurora kinase family that, differently to 
its paralogues B and C, mainly implicated in chromosome dynamics, is primarily involved in 
centrosome function and is one of the major regulators of its maturation. 
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Figure 4.5 GSCs have a more pronounced centrosome maturation.  
Cells were stained for α tubulin (green), γ tubulin (red) and DAPI (blue), to visualize the accumulation of 
γ tubulin as a measure of centrosome maturation. A. A graph shows the ratio between centrosomal γ-
tubulin in mitotic and interphase cells in GSC and non-GSCs. An average of 144 
cells/condition/experiment were randomly imaged and scored.  Results are representative of three 
independent experiments. Error bars indicate means ± SD. B-C. Representative images of GSCs (B) and 
non-GSCs (C), with inserts showing γ tubulin staining in interphase (I) and mitotic (M) cells. Scale bar in 
main images 5µm and in inserts 500nm.   
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Figure 4.6 Gamma-tubulin and centrin-2 staining co-localize and show that GSCs have abnormal 
centrosomal patterns more frequently. 
GSCs and non-GSCs were stained for centrin-2 (green), γ tubulin (red) and DAPI (blue), to confirm 
specific localization of γ tubulin staining at centrosomes. Representative images of GSCs (A-B) and non-
GSCs (C-D) with inserts showing centrosomal area.
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4.5 Distinctive centrosome features in glioblastoma stem cells are not a consequence of 
different levels of Aurora kinase A expression or activity 
As a first step in investigating AurA, I quantified its expression in GSCs and non-GSCs. Western 
blot analysis of total AurA in the two subpopulations from three glioblastoma primary cell lines 
demonstrated no difference in its levels (see figure 4.7.A-B). Quantification with western blot 
of the phosphorylated fraction in the G7 cell line showed that GSCs and non-GSCs did not 
differ significantly in the active form either (see figure 4.7.C). In order to verify whether there 
was a distinct accumulation of phosphorylated AurA in mitotic GSCs, I evaluated its pattern of 
distribution with immunofluorescence in dividing cells from the two subpopulations: I 
observed a wide variation in the levels of this protein within each subpopulation and did not 
find a significant difference when comparing GSCs and non-GSCs (see figure 4.8). These 
findings suggest that the distinctive centrosome features detected in GSCs cannot be ascribed 
to dissimilarities in the levels of AurA activity in the two subpopulations.      
The western blot quantification data is in contrast with results from a study evaluating the role 
of AurA in regulating self-renewal capacity of GSCs: the authors reported a reduction in total 
AurA expression levels following in vitro differentiation induced by exposure to serum275. The 
reasons for this discrepancy are difficult to identify, given that both studies, mine and theirs, 
performed the quantification using multiple primary cell lines and various techniques. 
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Figure 4.7 GSCs and non-GSCs do not differ in terms of total and phosphorylated Aurora A expression. 
A-B. Representative images of western blots showing total Aurora A expression in GSCs and non-GSCs of 
three different primary cell lines (E2, G7 and S2). C. Representative image of western blot showing total 
and phosphorylated Aurora A expression, baseline and after 24 hours of incubation with 0, 50 and 500 
nM of MLN8237, in G7 GSCs and non-GSCs. “Control” is a sample of HeLa cells treated with 100 ng/uL 
nocodazole for 16-18 hours to obtain synchronization in M phase. Histone H3 was used as loading 
control in all experiments.    
A B
C
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Figure 4.8 GSCs and non-GSCs do not differ in terms of distribution of  phosphorylated Aurora A 
during mitosis. 
GSCs and non-GSCs were stained for phosphorylated Aurora A (red) and its distribution was analysed in 
mitotic cells. A. A box plot shows the quantification of centrosomal phosphorylated Aurora A in mitotic 
GSCs and non-GSCs. An average of 22 mitotic cells/condition/experiment were randomly imaged and 
scored. B-E. Representative images of mitotic GSCs (B-C) and non-GSCs (D-E), showing considerable 
variability of phosphorylated Aurora A staining in both subpopulations. Scale bar 2µm. 
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4.6 Glioblastoma stem cells have more mitotic spindle abnormalities following inhibition of 
Aurora A activity 
In order to test whether GSCs and non-GSCs differed in the requirement for AurA activity, I 
treated the two subpopulations with the selective AurA inhibitor MLN8237 and evaluated the 
effects on mitotic spindle phenotypes. I used low dose levels that had subtle effects on overall 
AurA kinase activity, based on the western blot quantification of phosphorylated AurA 
following MLN8237 treatment. This approach had the aim of addressing possible inhibitory 
effects on other mitotic kinases, particularly those on Aurora kinase B (AurB). Given that 
MLN8237 inhibits AurA with a selectivity of more than 200-fold over AurB276, I considered as 
AurA-specific any observed effects. MLN8237 increased mitotic spindle abnormalities more 
frequently in GSCs than in non-GSCs, with the following percentages in the G7 cell line: 56% vs 
14% at 25nM, 75% vs 29% at 50nM and 79% vs 47% at 100nM, respectively (see figure 4.9.A). 
The difference in response to MLN8237, despite the similar levels of AurA in the two 
subpopulations, is partially consistent with the results of a study reporting a correlation 
analysis between MLN8237 IC50 and AurA expression in established and primary glioblastoma 
cell lines: no association was found with levels of total AurA, while there was a week 
correlation with the phosphorylated fraction277.  
Analysis of specific types of mitotic spindle abnormalities showed that there was also a 
difference in the type of defect observed in the two subpopulations: non-GSCs displayed a 
moderate increase in both monopolar and multipolar spindles, while in GSCs there was a 
dramatic increase only in the monopolar phenotype, which is the most commonly reported 
spindle defect following AurA inhibition both in vitro and in vivo276 (see figure 4.9.B-C). Figure 
4.10 shows representative images of the most frequent mitotic spindle phenotype at each 
dose level of MLN8237 in the two subpopulations. As seen in these images, non-GSCs were 
able to maintain a bipolar phenotype, but displayed a reduction in the size of the mitotic 
spindle following AurA inhibition. This observation is in line with published data from the 
Hochegger team (with whom I worked from September 2010), reporting that AurA knockdown 
reduces spindle volume and width278.  
These findings suggest that the effects of subtle changes in AurA activity, induced by MLN8237 
treatment, differ both quantitatively and qualitatively in GSCs and non-GSCs.  
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Figure 4.9 GSCs have more spindle abnormalities following treatment with MLN8237 than non-GSCs. 
GSCs and non-GSCs were treated with 0, 25, 50 and 100 nM of MLN 8237. Following 24 hours of 
incubation, they were fixed and stained for α tubulin, γ tubulin and DAPI, to visualize the morphology of 
mitotic spindles in the two subpopulations. A. A graph shows the percentages of abnormal mitotic 
spindles in GSCs and non-GSCs. An average of 26 mitotic cells/condition/experiment were randomly 
imaged and scored. Results are representative of three independent experiments. Error bars indicate 
means  SD. B-C. Two diagrams display the distribution of different spindle phenotypes in GSCs and 
non-GSCs at the various MLN8237 dose levels.  
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Figure 4.10 Aurora A inhibition disrupts the bipolarity of mitotic spindles more frequently in GSCs 
than in non-GSCs. 
GSCs and non-GSCs were treated as described in figure 4.10 and stained for α tubulin (green), γ tubulin 
(red) and DAPI (blue) to visualize modifications in mitotic spindle morphology induced by MLN8237. 
Representative images of GSCs (A) and non-GSCs (B) treated with 0, 50 and 100 nM of MLN8237. Scale 
bar 2µm. 
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4.7 AuroraA inhibition does not induce a prolonged G2/M arrest in glioblastoma stem and 
non-stem cells 
In order to characterize further the effects of AurA inhibition on GSCs and non-GSCs, I 
performed FACS analysis of the cell cycle distribution of the two subpopulations, baseline and 
following treatment with 25, 50 and 100 nM of MLN8237 (see figure 4.11). I observed a 
significant difference in the cell cycle profiles of untreated cells: GSCs displayed a higher 
percentage of cells with ≥4N DNA content than non-GSCs. Interestingly, FACS profiles of GSCs 
have a bifid appearance in the 4N area (see figures 4.11 and 4.14), which is consistent with the 
presence of populations with distinct degrees of aneuploidy, although the distribution into two 
discrete peaks is of uncertain interpretation, as one would expect a single broad peak as the 
result of cells with small and continuous variations in the number of chromosomes. Given that 
cells with a 4N FACS profile, simply obtained with propidium iodine staining, can be in G2, M or 
a tetraploid G1 phase, I identified and quantified the percentage of cells in G2 and M by 
immunofluorescence using antibodies against CENP-F and α-tubulin in conjunction with DAPI 
staining. As seen in figure 4.12, the two subpopulations had similar percentages of G2/M cells, 
confirming that the difference in the fraction of cells with 4N DNA content, observed in 
untreated samples, was due to a higher percentage of polyploid cells amongst GSCs.  
With regards to the cell cycle distribution of treated samples from the two subpopulations, 
there was an increase in the ≥4N DNA content fraction in GSCs as well as non-GSCs. 
Immunofluorescence analysis, using antibodies against CENP-F and α-tubulin in conjunction 
with DAPI staining, demonstrated only slight increases in the G2/M fraction following 
treatment with 25, 50 and 100 nM of MLN8237. These data suggest that GSCs and non-GSCs 
do not differ significantly in their response to AurA inhibition in terms of variations in cell cycle 
distribution and that MLN8237 does not cause a considerable G2/M arrest in the two 
subpopulations.  
These findings are in contrast with those from several studies reporting an increase in the 
G2/M fraction following inhibition of AurA, using small molecule inhibitors or RNAi273, 276, 279-281. 
The reasons for the difference in our results are difficult to interpret and might be: cell line 
dependent, as suggested by the wide variation in the magnitude of the G2/M arrest observed 
in various cell lines tested in one of these studies281; and dose-dependent, as indicated by the 
results of in vitro and in vivo experiments reported in two publications276, 280.  
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Figure 4.11 GSCs have a higher percentage of cells with ≥4N DNA content at baseline. 
GSCs and non-GSCs were treated with 0, 25, 50 and 100 nM of MLN8237. Following 24 hours of 
incubation, they were fixed, stained with propidium iodide and analysed for DNA content, to evaluate 
cell cycle distribution of the two subpopulations. A-B. Two graphs show percentages of GSCs (A) and 
non-GSCs (B) in the various phases of the cell cycle, as quantified in the FACS analysis. Results are 
representative of three independent experiments. Error bars indicate means  SD. C. Representative 
FACS diagrams of GSC and non-GSCs. 
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Figure 4.12 Aurora A inhibition does not cause a significant G2/M arrest in GSCs and non-GSCs. 
GSCs and non-GSCs were treated with 0, 25, 50 and 100 nM of MLN8237. Following 24 hours of 
incubation, they were fixed and stained for α tubulin (green), CENP-F (red) and DAPI (blue), to visualize 
and quantify G2/M cells. A. A graph shows the percentages of cells in G2 and M phase in the two 
subpopulations at the various dose levels. An average of 309 cells/condition/experiment were randomly 
imaged and scored. Results are representative of three independent experiments. Error bars indicate 
means ± SD. B-C. Representative images of untreated GSCs (B) and non-GSCs (C). White arrows indicate 
mitotic cells, red arrows G2 cells. Scale bar 10 µm. 
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In order to further characterize the ability to undergo G2/M arrest of GSCs and non-GSCs, used 
in this project, I evaluated their response to nocodazole and paclitaxel, two compounds that 
induce increase in the G2/M fraction by disrupting microtubule dynamics and mitotic spindle 
assembly. Figures 4.13 and 4.14 display the results of an experiment testing the effect of these 
drugs on cell cycle distribution in GSCs and non-GSCs and in HeLa cells, used as a control 
population. In HeLa cells, MLN8237, nocodazole and paclitaxel (alone or in combination with 
MLN8237), all induced a significant increase in the fraction of cells with 4N DNA content 
positive for phosphorylated histone H3: from 2% to 26%, 35% and 33%, respectively, for the 
drugs used individually. While in GSCs and non-GSCs from the G7 cell line, there was only a 
slight increase, with percentages lower than 4% in both subpopulations following treatment. I 
further confirmed these findings, evaluating positivity for phosphorylated histone H3 with 
immunofluorescence in GSCs and non-GSCs treated with paclitaxel. As seen in the 
representative images shown in figure 4.15, paclitaxel treatment did not induce a considerable 
increase in the fraction of G2/M cells in both subpopulations. 
Taken together, all the experiments analysing cell cycle distribution and induction of G2/M 
arrest suggest that the tested glioblastoma cells are prone to mitotic slippage, even in the 
presence of significant mitotic abnormalities observed in GSCs treated with MLN8237. 
Molecular mechanisms responsible for mitotic slippage are still partially unclear and their 
investigation in GSCs was beyond the scope of my project. This field will be investigated 
further by members of the Helfrid Hochegger laboratory. 
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Figure 4.13 A small proportion of GSCs and non-GSCs undergoes G2/M arrest following treatment with nocodazole, paclitaxel and MLN8237. 
HeLa cells, GSCs and non-GSCs were treated with nocodazole (200 nM), paclitaxel (200 nM), MLN8237 (50nM), nocodazole and MLN8237, paclitaxel and MLN8237, or left 
untreated. Following 16 hours of incubation, they were fixed and stained with anti-phosphorylated histone H3 antibody and propidium iodide, to evaluate the percentage 
of cells that underwent G2/M arrest. The dot plots show the results of one of the experiments. P1 (red) gate defines the population of interest, P2 (green) includes all cells 
that are positive for phosphorylated histone H3, P3 (blue) gates the positive cells with 4N DNA content that are likely to be arrested in G2/M phase. 
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Treatment
HeLa cells Non-GSCs GSCs
P2 P3 P2 P3 P2 P3
Control 3.3 2.2 0.7 0.4 1.7 0.5
Nocodazole 41.2 34.7 4.0 3.0 8.2 3.6
Paclitaxel 38.5 33.3 1.4 0.9 10.9 3.9
MLN8237 31.7 26.4 1.8 1.4 4.7 1.6
MLN8237 + Nocodazole 31.6 25.6 1.6 1.2 5.8 2.6
MLN8237 + Paclitaxel 36.0 29.9 2.8 2.3 5.8 2.6
Figure 4.14 A small proportion of GSCs and non-GSCs undergoes G2/M arrest following treatment 
with nocodazole, paclitaxel and MLN8237. 
HeLa cells, GSCs and non-GSCs were treated as described in figure 4.14. The histograms above and the 
table display the results from the experiment shown in figure 4.14, with the same colour coding. 
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Figure 4.15 GSCs and non-GSCs do not display a significant G2/M arrest following paclitaxel 
treatment.  
GSCs and non-GSCs were treated with 0 or 200 nM of paclitaxel, incubated for 16 hours, fixed and 
stained for phosphorylated histone H3 (green) and DAPI (blue), to visualize cells in G2 and M phase. 
Representative images show GSCs and non-GSCs, at baseline and after incubation with paclitaxel. Red 
arrows indicate examples of cells in G2, yellow arrows mitotic cells and white arrows dying cells. 
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4.8 Aurora A inhibition induces an increase in polyploid cells 
In order to characterise the fraction of cells with ≥4N DNA content increased after AurA 
inhibition, I evaluated polyploidy using phalloidin and DAPI staining in the two subpopulations 
treated with MLN8237. I observed increasing percentages of giant polynucleated cells that 
were higher in GSCs: following treatment with 25, 50 and 100 nM of MLN8237, the scores 
were 37%, 47% and 54% in GSC samples, while they were 12%, 12% and 20% in non-GSCs (see 
figure 4.16.A). Representative images of treated cells from the two subpopulations are shown 
in figures 4.16.B-C. 
The increase in polyploidy following MLN8237 treatment is consistent with results from other 
studies, though these reported this effect at higher dose levels or after longer incubation 
times276, 280-282. 
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Figure 4.16 Aurora A inhibition induces an increase in polyploid cells that is more pronounced in GSCs. 
GSCs and non-GSCs were treated with 0, 25, 50 and 100 nM of MLN8237. Following 24 hours of 
incubation they were fixed, stained with phalloidin (red) and DAPI (blue), to evaluate polyploidy by 
visualizing the cell cortex and nucleus. A. A graph shows the percentages of polynucleated cells in the 
two subpopulations at the various dose levels. An average of 221 cells/condition/experiment were 
randomly imaged and scored. Results are representative of three independent experiments. Error bars 
indicate means ± SD. B-C. Representative images of GSCs (B) and non-GSCs (C) treated with 50 and 100 
nM of MLN8237. Scale bar 10µm.
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4.9 Glioblastoma stem cells form clumps when viewed with live cell imaging  
In order to characterise the mechanism leading to polyploidy, I evaluated the feasibility of 
analysing cell fate of GSCs using live cell imaging. As seen in figure 4.17, single cell analysis was 
hampered by the formation of clumps during time-lapse microscopy. Based on the 
methodology used in the published study analysing cell division of GSCs, I tested whether 
coating the incubation chambers with laminin solved this issue by inducing attachment, but 
found no difference in cell clumping. 
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Figure 4.17 Live cell imaging shows that GSCs form clumps in the absence of treatment. 
Representative images of a time-lapse sequence, showing behaviour of GSCs during a time interval of 
approximately 16 hours. The red and yellow shapes each identify and follow a group of cells in the 
whole time interval. 
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4.10 Polyploidy is not a result of cell fusion or entosis 
Based on the observations of the live-cell imaging experiments, I considered processes other 
than aberrant mitosis that can be responsible for polyploidy in cancer cells, such as cell fusion 
and entosis, a form of cannibalism involving ingestion of live cells283. Considering that it is not 
possible to discriminate polyploid cells derived from cell fusion and mitotic defects simply 
based on their appearance, and that non-adherent growth conditions appear to facilitate 
entosis284, I evaluated whether these processes contribute to the observed polyploidy amongst 
GSCs, baseline and following MLN8237 treatment. For this experiment, I marked cells 
separately with cell tracking dyes, mixed them and then treated them for 24 hours with 0 or 50 
nM of MLN8237. The presence of polyploid cells containing both dyes was negligible in 
untreated and treated samples (see figure 4.18 for representative images), suggesting that cell 
fusion and entosis do not contribute significantly to polyploidy amongst GSCs and confirming 
that this is a result of the higher frequency of mitotic abnormalities. 
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Figure 4.18 Cell fusion and entosis are responsible for a negligible percentage of polyploid cells 
amongst GSCs. 
Two samples of GSCs were incubated separately with CellTracker Green and Blue, re-suspended in fresh 
medium and mixed prior to treatment with 0 or 50 nM MLN8237. Following 24 hours of incubation, they 
were fixed and stained with phalloidin, to visualize whether polyploid cells were due to fusion or 
entosis. Representative images of GSCs  50 nM of MLN 8237. White arrows indicate a polyploid cell 
resulting from cell fusion or entosis. Yellow arrows indicate polyploid cells resulting from mitotic 
defects. Scale bar 10µm. 
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4.11 Aurora A inhibition reduces clonogenicity of glioblastoma stem cells more efficiently 
The data discussed above suggest that GSCs are prone to mitotic abnormalities, which do not 
induce a prolonged cell cycle arrest, as these cells are also prone to mitotic slippage. As a 
consequence, GSCs have higher percentages of polyploid cells, which increase rapidly following 
AurA inhibition. In order to test whether these features can be exploited therapeutically to 
improve outcome of glioblastoma patients, I evaluated sensitivity to MLN8237 of GSCs and 
non-GSCs from three primary cell lines (G7, E2 and G1). In two of these (G7 and E2), GSCs 
displayed a significantly more pronounced reduction in clonogenicity following AurA inhibition 
than non-GSCs, while in one cell line (G1) the survival curves did not indicate a clear superiority 
in the ability of MLN8237 to kill the GSC subpopulation (see figure 4.19). The reasons for the 
latter result are difficult to identify with the available data, but one contributing factor could 
be the high passage number (above 50) of the G1 cell line. 
To my knowledge, this is the first comparative analysis of MLN8237 sensitivity of GSCs and 
non-GSCs. Another group evaluated response to MLN8237 in terms of clonogenic survival in 
different subpopulations of glioblastoma cells in two distinct studies. The first used a panel of 
ten cell lines, established and primary low-passage, grown in serum-containing medium as 
adherent cultures; these cells were treated with MLN8237 for 24 hours and colonies were 
quantified after 7 days272. The second used two primary cell lines, grown in serum-free 
medium as neurosphere cultures, and treated them with MLN8237 for the whole duration of 
the experiment, i.e. two weeks277. The authors reported IC50’s between 60 and 225 nM for 
adherent cells, and 2.8 and 5.9 nM for the two GSC cell lines, suggesting that MLN8237 kills 
GSCs more effectively. Although the difference in IC50 is striking, the value of this comparison is 
hindered by the dissimilarities in the experimental design of the two studies.  
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Figure 4.19 GSCs are more sensitive to Aurora A inhibition than non-GSCs. 
Clonogenic survival assays comparing sensitivity of GSCs and non-GSCs from three primary glioblastoma 
cell lines (G7, E2 and G1) to MLN8237. Results are representative of three independent experiments. 
Error bars indicate means  SD. 
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4.12 Apoptosis does not contribute significantly to MLN8237 cytotoxicity in GSCs and non-
GSCs 
Based on the results of the clonogenic survival assays, I investigated the possible mechanisms 
leading to cell death following MLN8237 treatment. First, I measured the contribution of 
apoptosis evaluating levels of cleaved caspase 3 in the two subpopulations in two experiments: 
in one, I performed western blot analysis after 24 hours of treatment with 0, 50 and 500 nM of 
MLN8237 (see figure 4.20.A); in the other, I used immunofluorescence to obtain a 
quantification at 24, 48 and 72 hours in samples treated with 50 nM of the AurA inhibitor (see 
figure 4.20.B). Western blot evaluation yielded no change in total caspase 3 and could not 
detect caspase 3 fragment at 24 hours in both subpopulations, even at the highest dose level. 
Quantification of one of the immunofluorescence experiments showed no change in non-GSCs 
and an increase in the percentage of cleaved caspase 3 positive cells, from 1% to 3%, at 24 
hours in GSCs treated with MLN8237. These data suggest that apoptosis, at the most, is 
responsible for a small proportion of the cytotoxic effect of MLN8237 in GSCs. 
The literature regarding apoptosis induction by AurA inhibitors is conflicting, with some studies 
showing negligible or modest levels of apoptosis following treatment and others reporting a 
considerable increase in this mode of cell death276, 279, 281, 282, 285-289. Several factors might be 
responsible for this inconsistency: analysis of various cell lines, as suggested by the difference 
in the results obtained in distinct cell lines within the same study276, 282; use of assays with 
different specificity for apoptosis detection (FACS analysis of Annexin V staining and sub-G1 
fraction, western blot evaluation of cleaved caspases and PARP) and variation in experimental 
protocols (drugs, dose levels and treatment times). The importance of the methodology is 
demonstrated by the only publication, to my knowledge, reporting apoptosis evaluation in 
GSCs following MLN8237 treatment285. This study showed a considerable increase in Annexin V 
detection only after 9 days of incubation with 200 nmlo/L of MLN8237 in two neurosphere cell 
lines, while PARP cleavage increased from day 2 or 5. 
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Figure 4.20 Aurora A inhibition does not induce a significant increase in Caspase 3 dependent death in 
GSCs and non-GSCs. 
A. Representative image of western blot showing caspase 3 expression, baseline and after 24 hours of 
incubation with 0, 50 and 500 nM of MLN8237, in G7 GSCs and non-GSCs. Histone H3 was used as 
loading control. B. A diagram shows percentages of cleaved caspase 3 positive cells evaluated with 
immunofluorescence, at baseline and after 24, 48 and 72 hours of incubation with 50 nM of MLN8237, 
in G7 GSCs and non-GSCs. Results are from quantification of one out of two experiments performed.
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4.13 Aurora A inhibition induces a dramatic increase in senescence in glioblastoma stem cells 
Based on previous studies reporting the ability of MLN8237 to induce senescence281, 287, 289, I 
evaluated levels of β-galactosidase in the two subpopulations, baseline and after 2 and 7 days 
of treatment with 50 nM of MLN8237 (see figure 4.21). I observed a significant increase in the 
percentage of senescent cells amongst GSCs, with 55% of these expressing the senescence 
marker at day 7, compared to 19% in non-GSCs. Consistently, the recent study, mentioned in 
the previous paragraph, also showed senescence induction in GSCs, but did not quantify it or 
perform a comparative analysis with non-GSCs285. In the light of these findings and given that 
senescent populations show an increase in Annexin V staining290, it is likely that a proportion of 
Annexin V positive cells, observed in GSCs after 9 days of MLN8237 treatment in the latter 
study, were the result of senescence.  
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Figure 4.21 Aurora A inhibition induces senescence in glioblastoma cells that is markedly more 
pronounced in GSCs. 
GSCs and non-GSCs were treated with 0 and 50 nM of MLN8237. Following 2 or 7 days of incubation, 
they were fixed and stained for -galactosidase, to evaluate induction of senescence. A. A graph shows 
the percentages of senescent cells in the two subpopulations  MLN8237. An average of 233 
cells/condition/experiment were randomly imaged and scored. Results are representative of three 
independent experiments. Error bars indicate means  SD. B-C. Representative images of GSCs (B) and 
non-GSCs (C), showing -galactosidase staining (blue) at baseline and after 2 or 7 days of MLN8237 
treatment. Scale bar 10µm.  
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4.14 Increased sensitivity of glioblastoma stem cells to Aurora A inhibition is not dependent 
on p53 status 
Given the pivotal role of p53 in regulating fate of cancer cells following cytotoxic treatment, 
several studies analysed whether its status influences response to AurA inhibition, yielding 
conflicting results286, 289. Data produced by a member of Anthony Chalmers’ group, Ross 
Carruthers, who performed DNA sequencing of p53 on GSCs and non-GSCs from G7 and E2 cell 
lines, demonstrating that they are all p53 wild type (data not shown), does not support a role 
of p53 status in determining the observed differential sensitivity of GSCs to AurA inhibition. 
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4.15 MLN8237 does not significantly radiosensitize GSCs and non-GSCs 
Given that standard treatment against glioblastoma includes radiotherapy, I performed 
clonogenic survival assays with both subpopulations to test whether MLN8237 has a 
radiosensitizing effect and can be used in combination with ionizing radiation to improve 
patient outcome. While non-GSCs displayed no difference in the two treatment arms, in GSCs 
the addition of MLN8237 was slightly favourable, but this effect did not reach statistical 
significance at all dose levels (see figure 4.22). As I performed the experiment twice, a final 
repeat and a more detailed statistical analysis will help with the interpretation of these results. 
Two studies mentioned above analysed, in distinct experiments, the effect of combining 
MLN8237 with ionizing radiation on clonogenic survival of two GSC lines and four non-GSC 
lines272, 277. A comparison is not possible, given that the two sets of experiments had distinct 
protocols and used different doses, for each study as well as for each GSC line. The authors 
reported a potentiation of the effect of ionizing radiation by MLN8237, suggesting a synergistic 
effect. Another group testing the combination of another AurA inhibition with ionizing 
radiation in glioblastoma established and primary cell lines, found that depending on the 
radiation dose, the effect was synergistic, additive or antagonistic273.  
Based on the results of my preliminary clonogenic survival assays and on the findings of these 
studies, further characterization of the interaction between the two treatment modalities is 
needed to evaluate whether there is a rationale for a combined approach, especially if the 
absence of a significant G2/M arrest is confirmed, and, if so, which schedule (i.e. MLN8237 
dose and timing) is the most advantageous.    
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Figure 4.22 Aurora A inhibition does not have a significant radiosensitizing effect on GSCs or non-
GSCs. 
Clonogenic survival assays testing sensitivity of G7 GSCs and non-GSCs to ionizing radiation (IR) in 
combination with 25 nM of MLN8237. Results are representative of two independent experiments. Error 
bars indicate means  SD. 
1
10
100
0 1 2 3 4 5
%
 c
ol
on
ie
s
IR dose (Gy)
IR ± MLN8237
IR + MLN8237
IR only
G7 GSCs
1
10
100
0 1 2 3 4 5
%
 c
ol
on
ie
s
IR dose(Gy)
IR ± MLN8237
IR + MLN8237
IR only
G7 non-GSCs
119
4.16 Discussion 
In this chapter I show that GSCs have distinctive features with regards to centrosome cycle and 
mitotic spindle phenotypes. I also demonstrate that GSCs are highly susceptible to subtle 
changes in AurA activity, which induce a rapid increase in polyploidy and subsequently in 
senescence, with a consistent reduction in clonogenicity. Given that these effects were more 
pronounced in GSCs than in non-GSCs, it is reasonable to propose that GSCs have distinctive 
features in processes preceding and regulating cell division which, on the one hand, enable 
them to display regenerative responses following cytotoxic treatment, while, on the other, 
they may constitute an Achilles’ heel for GSCs, making them more susceptible to mitotic 
failure.  
A particularly interesting outcome of my experiments is the correlation between levels of 
MLN8237-induced senescence and reduction in clonogenic survival in GSCs and non-GSCs. The 
value of this observation is confirmed by the findings of a recent in vivo study, testing the 
efficacy of MLN8237 against xenografts obtained through injection of GSC populations285. The 
authors reported prolonged survival in treated mice, which displayed tumours with 
morphological changes resembling abnormal arrested mitosis and senescence. The significance 
of these data is in the context of the proposed ability of CSCs to escape senescence and the 
reversible nature of drug-induced senescence used by a minority of cancer cells as a survival 
mechanism291, 292. My data, together with the results of the in vivo study, confute these 
theories and suggest that senescence induction is an effective mechanism to target GSCs 
effectively. Though, given that senescent cells acquire a secretory phenotype and release, 
amongst several factors, IL-6, which has been shown to have a positive effect on GSC survival 
and tumour growth293-295, the possible role of senescence induction as an anti-GSC strategy 
needs to be confirmed in the clinical setting by pathology studies, aimed at verifying whether 
the in vitro and in vivo behaviour of GSCs applies to these cells in their natural tumoral niche. 
In conclusion, the data shown in this chapter strengthens the rationale for the theory that links 
centrosome cycle, mitotic kinase inhibition and GSC targeting, supporting the approach 
undertaken in the second section of my project and highlighting the need for a more detailed 
characterization of centrosome biology and mitosis regulation in GSCs.  
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Chapter 5 
Preliminary data on Polo-like kinase 1 inhibition and primary cilia 
 in glioblastoma stem cells 
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5.1 Introduction 
In this chapter I report unpublished results generated for two projects that were inspired by 
my findings on centrosome features and mitotic kinases in GSCs and non-GSCs: the first 
section investigates the effects of inhibiting Plk1 on GSCs and non-GSCs; the second analyses 
the presence of primary cilia in the two subpopulations, exploring the feasibility of studying 
these organelles in cells grown within the 3D culture system described in chapter three. 
Given the role of Plk1 in centrosome cycle and mitosis progression, the main rationale for 
evaluating the outcome of its inhibition in GSCs and non-GSCs is that linking centrosome cycle, 
mitotic kinase inhibition and GSC targeting, as outlined at the end of the general introduction 
and at the beginning of chapter four.  
The interest in primary cilia aroused in the context of centrosome cycle characterization in 
GSCs and non-GSCs and was emphasised by the known role of AurA in regulation of assembly 
and disassembly of this organelle296, 297. I will now give a brief introduction on primary cilia and 
the evidence supporting its investigation in GSCs. The primary cilium is a sensory organelle 
formed by: the basal body, which is derived from the mother centriole after its migration and 
anchorage to the plasma membrane during G1 phase; and the axoneme, which consists of 9 
microtubule doublets that are in continuation with the basal body and protrude from the cell 
surface267. Despite important advances, our understanding is still limited with regards to the 
mechanisms underlying the switch between centriole and basal body and its correlation with 
cell cycle control, but increasing data suggests that disruption of these processes could 
contribute to the deregulated cancer growth298. The rationale for studying cilia in GSCs is 
mainly based on the implication of these organelles in several pathways, such as hedgehog, 
PDGF, Wnt and Notch signalling299. Although most of these pathways have been linked to GSC 
survival300-302, the relevance of their ciliary component in GSCs is unknown. At the time of my 
experiments, no studies had been published on primary cilia in GSCs and there was only one 
publication regarding glioblastoma established cell lines303. Immunofluorescence analysis and 
electron microscopy observation showed no or immature cilia in four of five cell lines, 
suggesting that ciliogenesis was absent or incomplete; in one cell line, the authors identified 
less than 1% of cells with primary cilia in the latter stages of maturation. Recently, a study 
analysing primary cilia in GSCs in vitro was published and reported that in five primary cell lines 
8 to 25% of cells presented cilia, with normal structure and trafficking ability304. This 
inconsistency is probably due to the differences in the cell lines used in the two studies. 
Analysis of glioblastoma patient specimens was performed by the same groups and also gave 
partially conflicting results: one reported the presence of primary cilia in all (twenty three) 
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biopsies, with a mixture of normal and aberrant forms304; the other found these organelles in 
all (seven) specimens, but these were defective in all but one305. These findings highlight the 
need for pathology studies on larger numbers of patient samples, with the aim of defining the 
relevance of ciliated cells in glioblastoma biology, as well as in vitro evaluation of the role of 
these organelles in survival responses of GSCs and non-GSCs, to identify possible therapeutic 
targets to improve patient outcomes. 
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5.2 Polo-like kinase 1 inhibition targets glioblastoma stem cells more effectively 
In order to test whether GSCs and non-GSCs differ in their response to Plk1 targeting, I 
performed clonogenic survival assays testing the sensitivity of the two subpopulations to 
BI2536, a highly specific Plk1 inhibitor. In both cell lines (E2 and G7), GSCs showed significantly 
lower clonogenicity than non-GSCs, following treatment (see figure 5.1). To my knowledge, 
there are no other comparative analyses of sensitivity of GSCs and non-GSCs to Plk1 inhibition. 
Consistently with my findings, a study evaluating the effect of Plk1 inhibition on GSC features 
showed a drastic reduction in neurosphere ability following BI2536 treatment and, most 
importantly, also reported a prolonged survival of treated mice, suggesting the possible clnical 
relevance of this approach245.  
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Figure 5.1 GSCs are more sensitive to BI2536 than non-GSCs.  
Clonogenic survival assays comparing sensitivity of GSCs and non-GSCs from two primary glioblastoma 
cell lines (G7 and E2) to BI2536. Results are representative of three independent experiments. Error bars 
indicate means  SD.
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5.3 Higher sensitivity of glioblastoma stem cells to Plk1 inhibition is not correlated to 
induction of mitotic spindle abnormalities 
Given the role of Plk1 in centrosome maturation and bipolar spindle formation, I tested 
whether GSCs and non-GSCs differed in their response to BI2536 in terms of mitotic spindle 
defects. As seen in figure 5.2, I observed no difference in the induction of spindle 
abnormalities between the two subpopulations and the higher dose level (4nM) caused an 
increase of aberrant mitosis only to about 30%, a much lower value than that seen with 
100nM of MLN8237 (around 80%), which had a comparable cell killing effect (around 95% 
decrease in clonogenicity). These findings suggest that, at the dose levels used in my 
experiments, the reduced clonogenic survival following BI2536 treatment is only partially due 
to mitotic defects and that other mechanisms contribute to the cytotoxic effect of Plk1 
inhibition and determine the higher sensitivity of GSCs.  
This is the first comparative analysis of mitotic defects induced by a Plk1 inhibitor in matched 
GSCs and non-GSCs. The only published data on this topic comes from a study evaluating the 
effect of targeting Plk1 in GSCs306. The authors reported a much higher increase in spindle 
defects following treatment with BI2536, but did not state the dose used in the experiment. 
Given the lack of information and the much higher dose levels (10 to 100nM) used in other 
assays in the study, it is not possible to make a comparison with my findings.   
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Figure 5.2 GSCs and non-GSCs do not differ in the frequency of spindle abnormalities following 
treatment with BI2536. 
GSCs and non-GSCs were treated with 0, 2 and 4 nM of BI2536. Following 24 hours of incubation, they 
were fixed and stained for α tubulin, γ tubulin and DAPI, to visualize the morphology of mitotic spindles 
in the two subpopulations. The graph shows the percentages of abnormal mitotic spindles in GSCs and 
non-GSCs. An average of 29 mitotic cells/condition were randomly imaged and scored. 
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5.4 Cytotoxic doses of BI2536 do not induce a G2/M arrest in glioblastoma stem and non-
stem cells 
Given the role of Plk1 in regulation of mitotic entry and exit, I tested whether its inhibition 
caused a G2/M arrest in GSCs and non-GSCs. As seen in figure 5.3.A, the two subpopulations 
did not display a significant increase in the percentage of cells in G2 and M phases, following 
treatment with cytotoxic doses of BI2536. To my knowledge, the study mentioned in the 
previous paragraph is the only one published reporting a cell cycle analysis of primary GSCs 
following PLk1 inhibition306. The authors showed a considerable increase in the 4N DNA 
content fraction in the FACS profiles, following treatment with BI2536. Though, again it is not 
clear what dose they used in the specific experiment as they simply state that several doses, 
between 10 and 100 nM, were tested. The inconsistency in the findings could be due to two 
main factors: use of higher doses, given that the G2/M arrest might be dose-dependent, as 
suggested by the results of another study testing the effect of BI2536 on established 
glioblastoma cell lines307; different methodology, as FACS analysis of DNA content with PI 
staining does not distinguish between cells in G2/M and tetraploid cells in G1. A role of the 
latter factor is suggested by the presence of giant cells amongst GSCs, following treatment 
with BI2536, as seen in figures 5.3.B-C. Interestingly, these apparently polyploid cells were not 
visibly increased amongst non-GSCs despite the two subpopulations had similar percentages of 
mitotic spindle defects, suggesting that GSCs are more prone to rapid polyploidization. Further 
analysis of mitotic phenotypes and quantification of polyploid cells, using phalloidin staining, 
following BI2536, are needed to test this hypothesis and elucidate whether it represents one 
of the main determinants of the high sensitivity of GSCs to Plk1 inibition. 
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Figure 5.3 GSCs and non-GSCs do not undergo a considerable G2/M arrest following Plk1 inhibition. 
GSCs and non-GSCs were treated with 0, 2 and 4 nM of BI2536. Following 24 hours of incubation, they 
were fixed and stained for α tubulin (green), CENP-F (red) and DAPI (blue), to visualize and quantify 
G2/M cells. A. A graph shows the percentages of cells in G2 and M phase in the two subpopulations at 
the various dose levels. An average of 229 cells/condition were randomly imaged and scored. B-C.
Representative images of GSCs (B) and non-GSCs (C) treated with 4nM of BI2536. White arrows indicate 
mitotic cells, red arrows G2 cells and yellow arrows giant cells. 
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5.5 Analysis of interphase functions of Plk1 is of potential interest in the context of the 
cytotoxic effect of BI2537 in glioblastoma cells 
Several studies, using various established cancer cell lines, support a role of Plk1 in DNA 
replication and regulation of the checkpoint response during S phase, suggesting that it 
promotes DNA synthesis and progression through S phase308-311. These functions are of 
potential therapeutic interest and could be relevant to GSCs and their response to treatment, 
in the light of the results of a study showing that GSCs do not display inhibition of DNA 
synthesis post-radiation, with no or small reduction in new initiations, suggesting a lower 
activation of the intra-S-phase checkpoint312. The authors do not explore a mechanistic 
correlation between these observations and Plk1 activity, allowing speculation that this kinase 
might contribute to the distinctive response of GSCs in terms of DNA replication and regulation 
of the checkpoint response during S phase.  
Based on these data, I started investigating the effect of Plk1 inhibition on the S phase fraction 
in the two subpopulations, by evaluating EdU staining with immunofluorescence. In the initial 
experiment, GSCs did not display a consistent change in the percentage of cells in S phase, 
while, amongst non-GSCs, there was a moderate increase (see figure 5.4). Representative 
images are shown in figure 5.5. Given that these preliminary observations are not sufficient to 
perform statistical analysis, their value is limited and they need to be substantiated by further 
experiments.  
To my knowledge, there are no data in the literature regarding quantification of GSCs in S 
phase following Plk1 inhibition. The study mentioned in the previous paragraphs did not 
measure the fraction of GSCs in S phase in their FACS analysis306. Two other studies quantified 
the percentage of cells in the various phases of the cell cycle in glioblastoma established cell 
lines, with conflicting results: one reported a moderate increase in the S phase fraction, while 
the other showed no change or even a decrease, following treatment with BI2536245, 307. Given 
the preliminary nature of my data, other experiments are needed to confirm the small 
difference in S phase regulation observed between GSCs and non-GSCs, following BI2536 
treatment, and, most importantly, investigate its relevance in terms of sensitivity of 
glioblastoma cells to Plk1 inhibition alone or in combination with DNA damaging agents, such 
as radiation and temozolomide.  
In this context, based on findings of a study showing that Plk1 depletion induces DNA 
damage313, I also tested the feasibility of combining foci analysis with Edu labelling. As seen in 
figure 5.5, I was able to obtain discrete 53BP1 foci in association with Edu staining, with an 
image quality suitable for quantification with the semi-automated method described in 
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chapter three. Furthermore, observation of the images from this preliminary experiment 
indicates that Plk1 inhibition might induce an increase in 53BP1 foci, particularly in GSCs (see 
figure 5.5), suggesting that DNA damage might be involved in determining the differential 
sensitivity of the two subpopulations to BI2536. More detailed analysis of BI2536-induced DNA 
damage and repair kinetics is necessary to confirm this hypothesis and give indications of 
possible strategies to exploit this effect therapeutically.   
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Figure 5.4 Quantification of S phase fraction in GSCs and non-GSCs with EdU labelling is feasible. 
GSCs and non-GSCs were treated with 0, 2 and 4 nM of BI2536. Following 24 hours of incubation, they 
were labelled with Edu (red) with the Click-iT® kit (according to the manufacturer’s protocol) and 
stained for 53BP1 (green) and DAPI (blue). The graphs show percentages of cells in S phase (specifying 
early, mid and late, based on the staining pattern, as seen in figure 5.6) in the two subpopulations at the 
various dose levels. An average of 141 cells/condition were randomly imaged and scored.   
0%
20%
40%
60%
80%
100%
0 2 4
ce
lls
BI2536 (nM)
S phase GSCs
Late
Mid
Early
0%
20%
40%
60%
80%
100%
0 2 4
ce
lls
BI2536 (nM)
S phase non-GSCs 
Late
Mid
Early
132
Figure 5.5 Simultaneous analysis of Edu labelling and 53BP1 foci in GSCs and non-GSCs is feasible.  
GSCs and non-GSCs were treated as described in figure 5.5. Representative images of GSCs (A) and non-
GSCs (B) treated with 0 or 4 nM of BI2536. White, red and yellow arrows indicate examples of cells in 
early, mid and late S phase, respectively. 
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5.6 Glioblastoma stem and non-stem cells display primary cilia in vitro
As a first step in analysing the presence of cilia in glioblastoma cells in vitro, I evaluated 
whether I could identify these organelles in cells processed with the standard 
immunofluorescence protocol, i.e. in cells retrieved from flasks and cytospun on coverslips. I 
was not able to identify cilia following staining for acetylated alpha-tubulin. Given that the 
study published at the time directly stained cells grown on poly-L-lysine coated coverslips, I 
speculated that retrieval or cytospinning might have an impact on visualization of cilia. To 
address this issue without changing culture conditions for GSCs, I tested whether I could 
visualize cilia in cells grown within Alvetex®. Use of an antibody against acetylated alpha-
tubulin resulted in strong staining of microtubule structures throughout the cells in two GSC 
lines. As seen in figure 5.6, it was not possible to distinguish primary cilia amongst the other 
cellular structures bound by the antibody. 
I then tested the use of an antibody against a protein more specifically localized in primary 
cilia, ADP-ribosylation factor-like protein 13B (Arl13B), involved in regulation of intraflagellar 
transport and ciliogenesis314. I found that a portion of GSCs and non-GSCs presented cilia (see 
figure 5.7). Although I did not quantify the percentage of cells with cilia in random images, 
observation of these suggests that a larger fraction of non-GSCs presents these organelles. 
Also, Arl13B staining was less strong in GSCs, as I obtained fainter images, even after increasing 
the acquisition settings, suggesting that there might be structural and functional differences 
between cilia in GSCs and non-GSCs. Quantitative and qualitative analysis of staining patterns 
of Arl13B and other ciliary components in GSCs and non-GSCs from several primary 
glioblastoma cell lines is needed to substantiate these observations. If the two subpopulations 
are confirmed to have distinctive ciliary features, future studies will investigate their 
correlation with processes regulating the transition from GSC to non-GSC phenotype, i.e. their 
link with differentiation, focusing at first on the role of molecules which have been involved 
both in ciliary function and stemness-maintenance, such as hedgehog and Notch.   
134
Figure 5.6 Staining for acetylated alpha-tubulin is very intense throughout the cells in GSCs grown 
within the scaffold. 
Fluorescence confocal microscope images of G7 (A-B) and E2 (C) GSCs grown within the scaffold and 
stained for acetylated alpha-tubulin (green), gamma-tubulin (red) and DAPI (blue). Figure B is one of the 
images composing the Z-stack displayed in A, showing a cell undergoing mitosis in the heart of the 
sphere. Scale bar 10µm.   
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Figure 5.7 Staining for Arl13B shows presence of primary cilia in GSCs and non-GSCs grown within the 
scaffold.
Fluorescence confocal microscope images of G7 GSCs (A) and non-GSCs (B) grown within the scaffold 
and stained for Arl13B (green), gamma-tubulin (red) and DAPI (blue). White arrows indicate examples of 
primary cilia, with the basal body (identified with gamma-tubulin) shown in red and the axoneme 
(identified with Arl13B) in green. 
B
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5.7 Primary cilia are influenced by culture conditions 
Given that serum withdrawal is one of the methods used to increase expression of cilia in 
normal cells, I tested whether changing culture conditions had an effect on Arl13B expression 
in the two subpopulations. Following 24 hours of incubation in non-GSC medium, GSCs 
displayed a staining pattern closer to that seen in non-GSCs, i.e. more cells presented cilia and 
Arl13B intensity was stronger (see figure 5.8.A). Consistently, after 24 hours of incubation in 
GSC medium, fewer non-GSCs had cilia and these appeared fainter (see figure 5.8.B). Given the 
preliminary nature of these observations, further experiments and quantitative analysis need 
to confirm these findings, investigating whether these variations are linked to changes in the 
differentiation status of these cells or to other mechanisms induced by modifications in the 
culture conditions. 
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Figure 5.8 Swapping culture conditions affects Arl13B expression in GSCs and non-GSCs.
Fluorescence confocal microscope images of G7 GSCs (A) and non-GSCs (B) grown within the scaffold, 
incubated for 24 hours in non-GSC medium and GSC medium, respectively, and stained for Arl13B 
(green), gamma-tubulin (red) and DAPI (blue). White arrows indicate examples of primary cilia, with the 
basal body (identified with gamma-tubulin) shown in red and the axoneme (identified with Arl13B) in 
green. 
A
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5.8 Aurora A inhibition with MLN8237 affects ciliogenesis in GSCs and non-GSCs 
Based on published data showing that inhibition of AurA with MLN8237 increases defects in 
primary cilia formation in cells from a mouse autosomal dominant polycystic kidney disease 
model315, I evaluated whether similar effects were visible in GSCs and non-GSCs grown and 
treated within the scaffold. Following 24 hours of incubation with MLN8237, both 
subpopulations displayed changes in the appearance of cilia: amongst non-GSCs there was a 
clear increase in cilia malformations, with many organelles presenting two axonemes or 
bulges; while in GSCs the changes induced by the drug were more difficult to pinpoint based 
on simple observation, given that less cells presented cilia in untreated samples and that there 
was a variety of phenotypes amongst MLN8237-treated GSCs (see figure 5.9). Although 
consistent with published data, these findings need to be supported by further experiments, 
with a more detailed analysis of structural and functional modifications of cilia following AurA 
inhibition.    
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Figure 5.9 Ciliogenesis is altered in GSCs and non-GSCs following Aurora A inhibition.
Fluorescence confocal microscope images of G7 GSCs (A) and non-GSCs (B) grown within the scaffold, 
incubated for 24 hours with 50nM of MLN8237 and stained for Arl13B (green), gamma-tubulin (red) and 
DAPI (blue). White arrows indicate examples of aberrant primary cilia, with the basal body (identified 
with gamma-tubulin) shown in red and the axoneme (identified with Arl13B) in green. Scale bar 10µm.   
BA
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5.9 Discussion 
In this final chapter, I present preliminary data on the effects of Plk1 inhibition in glioblastoma 
primary cell lines, showing that GSCs are significantly more sensitive to BI2536 than non-GSCs. 
Unlike with AurA inhibition, the pronounced difference in terms of clonogenicity following Plk1 
targeting cannot be correlated to induction of distinct levels of mitotic spindle defects in the 
two subpopulations, but the major consequence of both AurA and Plk1 inhibition in GSC 
appears to be polyploidization. It is likely that Plk1 inhibition causes a strong cytokinesis defect 
in the GSC that could only be scored appropriately using a live cell imaging assay. In my 
preliminary experiments, I started exploring the hypothesis that non-mitotic functions of Plk1 
might play an important role in the cytotoxic effect observed following its inhibition. If 
confirmed by further tests and statistical analysis of quantitative data, this mechanism could 
address some of the doubts raised on the clinical relevance and utility of mitotic kinase 
inhibitors, based on the argument that these drugs target only dividing cells, which represent a 
negligible fraction (<1% to few percent) of tumoral cells in patients263.  
I also report preliminary observations on primary cilia in GSCs and non-GSCs, showing that 
these can be visualised and analysed in cells grown in a 3D culture system. The feasibility of 
studying cilia in an in vitro model, in which one can introduce several elements from the 
tumoral niche, is particularly intriguing given that these organelles function as antenna for 
cells, sensing chemical and mechanical signals from the microenvironment. In this context, 
given the increasing evidence supporting the importance of the interaction between primary 
cilia and ECM316, the possibility of studying ciliary signalling in GSCs and non-GSCs grown within 
the scaffold coated with specific ECM components (shown in chapter three) is extremely 
exciting and might uncover mechanisms underlying how these cells sense and adapt to 
microenvironmental stimuli. Furthermore, if ciliary signalling plays a role in glioblastoma 
biology, another interesting line of research arising from my experiments is that regarding the 
role of disruption of cilia regulation by AurA in the anticancer effect of MLN8237. Given that 
Plk1 has also been involved in the pathway controlling cilia disassembly317, this question should 
be extended to BI2536.  
The data presented in this chapter are highly preliminary and do not allow any firm 
conclusions without further experimental data. However, an important point of these 
observations is that they strengthen the rationale for targeting mitotic kinases as an effective 
strategy against GSCs, but also suggest that the interphase functions of these proteins need to 
be investigated further, as their disruption is likely to be responsible for part of the cytotoxic 
effect of AurA and Plk1 inhibitors.   
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Chapter 6 
Conclusions
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This thesis presents the results of my research on patient-derived GSCs and non-GSCs, aimed 
at increasing our understanding of the biology of this aggressive brain tumour and, therefore, 
designing more efficacious anticancer treatments. For this scope, at first I optimized in vitro
methods that allow analysis of sensitivity of GSCs and non-GSCs to ionizing radiation and 
chemotherapeutic drugs. Then, I focused on characterization of mitotic phenotypes and 
centrosome cycle in the two cellular subpopulations, with the aim of identifying targets for 
novel therapeutic approaches against glioblastomas. I tested sensitivity of GSCs and non-GSCs 
to these treatments employing the techniques I optimized in the first part of my project. In 
parallel, I developed the use of a 3D culture model for the two subpopulations and I showed 
how it can be applied to study centrosome cycle related features in GSCs and non-GSCs. 
The optimization process of in vitro methods is described in chapter three, which includes two 
main sections: one reporting the experiments performed to develop a clonogenic survival 
assay that allows comparative analysis of sensitivity of GSCs and non-GSCs to ionizing radiation 
and cytotoxic agents, with each subpopulation cultured in its appropriate growth condition; 
the other showing how a 3D culture model can be used to investigate many features, including 
treatment responses, of GSCs and non-GSCs in the presence of various factors characteristic of 
their tumoral niche. The contribution of this work to cancer research is potentially significant, 
given that these techniques allow a more comprehensive approach, providing tools to analyse 
treatment responses related to intrinsic cellular characteristics as well as those induced by 
microenvironmental factors. Further development of such methodologies is likely to improve 
reliability and clinical significance of in vitro experiments, resulting in more accurate selection 
of therapeutic agents for in vivo pre-clinical studies. 
The results of my analysis of cell division and centrosome morphology are described in chapter 
four, which also includes two parts: one showing that GSCs display a higher percentage of 
spindle abnormalities and more pronounced maturation of centrosomes preceding mitosis; 
the other demonstrating that inhibiting AurA, one of the main regulators of the centrosome 
cycle, is particularly effective in targeting GSCs, which, compared to non-GSCs, exhibit a higher 
increase in polyploidy and senescence, with a more pronounced reduction of clonogenicity. 
This section, therefore, addresses the central hypothesis of my project, demonstrating that it 
can be accepted as true, given that I show that centrosome cycle and cell division regulation of 
GSCs have distinctive features, which can be exploited to design therapeutic strategies that are 
both specific and effective against these cells.  
Having recognised the need for further investigation of mitosis and centrosome biology in 
GSCs, I decided to build on these findings. So, I started analysing the effects of inhibiting Plk1 
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and characterizing primary cilia in glioblastoma cells. The preliminary data from these studies, 
presented in chapter five, on the one hand, strengthen the rationale for targeting mitotic 
kinases, on the other, they highlight the relevance of their interphase functions, suggesting 
that future research should also explore these in detail to enable the design of treatment 
combinations that exploit fully the potential benefits of inhibiting these proteins. 
Characterization experiments of primary cilia also have a methodological output, as they show 
the feasibility of analysing these organelles in GSCs and non-GSCs cultured in their appropriate 
growth condition within the 3D model described in chapter three. 
My research on centrosome cycle and cell division is likely to give a meaningful contribution to 
our understanding of glioblastoma biology, as it demonstrates for the first time that in vitro
GSCs differ from non-GSCs with regards to mitotic spindle phenotypes and centrosome 
maturation, providing a possible explanation for the high susceptibility of these cells to mitotic 
kinase inhibitors, observed in my experiments as well as in other studies.  
Planned future studies arising from my work include the following: 
o pathology analysis of xenografts and glioblastoma patient specimens, evaluating mitotic 
phenotypes and centrosome proteins in tissues co-stained with GSC markers. The aim of 
these studies is to test whether my in vitro findings truly reproduce behaviour of 
glioblastoma cells in their natural environment and, therefore, validate their clinical 
relevance. 
o further pre-clinical evaluation of the anti-glioblastoma activity of AurA inhibitors: 
 analysis of fate of GSCs and non-GSCs, after AurA inhibition, using live-cell imaging; 
 evaluation of AurA inhibition as a targeted GSC treatment in xenografts, following 
establishment of biomarkers, such as aberrant spindle phenotypes and AurA 
phosphorylation; 
 more detailed in vitro analysis of potential synergistic effect of AurA inhibition and IR; 
 in vivo evaluation of activity of various treatment schedules (also with IR if in vitro
experiments indicate advantageous interaction), measuring prevention of tumour 
formation and tumour regression.   
o further pre-clinical evaluation of the anti-glioblastoma activity of Plk1 inhibitors: 
 analysis of fate of GSCs and non-GSCs, after Plk1 inhibition, using live-cell imaging; 
 evaluation of DNA damage induction following Plk1 inhibition and investigation of 
effect of combined treatment with IR. 
o characterization of cilia in glioblastoma cells: 
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 quantitative and qualitative analysis of staining patterns of ciliary proteins in GSCs and 
non-GSCs grown within the 3D culture model, with or without specific ECM coating; 
 investigation of the role of ciliary disruption in the anticancer effect of AurA and Plk1 
inhibition, analysing treated cells grown on the 3D scaffold and xenografts.  
Depending on their outcome, these studies might form the basis for designing future clinical 
trials testing the activity of mitotic kinase inhibitors in glioblastoma patients. 
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A B S T R A C T
There is increasing evidence that glioblastoma possess ‘stem-like’ cells, low concentrations
of which can initiate a tumour. It has been proposed that these cells are radioresistant, and
that this property contributes to the poor treatment outcomes of these tumours. In this
paper we propose that radioresistance is not simply an intrinsic characteristic of glioma
stem cells but a result of interactions between these cells and microenvironmental factors,
i.e. the ‘microenvironment e stem cell unit’. The critical role of the microenvironment,
along with glioma stem cells, is supported directly or indirectly by the following observa-
tions: glioma stem cells have been shown to reside preferentially in specific niches, the
characteristics of which are known to influence cellular responses to radiation; radiation
modifies environmental factors; and, contrarily to the consistency of clinical data, in vitro
experiments have reported a wide variety in the radiation response of these cells.
The paper, therefore, focuses on the interaction between tumour stem cells and the micro-
environment, analyzing how its various elements (endothelial cells, extracellular matrix,
cytokines, nitric oxide, oxygen levels) are affected by radiation and how these might influ-
ence the response of tumour stem cells to radiation.
Finally, we summarize the ongoing debate on the optimal culture conditions for glioma
stem cells and the difficulties in designing assays that reliably characterize their radiation
response.
ª 2011 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
1. Introduction
There is increasing evidence that human glioblastoma pos-
sess ‘stem-like’ cells, small numbers of which are capable of
initiating a tumour that closely resembles the original cancer.
It has been proposed that these tumour initiating cells are re-
sistant to radiation therapy, and that this property contributes
to the poor treatment outcomes associated with these tu-
mours. After analyzing the conflicting data published on this
subject over the past seven years, this article proposes that
radioresistance is not simply an intrinsic characteristic of gli-
oma stem cells but a result of the interaction between these
cells and microenvironmental factors, i.e. a property of the
‘microenvironment-stem cell unit’. The latter term is used to
* Corresponding author. Tel.: þ44 141 301 7097; fax: þ44 141 301 7095.
E-mail address: anthony.chalmers@glasgow.ac.uk (A.J. Chalmers).
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define a functional entity which includes both tumour stem
cells and microenvironmental factors. The critical role of in-
teractions between the microenvironment and glioma stem
cells is supported directly or indirectly by the following obser-
vations: (1) glioma stem cells have been shown to reside pref-
erentially in specific niches, the characteristics of which are
known to influence cellular responses to radiation; (2) radia-
tion modifies environmental factors; and (3) contrarily to the
relative consistency of clinical data, in vitro experiments
have reported a wide variation in the radiation responses of
glioma stem cells.
The paper, therefore, focuses on the interaction between
tumour stem cells and the microenvironment, analyzing
how its various elements (endothelial cells, extracellular ma-
trix, cytokines, nitric oxide, oxygen levels) are affected by ra-
diation and how these factors might influence the response
of tumour stem cells to radiation.
Finally, wewill summarize the ongoing debate on how best
to culture glioma stem cells to facilitate their study in vitro,
and consider the difficulties encountered when designing as-
says to characterize their radiation responses.
2. Glioma stem cells: how strong is the evidence for
their intrinsic radioresistance?
2.1. ‘Stem-like’ cells in glioblastoma
The first experimental evidence for the existence of “stem-
like” cells in glial brain tumours was reported in 2002, when
these malignancies were shown to contain cells that were ca-
pable of clone-formation under culture conditions used in the
study of ‘normal’ neural stem cells, and could also be induced
to undergo differentiation along astrocytic and neural line-
ages (Ignatova et al., 2002). Two years later, a study using an
intracranial xenograft model provided evidence for the ability
of a subpopulation of cells isolated from glioblastoma speci-
mens to induce tumours in vivo at a very high frequency. Injec-
tion of as few as 100 selected cells into the brains of NOD-SCID
(non-obese diabetic, severe combined immunodeficient) mice
was sufficient for the formation of human brain tumours,
which phenotypically resembled the patient’s original speci-
men and could be serially transplanted. In contrast, injection
of up to 105 negatively-selected cells did not generate tumours
(Singh et al., 2004). Thereafter, several studies have analysed
the behaviour of primary glioblastoma cell lines sorted by ex-
pression of candidate stem cell markers (CD133, A2B5, SEEA-1)
or by growth pattern (sphere or adherent) in serum free me-
dium (SFM) supplemented with growth factors. These cells
were characterised in terms of self-renewal (tested with the
neurosphere formation assay, NFA), differentiation potential
and in vivo tumorigenicity (tested in intracranial xenograft
models). On one hand, the reported data strongly support
the existence of a subpopulation of highly tumorigenic cells,
as indicated by the tumour induction rates observed for puta-
tive stem cells in individual studies (see Table 1). On the other
hand, the inconsistencies between the various studies high-
light the limitations of present cell sorting methods and the
need for standardisation of assays that test for ‘stemness’
(Singh et al., 2004; Hemmati et al., 2003; Galli et al., 2004;
Yuan et al., 2004; Bao et al., 2006a,; Beier et al., 2007; Wang
et al., 2008; Gunther et al., 2008; Ogden et al., 2008; Son et al.,
2009; Liu et al., 2009; Kondo et al., 2004; Chang et al., 2009;
Clement et al., 2010). A detailed analysis of the validity of indi-
vidualmarkers or techniques is beyond the scope of this paper
but an excellent overview of the topic is provided in a recent
review (Campos and Herold-Mende, 2011).
2.2. Radiation responses of glioma stem cells
The accumulating evidence that only a small subpopulation of
cells is capable of giving rise to a tumour has led to the theory
that the almost inevitable recurrence of glioblastoma is due to
persistence of these cells despite multimodality treatment.
Several clinical studies have investigated the prognostic value
of putative stem cell markers and related cellular features in
tumour specimens. Although these studies have generally in-
volved relatively small numbers of patients and have tended
to focus on only one or two markers, the results have consis-
tently supported the implication of glioma stem cells in treat-
ment resistance. In a retrospective study of 95 glioma
specimens of different grades (47 glioblastomas), multivariate
analysis including histological grade, patient age and extent of
resection showed significant associations of CD133 expression
(>1% vs 1% positive cells) and organization of these cells in
clusters (cluster vs single cells) with shorter overall survival
(Zeppernick et al., 2008). Similarly, a prospective multivariate
analysis of specimens from 44 patients with glioblastoma in-
dicated that CD133 expression (>2% vs 2% positive cells)
and in vitro neurosphere formation ability (present vs absent)
were prognostic factors for a higher risk of death. This associ-
ation was independent of symptom duration, extent of surgi-
cal resection, patient age, MGMT status and p53 status (Pallini
et al., 2008). Consistent with these results are two additional
retrospective analyses of glioma specimens. One reported sig-
nificantly lower survival in patients with gliomas co-express-
ing CD133 and nestin (Zhang et al., 2008), the other showed
a correlation between decreasing overall survival and increas-
ing levels of nestin expression in tumour cells (Strojnik et al.,
2007).
The greatest limitation of these data is the retrospective
design of three out of the four studies. Also, although the re-
sults of the latter two studies were generated by multivariate
analysis, their value is lessened because adjustments were
made only for tumour grade in the former study and for pa-
tient age and sex in the latter, without incorporating the other
established prognostic factors. Despite these weaknesses, the
consistency of the association between prognosis and expres-
sion of the putative stem cell marker CD133 in all four studies
is striking.
Evidence for a role of glioma stem cells in determining
treatment resistance also comes from a recent publication
that analysed expression of CD133 in glioma specimens
from ten patients that had undergone surgical resection be-
fore and after high-dose irradiation delivered by stereotactic
radiosurgery (Gamma Knife) followed by external beam radia-
tion (Tamura et al., 2010). The percentage of CD133þ cells was
significantly higher in the post-treatment tumour material
than in the original specimens. Although these data do not
MO L E C U L A R O N C O L O G Y 5 ( 2 0 1 1 ) 3 7 4e3 8 6 375
Table 1 e Studies characterizing glioma cells in terms of self-renewal (tested with the neurosphere formation assay) and in vivo tumorigenicity (tested in xenograft models).
Study Number of glioma
cell lines
Cell sorting
method
Neurosphere
formation assay
In vivo tumorigenicity
assay
Plating method Analysis Results Method Results
Hemmati
et al., 2003
10
(2 glioblastoma)
Culture
condition (SFM)
Serial dilution of cells from
dissociated neurospheres
(1000 cells/ml)
Presence of
neurospheres
(within 2e4 wks)
“In all cases
neurospheres
were visible”
IC injection of 5  104
cells (glioblastoma)
into neonatal rats (# NS)
Observed migration,
differentiation and
proliferation of cells
(after 4 wks)
Kondo
et al., 2004
1 rat glioma
cell line (C6)
Ability to extrude
actively Hoechst
33342
FACS sorting (1 cell/well) % of cells forming
neurospheres
SP: 70% Non-SP: 0 Intraperitoneal injection
of 105 cells (6 mice
per cell type)
Presence of tumour:
SP: 100%
Non-SP: w30%
Galli
et al., 2004
6 glioblastoma
(5 primary and 1
secondary
glioblastoma)
Culture
condition (SFM)
“Cells derived from the
dissociation of clonal
single neurospheres
were seeded in
48-well plates”
Number of
neurospheres
per dissociated clone
after 8e10 days
Primary
glioblastoma
cell lines: 28e85
Secondary
glioblastoma
cell line: 26
U87 cell line: 90
Injection of:
 2  105 cells into the
striatum (IC) of Scid/
bg mice (# NS)
 3  106 cells into the
flank (SC) of Scid/bg
mice (# NS)
Take efficiency:
 100% IC model (7 wks)
 50% SC model (6 wks)
Singh
et al., 2004
4 glioblastoma Magnetic sorting for
CD133 expression
Serial dilution
(range: 200 to
1 cell/well)
% of wells without
neurospheres
after 7 days
CD133þ cells:
 >90% with <
10 cells/well
 0 with w60
cells/well
CD133
cells: 100%
IC injection of:
 100 (4 mice) or 1000
(5 mice) CD133þ cells
 1  105 (12 mice)
CD133 cells
Presence of tumour:
 CD133þ cells: 100%
(6e13 wks)
 CD133 cells:
0 (12e13 wks)
Yuan
et al., 2004
6 glioblastoma Culture
condition (SFM)
Serial dilution
(1e2 cells/well)
Number of positive
wells after 14 days
Sphere culture
cells: 3e5%
Monolayer
culture cells: 0
IC injection of:
 5000 (6 mice)
or 5  104
(6 mice) sphere
culture cells
 5  104 (6 mice)
or 2.5  105
(6 mice) monolayer
culture cells
Presence of tumour
(after 6 wks):
 sphere culture
cells: 100%
 monolayer
culture cells: 0
Bao
et al., 2006a,b
3 glioblastoma
(þ3 xenografts)
Magnetic or FACS
sorting for CD133
expression
NS % of cells forming
neurospheres
CD133þ
cells: 76e83%
CD133- cells: 0
Total cells:
2.4e3.4%
IC injection of various
numbers of cells
Minimum number of
cells for tumor initiation
(after 8 wks):
 500e1000
for CD133þ cells
 No detected tumour
with 2  106
CD133 cells
 2e4  104
unsorted cells
Presence of tumour:
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Beier
et al., 2007
22 glioblastoma
(15 primary and 7
secondary
glioblastoma)
Magnetic sorting for
CD133 expression
Serial dilution
(1 cell/well)
% of neurospheres
per plated cells
(after 42 days)
CD133þ cells: 2e5%
CD133 cellsa: 0
CD133 cellsb: 0.5e2%
IC injection of 105 or 106
cells in T-lymphocyte-
deficient NMRI(nu/nu) mice
(6 mice per cell population)
 CD133þ cells: 100%
 CD133 cellsa: 0
 CD133 cellsb: 100%
(within 50 days)
Wang
et al., 2008
11 glioblastoma Culture
condition (SFM)
or FACS sorting for
CD133 expression
e e e IC injection into nude
immunodeficient rats of:
 10 spheroids
 CD133- cells (# NS)
Take rate:
 Spheroids: NS
(tumour present)
 CD133 cells:
19/28 rats
Gunther
et al., 2008
9 glioblastoma Culture
condition (SFM)
Serial dilution
(1 cell/well)
% cells forming
neurospheres
after 14 days
Sphere or semi-
adherent growing
cells: 16.9e53.8%
Adherent growing
cells: 0
IC injection of 1.5  105
or 1000 cells
into NMRI(nu/nu) mice
Presence of tumour:
 Sphere or semi-
adherent
growing cells:
B16/18 for
1.5  105 cells
B37/46 for
1000 cells
 Adherent
growing cells:
B1/6 for
1.5  105 cells
B0/6 for 1000 cells
Ogden
et al., 2008
25
(16 glioblastoma)
FACS sorting
for A2B5 
CD133 expression
e e e IC injection of:
 4000 to 1  105 A2B5þ
CD133þ cells (4 mice)
 1  104 to 2.2  105 A2B5þ
CD133 cells (14 mice)
 1  105 to 1.2  105 A2B5
CD133 cells (10 mice)
Presence of tumour:
 A2B5þ CD133þ
cells 100%
 A2B5þ CD133
cells 92%
 A2B5 CD133
cells 10%
Chang
et al., 2009
7 glioblastoma Magnetic sorting for
CD133 expression
NS Number of
neurospheres
CD133þ cells: w250
CD133 cells: w20
IC injection of 5000 or 1  104
cells (28 SCID mice per group)
Presence of tumour:
 CD133þ cells: 100%
 CD133 cells: 0.
Son
et al., 2009
12 glioblastoma
(þ12 established
cell lines)
Magnetically or FACS
sorting for SEEA-
1  CD133 expression
Limiting dilution
(5e50 cells/well)
% of wells without
neurospheres after
2e3 weeks
SSEA-1þ cellsc:
 20e80%
with <5 cells/well
 10e60% with w10
cells/well
 0 with >10
cells/well
SSEA-1- cellsc:
 70e95% with <5
cells/well
 50e85% with w10
cells/well
 40% with 25e50
cells/well
IC injection of 1000, 104 or
3  105 cells in
NOD/SCID mice
Presence of tumour:
 SSEA-1þ cells: 21/21
 SSEA-1- cells:
B0/13 for 1000
and 104 cells
B2/9 for 3  105
cells
 unsorted cells:
B2/5 for 1000 cells
B5/6 for 104 cells
B6/6 for 3  105
cells
(continued on next page)
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Table 1 (continued)
Study Number of glioma
cell lines
Cell sorting
method
Neurosphere
formation assay
In vivo tumorigenicity
assay
Plating method Analysis Results Method Results
Liu
et al., 2009
2 glioblastoma FACS sorting for
CD133 expression
e e e IC injection of:
 5e10  103 CD133þ
cells (12 SCID mice)
 5  105 CD133 cells
(20 SCID mice)
Presence of tumour:
 CD133þ cells: 11/12
 CD133 cells: 0/20
Clement
et al., 2010
5 glioblastoma
(4 primary,
1 secondary
glioblastoma)
Intrinsic
autofluorescence
and morphology
NS (1 cell/well) Number of spheres
per plated wells after
two or five in vitro
passages
Second sphered:
 FL1þ: 3/192
to 18/192 (1.6e9.4%)
 FL10: 1/192 to
6/192 (0.5e3.1%)
Fifth sphere:
 FL1þ: 1/192 to
12/315 (0.5e3.8%)
 FL10: 0 to
1/192 (0e0.5%)
IC injection of:
 103 to 105 FL1þ cells
(24 nude mice)
 104 to 105 FL10 cells
(23 nude mice)
Presence of tumour:
 FL1þ: 100%
 FL10: 13%
FACS, fluorescence activated cell sorting. IC, intracranial. NS: not specified. SC, subcutaneous. SFM, serum-freemedium. SP, side population. SSEA-1, stage-specific embryonic antigen 1. wks, weeks. #,
number.
a These cells were derived from CD133 þ sphere cultures.
b These cells were from adherently growing CD133- sphere cultures.
c These percentages are derived from graphs included in the publication.
d FL1þ cells were defined as those displaying autofluorescence emission around 520 nm (in the FL1 channel) upon laser excitation at 488 nm.
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establish a causative relationship, they are consistentwith the
hypothesis that glioma stem cells are capable of surviving
high doses of radiation.
Because radiation therapy is the primary treatmentmodal-
ity for patients with glioblastoma, the proposed radioresist-
ance of glioma stem cells is a corollary of the theory that
holds tumour stemcells responsible for the very low cure rates
observed.However, laboratory studies comparing radiation re-
sponses of glioma stem cells with those of differentiated or
‘non-stem’ glioma cells have until now produced conflicting
data. To our knowledge there are only two studies (Bao et al.,
2006a; McCord et al., 2009) that have performed a comparative
analysis of clonogenic survival assays in the two cellular sub-
populations. Clonogenic survival is traditionally recognized
as the ‘gold standard’ endpoint for testing intrinsic radiosensi-
tivity in a clinically relevant manner. In the first published pa-
per (Bao et al., 2006a,), colony formation assays were
performed using CD133þ and CD133 cells derived either
from a biopsy specimen or from glioma xenografts. Cells
wereeither irradiated (5Gray (Gy)) or leftuntreated.Colony for-
mation rateswere not quantified, but representative images of
survivingcolonieswerepresentedtosupporta relative radiore-
sistance of CD133þ cells. As a measure of post-irradiation clo-
nogenicity, the study also reported tumour formation rates of
CD133þ and CD133 cells derived from tumour specimens or
gliomaxenografts. The authors demonstrated that in vitro irra-
diationwith 2Gydidnot significantly affect tumourigenicity of
CD133þ cells,while ahigherdose of 5Gy resulted in a 5e10 fold
increase in theminimumnumber of cells required for tumour
initiation compared to unirradiated cells (evaluated after 8
weeks).AsCD133 cellsdidnot generate tumours, comparison
of radiation response curves, and therefore radiosensitivity, of
CD133þ and CD133 cells by this method was not feasible. In
the more recent study (McCord et al., 2009) reporting clono-
genic analysis of primary cell lines obtained fromglioblastoma
specimens, the surviving clonogenic fraction of CD133þ cells
was significantly higher than that of the CD133 population
in one of the two cell lines tested. Interestingly, when clono-
genic assays were performed on a panel of CD133þ primary
cell lines and three established glioma cell lines, substantial
variability was observed in their survival curves, with all six
CD133þ cell lines being more radiosensitive than the estab-
lished cell lines. These findings highlight the heterogeneity of
in vitro radiosensitivity that exists amongst primary cell lines,
despite prospective selection for putative stem cell markers,
and illustrate the inherent problems associated with compar-
ing radiosensitivity parameters across cell lines of different
origins.
To further investigate the intrinsic radiosensitivity of gli-
oma stem cells relative to non-stem cells, the authors of the
landmark Bao study (Bao et al., 2006a) analysed additional ra-
diation responses of the two subpopulations in vitro and in
vivo. An in vitro cell mixing and repopulation experiment, in
which CD133þ and CD133 cells from a tumour specimen
were differentially labelled, mixed in definite ratios and left
untreated or irradiated (5 Gy), showed that, after 8 days of cul-
ture, the percentage of CD133þ cells increased from 5% to
w80% in the irradiated population and to w25% in the un-
treated one. In the corresponding in vivo study, in which
CD133þ and CD133 cells were labelled,mixed and implanted
into the brains of athymic nude mice that were subsequently
irradiated (5 Gy) or left untreated, the ratio of CD133þ:CD133
cells increased from 0.2 to more than 4 in the irradiated mice
and tow2 in the control group. These data are consistent with
enhanced survival of glioma stem cells after radiation but also
indicate that, under these conditions, a component of the sur-
vival advantage of CD133þ cells over CD133 cells is indepen-
dent of radiation.
To identify possible mechanisms underlying an intrinsic
radioresistance of CD133þ cells, proteins involved in apoptosis
and earlyDNAdamage checkpoint responseswere analysed in
cells derived from tumour specimens and xenografts (Bao
et al., 2006a). Western blot for cleaved caspase-3 (before and
24 h after 2 or 5 Gy) and immunofluorescence staining for
Annexin-V-FITC (before and20h after 3Gy) both showed lower
rates of apoptosis in CD133þ cells compared to CD133 cells.
Furthermore, analysis of phosphorylated ATM, Rad17, Chk1
and Chk2 (before and 1 h after 3 Gy) demonstrated higher acti-
vation of these cell cycle checkpoint proteins in CD133þ cells
than inCD133 cells. Alkaline comet assays andquantification
of cells staining positively for phosphorylated histone 2AX
performed before and after irradiation (3 Gy) were consistent
with a potential mechanism involving faster resolution of
both single and double strand breaks in CD133þ cells than in
CD133 cells.
A more recent study also compared CD133þ and CD133
populations from primary glioma cell lines with regard to
early DNA damage checkpoint responses and DNA repair ca-
pacity. While increased activation of Chk 1 and Chk2was con-
firmed in both irradiated (1 h post 3 Gy) and unirradiated
CD133þ cells, no significant difference in DNA damage induc-
tion or repair was observed between the two cellular subpop-
ulations, as measured by comet assay and phosphorylated
histone 2AX positivity (Ropolo et al., 2009).
Two further studies have analysed in vitro viability of gli-
oma stem and non-stem cells (defined by expression of
CD133) after irradiation and demonstrated a higher percent-
age of surviving cells in the former population (Chang et al.,
2009; Lomonaco et al., 2009). These observations are of limited
value, however, as viability at early time points is not a mea-
sure of clonogenicity and may not correlate with a clinically
relevant response to radiation.
Finally, four studies have shown that radiosensitivity of
glioma stem cells can be increased by inhibiting specific pro-
teins (SirT1 (Chang et al., 2009), Notch (Wang et al., 2010b),
Chk1/Chk2 (Bao et al., 2006a), autophagy-related proteins
Beclin and ATG5 (Lomonaco et al., 2009)), two of which (Chang
et al., 2009; Wang et al., 2010b) have been associated with
stemness or tumorigenicity. Although these findings suggest
that there are intrinsic cellular features of glioma stem cells
that can be targeted to modify radiation responses, the speci-
ficity of these mechanisms to this cellular subpopulation
needs to be investigated further.
More detailed discussion of relevant aspects of the DNA
damage response in carcinogenesis and cancer treatment, in-
cluding glioblastoma, is provided in three articles that are also
published in this edition of Molecular Oncology. These re-
views cover chromosomal instability (Kr€amer et al.) and ther-
apeutic approaches targeting defects in DNA repair (Evers and
Helleday) and replication stress (Toledo et al.).
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In summary, although a number of findings indicate that
there are differences between the radiation responses of gli-
oma stem cells and their differentiated counterparts, it is dif-
ficult to evaluate their significance in terms of radiosensitivity
for the following reasons: 1) the importance of apoptosis in de-
termining clonogenicity after radiation has not been estab-
lished and probably varies between cell types (Steel, 2001); 2)
the apoptosis data refer to single time points whereas the
time-course of apoptosis after radiation varies considerably
between cell lines; 3) DNA damage responses need to be inter-
preted in the light of clonogenic survival data as their validity
in terms of predicting for radiosensitivity is still under debate
(Lobrich et al., 2010). Also, the inconsistency of the DNA repair
data suggest that some mechanisms may be cell line specific.
Considering the extensive heterogeneity of glioblastoma, the
conclusion that intrinsic radioresistance of CD133þ cells is re-
sponsible for treatment resistance should probably be applied
with caution at this stage.
The variability and scarcity of existing data regarding ra-
diosensitivity of glioma stem cells and non-stem cells can,
on one hand, be viewed as a reflection of the inherent difficul-
ties in designing clonogenic survival assays for cellular popu-
lations that present distinct growth patterns and require
different culture conditions. On the other hand, since existing
experimental models testing radiation responses do not take
into account factors present in the tumour microenviron-
ment, they can also be considered as an indication of the
need for more representative assays for determining cellular
radiosensitivity. This consideration together with the obser-
vation that glioma stem cells reside preferentially in specific
niches (Zeppernick et al., 2008; Calabrese et al., 2007; Li
et al., 2009; Christensen et al., 2008) leads to our proposal
that radioresistance is more likely to be a property of the ‘mi-
croenvironment-stem cell unit’, a functional entity within
which glioma stem cells are able to maintain or enhance in-
trinsic cellular features that contribute to radiation resistance.
Indirect evidence for the relevance of the ‘microenviron-
ment-stem cell unit’ in determining radiosensitivity comes
from a recent study comparing induction and repair of radia-
tion-induced DNA damage in CD133þ cells grown in vitro and
as intracranial xenografts. Levels of phosphorylated histone
2AX foci decreasedmore rapidly in the in vivo setting, suggest-
ing a more efficient DNA repair ability of these cells in the
presence of microenvironmental factors (Jamal et al., 2010).
Also consistent with the proposed theory are the results of
a study that used a 3-dimensional organotypic ‘explant’ sys-
tem of surgical glioblastoma specimens to test the effect of ra-
diation and/or Notch inhibition on glioma stem cells (Hovinga
et al., 2010). Radiation alone (10 Gy) had a dramatically lower
impact on self-renewal capacity of tumour cells in the ex-
plants than in neurosphere cultures. The effect of Notch inhi-
bition also varied between the two models, causing a further
decrease in neurosphere formation rate only when tumour
cells were treated in the explant setting. The importance of
the ‘microenvironment-stem cell unit’ is also indicated by
a study that usedmousemodels of medulloblastoma to inves-
tigate mechanisms responsible for regional differences in ra-
diation responses (Hambardzumyan et al., 2008). After
demonstrating that Akt signalling exerts different effects in
nestin-expressing cells residing in the perivascular niche
compared with cells forming the tumour bulk, the authors
conclude that in order to detect cell-type-specific responses
it is critical to use models that recapitulate the various cell
types within an appropriate environment.
Despite the limitations of these studies (for example, the
uncertain validity of radiation-induced foci and apoptosis
levels as predictive indices of cellular radiosensitivity and
the possibility that neurosphere culture conditions select for
specific subpopulations), they all highlight the importance of
interrogating the ‘microenvironment-stem cell unit’ when in-
vestigating the biology of therapeutic radiation responses.
3. ‘Microenvironment-stem cell unit’: is this the true
radioresistant entity in glioblastomas?
In order to understand how the tumourmicroenvironment in-
fluences radiation responses of glioma stem cells, it is essen-
tial to characterize the niche in which they are thought to
reside. Studies investigating whether glioma stem cells exist
in specific niches have analyzed the distribution in tumour
specimens of cells positive for CD133 or other markers associ-
ated with a stem cell phenotype. The first published series
(Calabrese et al., 2007) evaluated the distance of nestinþ and
nestin cells from the nearest CD34þ endothelial cell in fro-
zen sections from ten glioblastoma specimens. Nestinþ cells,
three quarters of which co-expressed CD133, were signifi-
cantly closer to capillaries than were nestin cells. Also, 3D
reconstruction of serial images from four glioma specimens,
using multiphoton laser-scanning microscopy, showed that
nestinþ tumour cells were often in direct contact with tumour
capillaries. A close relationship between CD133þ cells and
vascular structures was also found in a study (Christensen
et al., 2008) analyzing paraffin sections from seventy-two glio-
blastoma specimens: 54% of tumours exhibited CD133þ
niches, which were defined as “a limited entity of cells corre-
sponding to a minimum of 5e10 cells identifiable at low mag-
nification”. Many of these entities were perivascular or
associated with necrotic regions. The latter association was
indirectly confirmed by immunofluorescence studies on fro-
zen tumour samples, which demonstrated co-expression of
CD133 and hypoxia inducible factor 2a (HIF2a). Finally, a study
that was mentioned in the previous section reported that
CD133þ cells were found in clusters in 41 of 47 glioblastoma
specimens (Zeppernick et al., 2008).
The interaction of glioma stemcellswith blood vessels, and
more specifically with endothelial cells and vascular endothe-
lial growth factor (VEGF), is one of themain areas of interest in
this field (Knizetova et al., 2008). New insightswere recently of-
fered by two studies, which demonstrated that CD133þ cells
are capable of undergoing differentiation along the endothe-
lial lineage and that a subpopulation of endothelial cells
within glioblastomas are directly derived from tumour cells
(Ricci-Vitiani et al., 2010; Wang et al., 2010a). Regardless of
the function and/or fate of glioma stem cells in the perivascu-
lar area, their presence in this niche prompts the question of
whether there are specific elements in such regions that con-
tribute to radiation resistance. Apart from the obvious interac-
tion with endothelial cells, glioma stem cells residing in
perivascular regions are in contact with extracellular matrix
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(ECM) components that are preferentially expressed within
and around blood vessels. The vascular basement membrane
is composed of collagen, fibronectin, laminin, heparan sul-
phate, entactin and vitronectin, while the tumour ECM sur-
rounding blood vessels is rich in tenascin C, secreted protein
acidic and rich in cystein (SPARC) and thrombospondin. Inter-
estingly, all components but vitronectin are scarcely present
in the remaining tumour ECM. A clear and schematic repre-
sentation of the heterogeneous distribution of ECM proteins
in glioblastoma is provided in a review discussing their role
in modulating glioma cell invasion (Bellail et al., 2004). An ad-
ditional component of the perivascular niche is nitric oxide
(NO), synthesized by endothelial nitric oxide synthase (eNOS)
which is known to be highly expressed in vessels within glio-
blastomas (Iwata et al., 1999).
Expanding on these observations, the following para-
graphs will analyze evidence relating to the theory that ele-
ments of the perivascular niche (endothelial cells, ECM
proteins, NO and relevant cytokines) and hypoxic areas mod-
ulate cellular responses to radiation. This discussion will in-
clude data derived from studies of glioblastoma along with
information from other cancers. A schematic representation
of these interactions is given in Figure 1.
3.1. Endothelial cells
Several studies analyzing the association between endothelial
cells and glioma stem cells support the hypothesis that
interactions between these two cellular populations are recip-
rocal. On the one hand, glioma stem cells have been shown to
exert a pro-angiogenic effect that is mediated by stimulation
of endothelial cells through production of VEGF (Bao et al.,
2006a; Folkins et al., 2009; Salmaggi et al., 2006). A recent study
investigating the interaction between glioma and endothelial
cells in both a 3D co-culture system and an in vivomodel dem-
onstrated that glioblastoma cells became incorporated into
the tumour vasculature (Shaifer et al., 2010). Interestingly,
vascular networks formed in co-culture remained stable for
weeks, unlike those arising from endothelial cells alone,
which regressed soon after formation. On the other hand, en-
dothelial cells have been proven to play a role in glioma stem
cell maintenance. The evidence for this comes from the previ-
ously mentioned study by Hovinga (Hovinga et al., 2010) and
colleagues that used a 3-dimensional organotypic ‘explant’
system of surgical glioblastoma specimens. Selective elimina-
tion of endothelial cells from the model casued a >50% reduc-
tion in the neurosphere formation capacity of single cells
obtained by dissociation of the explants. Data from other cen-
tral nervous system tumour types are consistent with these
results. A study comparing the ability of endothelial and other
cells (CD133 tumour cells, fibroblasts or astrocytes) to main-
tain the viability of CD133þ/nestinþ tumour cells derived
from medulloblastoma and ependymoma demonstrated that
a larger percentage of tumour spheres survived if they were
co-cultured with endothelial cells for 5 days. After 2 weeks,
these spheres were up to five times larger than those grown
Figure 1 e Schematic representation of interactions (proven or suggested by data on other cell types) between glioma stem cells and components of
the microenvironment. Blue arrows indicate a positive regulation, the brown arrow a negative one, in terms of proliferation and/or radioresistance.
bFGF, basic fibroblast growth factor. BM, basement membrane. EC, endothelial cell. ECM, extracellular matrix. GSC, glioma stem cell. HS,
heparin sulphate. NO, nitric oxide. SPARC, secreted protein acidic and rich in cystein. T, tenascin C. TSP, thrombospondin.
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with control cells (Calabrese et al., 2007). Co-culture with en-
dothelial cells was also more likely to maintain self-renewal
of CD133þ/nestinþ brain tumour cells, demonstrated by the
ability of these cells to generate spheres after two weeks of
co-culture with the various cell types (Calabrese et al., 2007).
Evidence for reciprocal regulation of radiation responses
between endothelial and tumour cells is accumulating. The
above mentioned study investigating the interaction between
glioma and endothelial cells in a 3-dimensional co-culture
system demonstrated a survival advantage after irradiation
(6 Gy) for mosaic vasculature compared to blood vessels
formed by endothelial cells alone. Similarly, a study compar-
ing radiation-induced apoptosis in endothelial cells either in
mono-culture or in co-culture with glioma cells showed that
after 3 Gy there were significantly higher levels of apoptosis
in the mono-cultured cells (Brown et al., 2004). Consistent
with these findings are the results of a study analyzing the ef-
fect of endothelial susceptibility to apoptosis on radiation-in-
duced apoptosis in fibrosarcoma and melanoma in vivo
models. After a large single dose of 15 Gy, tumour cell apopto-
sis increased in tumourswith an apoptosis-sensitive endothe-
lium (grown in asmaseþ/þ or Baxþ/þ mice), but not in those
with apoptosis resistant endothelial cells derived from
asmase/ or Bax/ mice (Garcia-Barros et al., 2003).
Although suggestive of a radioprotective effect of glioma
cells on endothelial cells, the correlation between radiosensi-
tivity of gliomas and the endpoints used in these in vitro stud-
ies (regression of blood vessels and apoptosis of endothelial
cells) is not known. Furthermore, the use of large single doses
of radiation in these experiments limits extrapolation of the
findings to the clinical setting. Further evidence including clo-
nogenic survival data is required to confirm the existence of
an enhancing feedback loop between endothelial and glioma
stem cells that might modulate radiation responses and
thence survival. In the light of the two recent studies reporting
the existence within glioblastomas of a subpopulation of en-
dothelial cells derived directly from glioma stem cells (Ricci-
Vitiani et al., 2010; Wang et al., 2010a), the underlying mecha-
nisms of such a relationship are likely to be complex andmul-
tifaceted and their elucidation will require detailed analysis in
robust model systems.
3.2. ECM components
The spatial association of glioma stem cells with specific ECM
components expressed within and around blood vessels is
particularly intriguing given that evidence is accumulating
across cancer types for the importance of cell-ECM interac-
tions in influencing the response of tumour cells to radiation.
Review of the relevant literature identifies three main mecha-
nisms that might influence glioma stem cell survival and ra-
diosensitivity. ECM components have been proposed to 1)
serve as a deposit for proteins which modulate radiation re-
sponses, 2) operate as a substratum for the activation of pro-
survival integrin-mediated signalling cascades in tumour cells
following radiation, and 3) create a more favourable niche for
proliferation of cells that survive irradiation.
The first property is suggested by the ability of heparan sul-
phate, a component of the basement membrane, to bind basic
Fibroblast Growth Factor (bFGF) (Folkman et al., 1988), which
has been shown to stimulate growth (Loilome et al., 2009)
and inhibit radiation-induced apoptosis (Bao et al., 2006a) of
glioma stem cells in vitro. More evidence for a modulatory
role of this growth factor in radiation responses comes from
studies on other cell types. bFGF has been found to increase
radioresistance of endothelial cells both in clonogenic survival
assays and an in vivo model where it protected against devel-
opment of lethal radiation pneumonitis (Fuks et al., 1994). A
protective effect was also demonstrated in HeLa cells, using
clonogenic survival assays (CohenJonathan et al., 1997). Stud-
ies analysing the effect of bFGF on clonogenicity of glioma
stem cells post-irradiation are needed to test more rigorously
the potential radioprotective role of bFGF in these cells. Hep-
aran sulphate acts as a binding site for many additional pro-
teins (Lindahl and Li, 2009); these should also be interrogated
with regards to their effect on glioma stem cell survival.
The secondmechanism finds its basis in the literature cor-
relating increased radioresistance of glioma cell cultures with
expression and activation of integrins b1 (Cordes et al., 2006),
avb3 and avb5 (Monferran et al., 2008). The role of integrins in
modulating radiation responses has been demonstrated in
various cancer types (Sandfort et al., 2007). A study comparing
clonogenic survival of glioma cells irradiated 24 h after plating
on fibronectin, Matrigel, bovine serum albumin (BSA) or poly-
styrene showed that the first two substrata significantly in-
creased survival, but only in one of the four cell lines tested
(Cordes et al., 2003). However, substratum-dependent survival
has also been demonstrated in a lung carcinoma cell line and
a lung fibroblast stem cell line (Cordes and van Beuningeni,
2003). Characterization of the effects of glioma stem cell at-
tachment to the various ECM components present in the tu-
mour is essential in order to clarify whether any of these
factors play a role in determining the fate of glioma stem cells
after irradiation.
The thirdmechanism is supported by three observations re-
lated to tenascinC. Thismolecule stimulates tumour cell prolif-
eration (Midwood and Orend, 2009); its expression in glioma
specimens correlates inversely with the degree of cell differen-
tiation (Higuchi et al., 1993); and a study analysing radiation-in-
ducedconnective tissuechanges inwomenwhohadundergone
radiation therapy for breast cancer demonstrated an increased
expression of tenascin C in irradiated areas(Riekki et al., 2001).
Taken together, these data suggest that a post-irradiation in-
crease in tenascinC,which is alreadyoverexpressed in theperi-
vascular niche where glioma stem cells preferentially reside,
might have a protective role. The likely mechanism involves
tenascinCstimulatingproliferationofsurvivingcells thuscoun-
terbalancing radiation cell killing. The role of this molecule in
treatment resistance is also suggested by an immunohisto-
chemical study, in which a significant reduction in survival
was observed in glioblastoma patients whose tumours strongly
expressed tenascin C (87 patients), compared to those with re-
duced expression (12 patients) (Leins et al., 2003). Preliminary
butencouragingevidencesupportingtenascinCasatherapeutic
target in glioblastoma has been reported in radioimmunother-
apy studies (Reardon et al., 2002; Reardon et al., 2008) and a clin-
ical study in which tenascin C was downregulated by RNA
interference (Rolle et al., 2010).
Modulation of glioma stem cell radiation responses by
other ECM components such as SPARC and thrombospondin
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is less well supported, although data from other cancer sites
suggest they might exert a radiosensitizing effect (Tai et al.,
2005;Maxhimer et al., 2009). These factorsmerit further inves-
tigation in the context of glioblastoma, especially with regards
to SPARC, expression of which has been reported to correlate
inversely with survival in astrocytic tumours (Rich et al., 2005;
Capper et al., 2010).
Taken together thesedatahighlight the importanceof stud-
ies analysing the complex interactions between various ECM
componentsand tumourcells, in order to clarifyhow thevicin-
ity of glioma stem cells to specific elements influences their
survival post-irradiation. As mentioned previously, however,
the heterogeneity observed amongst glioblastomas indicates
that the individual mechanisms outlined above are likely to
exert different levels of influence on treatment responses in
different patients.
3.3. Nitric oxide
A role for NO in promoting radioresistance of glioma stem cells
is suggested by two recent publications. One, using a genetically
engineered mouse model of platelet derived growth factor
(PDGF)-induced glioma, demonstrated that endothelial nitric
oxide synthase (eNOS) co-localized with endothelial cells that
were surrounded by tumour cells which co-expressed nestin,
Notch and the NO receptor soluble guanylyl cyclase. Further-
more, NO activated Notch signaling and promoted stemness
in primary cultured mouse glioma cells (Charles et al., 2010).
The other study showed that inhibition of the Notch pathway
with g-secretase inhibitors (GSI) increased radiosensitivity of
glioma stem cells (defined as CD133þ cells). Expression of the
constitutively active intracellular domains of Notch1 orNotch2,
which function downstream of g-secretase, rendered glioma
stemcellsmore resistant to radiation than control cells, regard-
less of treatment with GSI (Wang et al., 2010b). Given this evi-
dence, it is plausible to speculate that, in the perivascular
niche, NO synthesized by highly expressed eNOS activates
the Notch pathway in adjacent glioma stem cells and increases
their radioresistance.
3.4. Hypoxia
The role of hypoxia in radioresistance of tumours was first ob-
served more than a century ago and is now well established
(Overgaard, 2007). In general, the reduced cellular radiosensi-
tivity observed in a hypoxic environment is thought to be due
to the different fate of free radicals produced in the cell by ra-
diation. The reaction of these radicals with oxygen changes
and stabilizes their chemical composition so that DNA dam-
age is more likely to occur. This is often described as chemical
‘fixation’. In the absence of oxygen, free radicals are more
likely to react with Hþ ions, returning to their original form
and reducing the level of DNA damage (Horsman and Over-
gaard, 2002). Tumour cells that survive hypoxic stress gener-
ate a range of pro-survival responses that are induced by
transcription of various genes in response to the hypoxia in-
ducible factor (HIF) family of transcription factors. Evidence
for a differential response of glioma stem cells to hypoxia
was found in a study that reported higher levels of HIF2a
and various HIF-regulated genes in these cells compared to
non-stem cells (Li et al., 2009). Furthermore, knockdown of
HIFs in glioma stem cells resulted in reduced stemness in vitro
and in vivo. A recent study conducted in orthotopic glioblas-
toma xenografts showed that increasing intratumoral oxy-
genation through normalization of the vasculature by
treatment with interferon-beta or bevacizumab enhanced ra-
diosensitivity of these tumours (McGee et al., 2010).
The hypoxia-stem cell interactionmay therefore be viewed
as a typical example of the role of the ‘microenvironment-
stem cell unit’, in the sense that hypoxic conditions maintain
and enhance intrinsic cellular features of glioma stem cells
rendering them more resistant to treatment.
4. Future directions for pre-clinical studies
Ever since the isolation of glioma stem cells, using cell culture
techniques developed for the study of neural stem cells, char-
acterization of the radiation responses of this cellular subpop-
ulation has proved to be very challenging. If, on one hand,
culturing glioma stem cells as non-adherent spheres in se-
rum-free medium supplemented with growth factors has
the advantage of exploiting a recognized feature of these cells
and has been shown to preserve tumour genotype and pheno-
type (Lee et al., 2006; Hamer et al., 2008), on the other it intro-
duces several uncertainties.
Fundamentally, comparisonsof radiation sensitivity in stem
and non-stem cell populations are limited by the requirement
fordifferentcultureconditionstomaintaintheir respectivephe-
notypic features. Furthermore, conventional clonogenic sur-
vival assays require some degree of cellular adhesion to the
substratrumonwhich the cells are cultured. Threemain strate-
gies have been adopted to try to circumvent these issues: 1) ex-
posure of both populations to serum-free medium without
growth factors for 24 h post-irradiation followed by transfer to
serum-containing medium (Bao et al., 2006a); 2) plating of both
populations on poly-L-lysine coated wells in serum-free me-
dium (McCord et al., 2009); 3) maintaining each cellular popula-
tion in the appropriate medium, and quantifying clonogenicity
of differentiated cells by colony formation and stem cell clono-
genicity byneurosphere formation (Wangetal., 2010b). Thefirst
two approaches have the advantage of exposing the two popu-
lations to the same conditions during the experiment and of
comparing the same type of colony, but it is very likely that
the pro-attachment methods (growth factor withdrawal, se-
rum-containing medium or poly-L-lysine coating) induce some
degreeofdifferentiationamongthestemcells.Also, it isnotpos-
sible tocontrol for apotentialdifferential effectof these changes
on cellular responses to radiation damage. The third approach
hastheadvantageofstudyingtheradiosensitivityof the twocel-
lular populations without compromising their culture condi-
tions, but it requires comparison of two distinct types of
colonies, formation rates ofwhichmightbe influenced indiffer-
ent and unpredictable ways by the different methodologies.
In order to address some of these problems, and other
issues related to characterization of cells growing as
non-adherent sphere cultures, alternative techniques for cul-
turing glioma stem cells are being investigated. To date two
studies have been published proposing protocols for adherent
cultures of glioma stem cells in serum-free medium, using
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ECM (Al-Mayhani et al., 2009) or laminin (Pollard et al., 2009b)
as attachment factors. Both studies claim that 2D (adherent
monolayer) cultures are superior to 3D (non-adherent sphere)
cultures because they provide uniformity of exposure to
growth factors, oxygen and nutrients, which would result in
a more homogeneous cellular population. Further evidence
is needed in order to evaluate whether these techniques offer
a more efficient method for culturing glioma stem cells and
whether they can be implemented in clonogenic survival as-
says to improve the reliability of radiosensitivity studies (Rey-
nolds and Vescovi, 2009; Pollard et al., 2009a).
As well as exploring such innovations, it is essential that re-
searchers in this field consider, and control for wherever possi-
ble, biases related to stemcell culture conditions. These include
potential effects of growth factors on cell cycle progression,
DNA repair pathways and apoptosis. There is increasing evi-
dence that epidermal growth factor (EGF) and fibroblast growth
factor (FGF) interactwith processes involved in the radiation re-
sponse. Studies analyzing the effect of these growth factors in
maintenance of glioma and neural stem cells suggest that EGF
and FGF activate pathways that modulate proteins involved in
cell cycle progression and apoptosis (Loilome et al., 2009; Sato
et al., 2010). An impact of EGF and FGF on apoptosis (measured
as percentage of Annexin-V positive cells) has been clearly
shown in both CD133þ and CD133 glioblastoma cells exposed
to serum-free medium, with or without irradiation (Bao et al.,
2006a). Evidence for a possible link between DNA repair path-
ways and EGF and FGF is derived from investigations on other
cancer cell lines. A study in bronchial carcinoma cells analyzed
the relationship between EGFR localization and DNA repair af-
ter irradiation and showed that nuclear translocation of the re-
ceptor resulted in increased activity of DNA-dependent protein
kinase (DNA-PK, a key component of the non-homologous end-
joining pathway) (Dittmann et al., 2005). Although the study
found a correlation of nuclear import of EGFR with irradiation
but not with exposure to EGF, an effect of long-term stimula-
tion with EGF cannot be excluded as the cells were treated
with the growth factor at a single concentration and were ana-
lyzed after a maximum of 20 min. The possible relevance of
these factors is supported by data from a model of wound re-
pair, which showed that long-term exposure to EGF was re-
quired in order to observe its stimulatory effect (Buckley
et al., 1985). Evidence for a link between FGF and DNA-PK activ-
ity comes from a study on HeLa cells, in which up-regulation of
the DNA repair enzyme correlated with the radioprotective ef-
fect of the growth factor (Ader et al., 2002). Given the cell spe-
cific nature of many of the biological effects of growth
factors, the relevance of these interactions to glioma stem cells
should be investigated before any conclusions are drawn.
It is hoped that the design of future radiation response
studies will take into consideration these factors, both to in-
crease the accuracy of comparative studies and to enhance
our understanding of the role of these proteins in regulating
radiosensitivity.
If radioresistance is a property of the ‘microenvironment-
stem cell unit’, as this paper proposes, it is essential that exper-
imentalmodels are developed that allow investigation of radia-
tion responses of glioma stem cells in conditions that resemble
as closely as possible their tumoral niche. Exciting advances in
3D tissue culture systems have been accomplished and to date
have been applied predominantly to embryonic or adult stem
cells used in studies of developmental biology and regenerative
medicine. Available models vary greatly in composition and
complexity, ranging fromsimple 3D scaffolds consisting of syn-
thetic self-assembling peptide hydrogels (Thonhoff et al., 2008),
biodegradable polymers (Levenberg et al., 2003) or polystyrene
(Bokhari et al., 2007), to in vitro systems that couple 3Dmatrices
withmicrofluidic devices that enablemulti-parametermanipu-
lation(Vickerman et al., 2008). Studies comparing the pheno-
types of a variety of cell types grown in 2D and 3D models
have clearly demonstrated the functional superiority of the lat-
ter. These systems have the capacity to allow exploration of the
interactions that occurbetween the various elements discussed
in this paper. A promising approach in this context is also the
three-dimensional explant systemused intheabovementioned
Hovinga study (Hovinga et al., 2010). It is hoped that these
models will prove to be efficient tools to accurately identify tar-
gets for themodulationof radiation responseandenable thede-
velopment of new therapeutic agents to improve outcomes for
patients with glioblastoma.
5. Conclusions
While data demonstrating the existence of glioma stem cells
continue to accumulate, the published evidence supporting
the hypothesis that radioresistance of glioblastoma is caused
simply by an intrinsic property of glioma stem cells is less con-
vincing. Data from gliomas and other cancer models strongly
support a complementary theory that radiation responses are
determined by the ‘microenvironment-stem cell unit’. Based
onpublisheddata, a varietyofmechanisms thatmight contrib-
ute to the radioresistanceof this functional unit havebeenpro-
posed. In order to identify therapeutically relevant targets, it is
critical that futurestudiesareconducted inmodelsystemsthat
enable these mechanisms to be investigated further.
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Abstract Glioma stem-cell-like cells are considered to be responsible for treatment resistance and tumour recurrence following
chemo-radiation in glioblastoma patients, but specific targets by which to kill the cancer stem cell population remain elusive. A
characteristic feature of stem cells is their ability to undergo both symmetric and asymmetric cell divisions. In this study we have
analysed specific features of glioma stem cell mitosis. We found that glioma stem cells appear to be highly prone to undergo aberrant
cell division and polyploidization. Moreover, we discovered a pronounced change in the dynamic of mitotic centrosomematuration in
these cells. Accordingly, glioma stem cell survival appeared to be strongly dependent on Aurora A activity. Unlike differentiated cells,
glioma stem cells responded tomoderate Aurora A inhibition with spindle defects, polyploidization and a dramatic increase in cellular
senescence, and were selectively sensitive to Aurora A and Plk1 inhibitor treatment. Our study proposes inhibition of centrosomal
kinases as a novel strategy to selectively target glioma stem cells.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
Introduction
In the past decade, stem-cell-like cancer cells have been
identified in several tumours and implicated in treatment
resistance. Glioblastoma is one of the most extensively studied
cancer types in relation to treatment resistance and the cancer
stem cell (CSC)model. This is probably due to the poor outcome
of patients treated for this disease (median overall survival of
14.6 months) (Stupp et al., 2009) and to the almost inevitable
recurrence following chemo-radiation, which renders glioblas-
tomas a valuable model for study of cancer cell resistance to
radiation and chemotherapy. Several clinical series have found
a correlation between glioma stem cell (GSC) features in
patient specimens (expression of putative GSC markers,
neurosphere formation ability in vitro) and tumour recurrence
and poorer prognosis (Strojnik et al., 2007; Zhang et al., 2008;
Zeppernick et al., 2008; Pallini et al., 2008). Furthermore, a
recent study using a genetically engineered mouse model of
glioma identified a relatively quiescent subpopulation of cells
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that was responsible for post-chemotherapy tumour growth,
through its capacity to produce transient subsets of highly
proliferating cells (Chen et al., 2012). These findings rein-
forced the rationale for the GSC theory and highlighted the
importance of processes regulating cellular growth, such as
DNA replication and mitosis, in the context of treatment
resistance.
Current standard therapy for glioblastoma consists of
debulking surgery followed by radiation with concomitant and
adjuvant administration of the alkylating agent temozolomide
(Stupp et al., 2009). Most studies investigating intrinsic GSC
resistance have focused on the role of DNA damage responses
and repair. However, experimental data from these studies are
conflicting and response mechanisms of GSCs to radiation and
chemotherapy remain controversial (Beier et al., 2011). Other
stem cell features, such as those involved in regulating cell
division, are only poorly understood in GSCs, but could provide
clinically relevant targets to improve treatment outcomes. A
paramount feature of stem cell mitosis is the ability to divide
both symmetrically and asymmetrically, giving rise to differen-
tiating daughter cells as well as maintaining a pool of
self-renewing stem cells (Lathia et al., 2011). Studies in fruit
fly neuronal stem cells have demonstrated a critical role for the
centrosome in establishing asymmetry during mitosis
(Yamashita et al., 2007). Centrosomes are the microtubule
organising centres in animal cells that form the poles of the
mitotic spindle. They are regulated by several mitotic kinases
including Aurora kinase A (AurA), Polo-like kinase 1 (Plk1) and
Cyclin dependent kinase 1 (Cdk1) (Nigg and Stearns, 2011).
Inhibitors of these kinases have long been implicated as
potential cancer therapies (Harrison et al., 2009). A recent
study has highlighted Plk1 inhibition as a strategy to selectively
kill GSC enriched populations (Lee et al., 2012). Moreover, AurA
is overexpressed in glioblastomas (Loh et al., 2010; Lehman et
al., 2012); its expression levels have been correlated with
patient outcome (Barton et al., 2010); and data from other
tumour sites suggest a role for AurA in CSC behaviour
(Cammareri et al., 2010; Chefetz et al., 2011). However, a
link between centrosome biology, mitotic kinase inhibition and
GSC targeting has not been established.
In this study we analysed centrosome and mitotic spindle
morphology in glioblastoma stem cell enriched and differen-
tiated populations. We report a higher frequency of abnormal
spindles and a more pronounced maturation of centrosomes
preceding mitosis in GSC enriched populations. This prompted
us to investigate whether differences in mitotic spindle dy-
namics could provide a novel therapeutic strategy by which
GSC populations could be specifically targeted. We show that
AurA and Plk1, both involved in centrosome maturation and
bipolar spindle assembly can be targeted to kill GSCs more
effectively, and propose that this strategy might improve
outcomes for patients with glioblastoma.
Results
Neurosphere cultures of primary glioblastoma cells
generate invasive intracranial xenografts in
immunodeficient mice
Consistent with previously published data (Fael Al-Mayhani et
al., 2009), primary glioblastoma cells cultured as non-adherent
neurospheres in serum-free medium expressed high levels
of stem cell markers including CD133, nestin and Sox2 (Fig. 1A,
supplementary Fig. S1A,B), low levels of astrocytic differen-
tiation markers including GFAP (supplementary Fig. S1B) and
generated invasive intracranial xenografts in CD1 nude mice.
Intracranial injection of 105 E2 cells cultured as neuro-
spheres (‘E2 GSC’) generates tumours in 100% of mice and
these tumours were highly invasive. In addition to a mass at
the injection site (Fig. 1B), tumour cells identified by human
specific HLA-1ABC and Ki67 stainingwere detected throughout
both hemispheres (Supplementary Fig. S1C). Quantitative
analysis of Ki67 positive cells in whole brain slices harvested
at various timepoints demonstrated increasing tumour cell
burden up to 20 weeks after injection (Fig. 1B, supplementary
Fig. S1C). In contrast, injection of 105 E2 cells cultured as
monolayers in serum-containing medium (‘E2 diff’) failed to
generate tumourmasses and tumour cells did not infiltrate the
brain. Very low numbers of HLA-1ABC or Ki67 positive cells
were detected (Fig. 1B). Injection of 105 G7 cells cultured as
neurospheres (‘G7 GSC’) generated tumours in 100% of mice;
all tumours were highly invasive at the tumour margins
(Fig. 1B). Injection of 105 G7 cells cultured as monolayers in
serum-containing medium (‘G7 diff’) also generated tumours
but these had well defined edges and did not exhibit the
invasive pattern observed in G7 GSC derived tumours (Fig. 1B).
Glioblastoma stem cells are prone to mitotic
failure and show a distinct pattern of
centrosome maturation
Cell division of GSCs remains scarcely characterised, despite
its role in maintaining stemness and generating cellular
diversity (Lathia et al., 2011). To understand whether mitosis
in these cells presents specific features that can be targeted
therapeutically, we analysed their mitotic spindles by immuno-
fluorescence. GSC enriched populations had a significantly
higher frequency of abnormal mitotic spindles (monopolar or
multipolar) compared tomore differentiated populations: 14%
vs. 4%, respectively (Fig. 1C). While scoring mitosis in the GSC
enriched populations we frequently observed cells with two
or more nuclei (Fig. 1C). To clarify whether these were cell
aggregates or truly polyploid cells, we stained both cell pop-
ulations with phalloidin to visualise the cell cortex. This
allowed us to differentiate between single cells with two or
more nuclei and closely attached cells with two single nuclei.
Consistentwith themitotic spindle data, this analysis revealed
that GSC enriched populations had a much higher percentage
of polyploid cells compared to more differentiated popula-
tions: 25% vs. 6%, respectively (Fig. 1D). In order to test
whether the increase in abnormal spindles was due to growth
in suspension, we analysed spindle phenotypes in differenti-
ated cells cultured as non-adherent aggregates and found
that all imaged cells had bipolar spindles (data not shown),
suggesting that the neurosphere growth is not a confounding
factor for the observed mitotic phenotypes. To our knowl-
edge, this is the first study reporting a higher frequency of
abnormal mitotic spindles and polyploidy in GSC enriched
populations in vitro.
While analysing spindle morphology we noted a distinct
pattern in the distribution of γ-tubulin at the centrosomes in
the GSC populations that was characterised by a marked
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increase in γ-tubulin at the mitotic centrosomes compared to
differentiated cells. Given the role of centrosomes in bipolar
spindle assembly, we further analysed the distribution of
γ-tubulin in the two glioblastoma cell populations. For this
purpose we measured the size of the γ-tubulin area in both
interphase and mitotic cells (Fig. 2A). The specificity of
the centrosomal γ-tubulin staining was confirmed by co-
localization with centrin (supplementary Fig. S2A). This quan-
titative analysis revealed a more pronounced centrosomal
accumulation of γ-tubulin at mitosis in GSCs, compared to
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Figure 1 Primary glioblastoma cells cultured as neurospheres in serum-free conditions express high levels of stem cell markers, form
invasive intracranial xenografts in immunodeficient mice and have a higher frequency of abnormal mitotic spindles and a distinct
pattern of centrosome maturation. (A) Immunoblot analysis of lysates of E2 and G7 primary glioblastoma cell cultures was performed,
probing for the stem cell markers Sox2 and nestin, with tubulin and actin as loading controls (GSCs—glioma stem cells cultured as
neurospheres in serum-free medium, diff.—differentiated, adherent cells cultured in serum-containing medium) (B) Immunohisto-
chemistry was performed on sections of brains of CD1 nude mice that had been injected with 105 E2 or G7 glioblastoma cells that had
been cultured to enrich for GSC or to promote differentiation. Sections were stained for Ki67 (G7 images on left) to interrogate local
brain invasion and for HLA-1ABC to identify tumour cells of human origin (E2 images below histogram). To measure tumour cell burden
in highly infiltrative E2 derived xenografts, quantitative analysis of Ki67 positive cells in whole brain sections was performed using
ZenBlue software. Number of Ki67 positive cells per section was plotted against time after injection of E2 GSC and differentiated cells
(Scale bar at 50 μm). (C) Cells were stained for α tubulin (green), γ tubulin (red) and DAPI (blue), to visualise the mitotic spindle
morphology: on the left, a diagram shows the percentages of normal and abnormal spindles in glioma stem cells and differentiated
cells. On the right are representative images of mitotic phenotypes (Scale bar 2 μm). PN: polynucleated cells. An average of 26 mitotic
cells/condition/experiment were identified randomly and scored (*p = 0.0232, two tailed t-test). (D) Cells were stained with
phalloidin (red) and DAPI (blue) to visualise the cell cortex and nucleus: on the left are representative images of GSC and diff. cells
(scale bar 10 μm); on the right, a diagram shows the percentages of polynucleated cells in the two populations. An average of 251
cells/condition/experiment were identified randomly and scored (***p = 0.000275, two tailed t-test).
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differentiated cells (Fig. 2A). Thus, centrosome matura-
tion, measured as the ratio between centrosomal γ-tubulin
in mitotic and interphase cells, was increased more than
twofold in GSCs. This finding, together with the difference
in mitotic phenotypes, highlights the importance of
investigating in detail GSC division and the processes
leading to it, in order to find effective and specific ways
of targeting this population.
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Figure 2 Glioblastoma stem cells have more abnormal spindles following treatment with Aurora A inhibitors. (A) Cells were stained
for α tubulin (green), γ tubulin (red) and DAPI (blue), to visualise the accumulation of γ tubulin during centrosome maturation: at the
top are representative images of GSC and diff. cells (scale bar 5 μm), with inserts showing γ tubulin staining in interphase (I) and
mitotic (M) cells (scale bar 500 nm); at the bottom, a diagram shows the ratio between centrosomal γ-tubulin in mitotic and
interphase cells, as a measure of centrosome maturation, in GSC and diff. populations. An average of 144 cells/condition/experiment
were identified randomly and scored. All results are representative of three independent experiments. Error bars indicate means ±
SD. (B) Cells were stained for P-AurA (red) and mitotic cells were analysed: on the left, a box plot shows the quantification of P-AurA
in mitotic centrosomes in diff. and GSC cells; on the right are representative images of mitotic cells in the two populations (scale bar
2 μm). An average of 22 mitotic cells/condition/experiment were identified randomly and scored. (C–D) Cells were treated with
MLN8237 (0, 25, 50 and 100 nM) and after 24 h they were fixed and stained for α tubulin (green), γ tubulin (red) and DAPI (blue), to
visualise the mitotic spindle morphology. (B) On the left, two diagrams show the distribution of different spindle phenotypes in GSC
and diff. cells; on the right a diagram shows the percentages of abnormal mitotic spindles in the two populations. (C) Representative
images of GSC and diff. cells ± MLN8237 (scale bar 2 μm). An average of 26 mitotic cells/condition/experiment were identified
randomly and scored. All results are representative of three independent experiments. Error bars indicate means ± SD.
138 M. Mannino et al.
Glioblastoma stem cell enriched populations have
more abnormal spindles following treatment with
Aurora A inhibitors
Since GSCs display a more pronounced accumulation of γ-
tubulin at the centrosome during mitotic entry, we reasoned
that this could be an interesting point of attack for a targeted
therapeutic approach. For this purpose we focused on AurA,
which is a major regulator of mitotic centrosome maturation.
The differences in centrosome dynamics could not be attri-
buted to different levels of activity of AurA in the two cell
populations (supplementary Fig. S2B–C and Fig. 2B). To
analyse the requirement for AurA activity in the two popula-
tions, we treated stem and differentiated glioma cells with
the AurA inhibitor MLN8237, using low dose levels that only
had subtle effects on overall AurA kinase activity (supplemen-
tary Fig. S2C). Given that MLN8237 has a selectivity of more
than 200-fold for AurA over Aurora kinase B (Manfredi et al.,
2011), we can assume that any observed effects are AurA
specific. Interestingly, treatment with the inhibitor induced
more abnormal spindles in GSC enriched populations at all
dose levels compared tomore differentiated cells: 56% vs. 14%
at 25 nM, 75% vs. 29% at 50 nM and 79% vs. 47% at 100 nM,
respectively (Fig. 2C). The two populations of cells also
exhibited a different response to AurA inhibition in terms of
the type of spindle defect. GSC enriched populations showed a
dramatic increase only in monopolar spindles, while their
more differentiated counterparts showed amoderate increase
in both monopolar and multipolar spindles (Fig. 2C). Fig. 2D
shows representative images of treated cells. These data
suggest that GSCs are highly susceptible to subtle changes in
AurA activity.
Aurora A inhibition induces an increase in polyploidy
To further understand the consequences of AurA inhibitor
treatment on GSCs we analysed parameters of cell cycle
distribution in the two cell populations. Several studies have
reported a G2/M arrest following inhibition of AurA, either
by small molecule inhibitors or by RNAi (Gorgun et al., 2010).
In our study the baseline cell cycle profiles of the two
populations differed significantly: GSC enriched populations
had a higher percentage of cells with 4 N and N4 N DNA
content (Fig. 3A). Cells with a 4 N FACS profile can be in G2,
M or a quatroploid G1 phase. To distinguish between these
cell cycle states, we scored the percentage of cells in G2 and
M by immunofluorescence using CENP-F, α-tubulin and DAPI
staining (for a representative example, see Fig. 3B). The G2/
M fraction was similar in the two populations, confirming
that the difference in cells with 4 N DNA content was due to
polyploidy. Cell cycle profiles of the two populations 24 h
after treatment with MLN8237 showed an increase in the 4 N
and N4 N DNA content fraction in both populations. Immuno-
fluorescence analysis showed only subtle increases in the
percentage of G2 and M phase cells after treatment, sug-
gesting that AurA inhibition does not induce a prolonged G2/
M arrest in these cells, despite a significant increase of
mitotic aberrations following MLN8237 treatment (Fig. 2).
To confirm and characterise the moderate increase in the
≥4 N fraction, we stained with phalloidin cells after AurA
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Figure 3 Aurora A inhibition does not cause a significant G2/M arrest in glioblastoma cells. (A) Cells were treated with MLN8237
(0, 25, 50 and 100 nM) and after 24 h they were fixed, stained with propidium iodide (PI) and analysed for DNA content: on the left are
representative FACS diagrams of GSC and diff. cells; on the right, two diagrams show percentages of cells in the various phases of the
cell cycle, quantified in the FACS analysis. (B) Cells were treated with MLN8237 (0, 25, 50 and 100 nM) and after 24 h they were fixed
and stained for α tubulin (green), CENP-F (red) and DAPI (blue), to visualise G2/M cells: on the left are representative images of GSC
and diff. cells; on the right, a diagram shows the percentages of cells in G2 and M in the two populations ± MLN8237. An average of 309
cells/condition/experiment were identified randomly and scored. All results are representative of three independent experiments.
Error bars indicate means ± SD.
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inhibition. This analysis detected an increasing number of
giant polynucleated cells that was more pronounced in the
GSC population: 37%, 47% and 54% of these cells were poly-
ploid after 25, 50 and 100 nM treatments, compared with
12%, 12% and 20% in the more differentiated populations
(Fig. 4A). That these percentages were higher than indicated
by the FACS data is probably explained by the large size of
some polyploid cells causing them to evade FACS analysis.
Polyploidy can be caused by several mechanisms: abnormal
mitosis, endoreduplication, cell fusion and entosis (Krajcovic
and Overholtzer, 2012). Given that cell appearance does not
distinguish between the products of cell fusion and mitotic
failure, and that entosis has been observed mainly under
non-adherent growth conditions (Overholtzer et al., 2007), we
tested the extent to which these different processes were
responsible for baseline and post-treatment levels of poly-
ploidy amongst GSCs. Cells were marked separately with cell
tracking dyes, mixed then incubated for 24 h with or without
MLN8237 (Fig. 4B). In both treated and untreated samples the
vast majority of polyploid cells originated from the same
mother cell, suggesting that in GSCs polyploidy is not a result
of cell fusion or entosis, but rather a consequence of mitotic
defects.
Increase in polyploidy correlates with increased
sensitivity to Aurora A inhibition and induction
of senescence
Our analysis suggests that GSCs are prone to undergoing
mitotic failure and are highly susceptible to subtle changes
in AurA activity levels. The observed increase in monopolar
spindles does not cause a prolonged mitotic arrest suggest-
ing that these cells are prone to mitotic slippage. This is
also reflected in the rapid polyploidization observed after
MLN8237 treatment. Taken together these observations
indicate that chemical inhibitors of mitosis might be useful
therapeutic agents that specifically target the GSC popula-
tion. We tested this hypothesis by measuring the sensitivity
of glioblastoma stem cell enriched and more differentiated
populations to MLN8237 and found that two independent
GSC lines were indeed killed more efficiently by the AurA
inhibitor (Fig. 4C). We further tested our hypothesis by
analysing the effect on clonogenicity of inhibiting another
centrosome kinase, Plk1, with BI2536: again, two indepen-
dent GSC lines had a lower survival than their differentiated
counterparts (supplementary Fig. 3).
In order to understand the cause of death in glioblastoma
stem cell enriched and more differentiated populations
following AurA inhibition, we measured levels of apoptosis
and senescence. While MLN8237 did not increase apoptosis
as judged by cleaved Caspase 3 levels in either popula-
tion (supplementary Fig. 4A), a significant increase in the
number of senescent cells was observed. Seven days after
AurA inhibition, 55% of GSCs expressed a marker of senes-
cence, compared with only 19% of differentiated cells
(Fig. 4D). The negligible level of apoptosis is consistent with
some published studies (Huck et al., 2010; Liu et al., 2013)
but not with others (Gorgun et al., 2010). Recent literature is
also conflicting with regard to the correlation between cell
fate following AurA inhibition and p53 status (Liu et al., 2013;
Nair et al., 2012; Liu et al., 2013). To test whether the
different response to MLN8237 was due to p53 status, we
analysed levels of p53 expression in glioblastoma stem cell
enriched and more differentiated populations in three
primary cell lines: there was no common pattern of p53
levels in the various cell lines when comparing the two
subpopulations (supplementary Fig. 4B–D). This suggests
that the increased sensitivity of GSCs to AurA inhibition is not
dependent on p53 status.
Several studies in a variety of cancer models have shown
that cellular senescence is induced in vivo by chemotherapy
and radiotherapy (Roninson, 2003). Although a large body of
evidence links senescence to tumour suppression, recent
data suggests that, in a minority of cancer cells, senescence
associated polyploidy can be reversible and might consti-
tute a survival mechanism. A clinicopathological analysis of
specimens from patients with non-small cell lung cancer
undergoing surgery after neo-adjuvant chemotherapy showed
that β-galactosidase staining was correlated with de-
creased overall survival (Wang et al., 2013). Moreover,
one of the features of senescent cells is the acquisition of a
secretory phenotype, which creates a niche that can affect
adjacent cells (Rodier and Campisi, 2011). Amongst the
released factors is IL-6 (Coppe et al., 2008), which has been
reported to promote GSC survival and tumour growth (Wang
et al., 2009). These findings suggest a possible link between
chemotherapy-induced senescence, GSCs and treatment
resistance. Our survival data clearly indicate that senes-
cence following MLN8237-induced mitotic failure causes a
reduction of neurosphere formation in GSCs and generally
decreases the clonogenic potential of glioma cells. Hence
we propose that induction of senescence by polyploidy
could be a promising anticancer strategy that targets GSCs,
rather than a survival mechanism. Given the limitations of a
single cell survival assay in this context, our findings highlight
the need for in vivo studies and pathological analysis to clarify
the role of senescence associated polyploidy in GSC biology
and treatment outcomes.
Another significant outcome of our study is the differ-
ence in centrosome maturation and mitotic spindle pheno-
types between GSC enriched and differentiated populations.
To our knowledge there are no previous reports on this
aspect of GSC biology. The high susceptibility of GSCs to
subtle changes in levels of kinases involved in the centro-
some cycle is particularly interesting if we consider the
literature on the role of symmetric and asymmetric divisions
in cancer. Defects in regulation of switch between asym-
metric and symmetric divisions have been speculated to be
involved in carcinogenesis (Morrison and Kimble, 2006), and
therefore might be strongly linked to generation of GSCs.
GSCs in vitro divide mainly by symmetric division, but are
able to increase the asymmetric mode following growth
factor withdrawal, i.e. a differentiation stimulus (Lathia
et al., 2011). Normal adult stem cells seem to switch
from asymmetrical to symmetrical division following injury
(Morrison and Kimble, 2006). The study mentioned previous-
ly (Chen et al., 2012), which used a genetically engineered
mouse model of glioma, reported data on transient subsets
of highly proliferating tumour cells post-chemotherapy. In
this study the growth patterns were consistent with an initial
prevalence of symmetric divisions followed by a switch to
asymmetrical mode. Based on this data and on our findings,
we speculate that GSC mitosis confers more plasticity and
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increased regenerative ability to these cells, but also
renders them more susceptible to mitotic failure.
Mechanisms regulating mitosis, as well as senescence, in
GSCs, are still poorly understood and need to be investigated
further, especially with pathology studies that would be able
to confirm whether our in vitro findings apply to GSCs in
their natural microenvironment.
Materials and methods
Cell lines and cell culture
E2 and G7 primary glioblastoma cell lines were derived from
freshly resected GBM specimens as previously described (Fael
Al-Mayhani et al., 2009) and generously provided by Colin
Watts (Cambridge). Tissue collection protocols were compli-
ant with the UK Human Tissue Act 2004 (HTA Licence ref
12315) and approved by the local regional Ethics Committee
(LREC ref 04/Q0108/60). Informed consent was obtained
from each patient before surgery. Briefly, anonymised pa-
tient resection specimens were homogenised and seeded in
serum free (SF) media to form spheroid aggregates which
were then collected and plated onto extracellular matrix
coated flasks. (ECM 1:10 dilution, Sigma). Cells were allowed
to form a primary monolayer then passaged in SF medium.
Each cell line was subsequently cultured as paired cancer
stem cell enriched (GSC) and differentiated (diff) cell lines
by passaging in either SF media or differentiating media
(DM). GSC enriched populations were cultured as neuro-
spheres in Neurobasal-A medium (Invitrogen) supplemented
with B-27 (Invitrogen), epidermal growth factor (20 ng/ml,
Invitrogen PHG0313), fibroblast growth factor (20 ng/ml,
Invitrogen PHG0263), glutamine and penicillin/streptomycin
(referred to as ‘sphere cells’ or ‘GSC’ in figures). Differen-
tiated populations were derived from these cells by culturing
them as adherent cells in MEM supplemented with HyClone
(Thermo Scientific HyClone, 12822966), NEAA, glutamine
and penicillin/streptomycin (referred to as ‘adherent’ or
‘diff’ cells in figures).
Reagents
In all experiments with AurA inhibition we incubated cells
with MLN8237 (Millenium) for 24 h. For clonogenic survival
assays we added the reagents to the plates and left them for
the whole duration of the experiment.
Immunostaining
For centrosome maturation, mitotic spindle and cell cycle
analysis, cells were collected from flasks, spun down, re-
suspended, pipetted on Concanavalin A (Sigma) coated cov-
erslips and fixed with 70% methanol for 5 min. For P-AurA
analysis, cells were cytospun on Concanavalin A coated
coverslips and fixed with 4% paraformaldehyde and 70%
methanol, sequentially for 5 min each. Cells were perme-
abilized in PBS 0.3% Triton for 5 min, blocked in 3% BSA for
30 min and probed with primary antibodies for 60 min. Slides
were rinsed and probed with Alexa Fluor secondary antibod-
ies (Invitrogen) for 60 min. Coverslips were mounted using
ProLong Gold mounting solution containing DAPI (Molecular
Probes). The following primary antibodies were used: HLA
Class 1ABC (EMR8-5, Abcam ab70328), Ki67, CD133, nestin,
Sox2, GFAP, α tubulin (Abcam ab7291, ab18251), γ tubulin
(Abcam ab11316), centrin-2 (gift from Elmar Schiebel),
CENP-F (Abcam ab5), and P-AurA (Cell Signalling 3079).
Images were acquired on a microscope (DeltaVision)
equipped with a UPLS Apochromat NA 1.40, 60× or 100× oil
immersion objective (Olympus), standard filter sets (excita-
tion 360/40, 490/20, and 555/28; emission 457/50, 528/38,
and 617/40), and a camera (CoolSNAP HQ2; Photometrics). Z
series of 0.3 μm stacks were acquired using softWoRx soft-
ware (version 4.0.0; Applied Precision) and deconvolution was
performed using SVI Huygens Professional Deconvolution
Software (Version 3.5). For quantitative data on γ tubulin
and P-AurA centrosomal localization, DeltaVision files were
imported into Imaris software (version 6.3.0; Bitplane) for 3D
rendering measurements using the surface rendering algo-
rithm for γ tubulin and P-AurA signals. Measurements were
then exported to Excel (Microsoft) and plotted. The data was
further analysed using Mann–Whitney U test.
For ploidy analysis, cells were collected from flasks, spun
down, re-suspended, pipetted on Concanavalin A coated cov-
erslips and fixed with 4% paraformaldehyde for 10 min. Cells
were permeabilized, blocked and probed with phalloidin
(Invitrogen) for 30 min. Coverslips were mounted as above.
FACS analysis
It was performed as previously described (Hegarat et al.,
2011).
Cell tracking
Cells were incubated separately with 1 μM CellTracker Green
CMFDA (5-Chloromethylfluorescein Diacetate) and 1 μM
CellTracker Blue CMAC (7-Amino-4-Chloromethylcoumarin)
(both from Molecular Probes) for 45 min, spun down, re-
suspended in fresh medium and incubated for 24 h ±50 nM
MLN8237. Cells were then fixed and stained with phalloidin
as in the ploidy analysis. Coverslips were mounted using
Fluoromount (Sigma).
Clonogenic survival assay
Clonogenics were performed plating the cell suspension in 96
well plates, at an ideal concentration of 1 cell/well (200 μl).
Each subpopulation of cells was plated in the appropriate
medium. EGF and FGF are added to the GSC plates on days 5,
10 and 15. Neurospheres and adherent colonies were counted
on day 21 using the Gel Count (Oxford Optronix) and meth-
ylene blue staining, respectively.
β-galactosidase staining
Cells were treated with MLN8237 and after 2 and 7 days they
were fixed and stained for β-galactosidase according to the
manufacture's protocol (Abcam). Images were acquired on a
microscope Axio Lb A1 (Zeiss) equipped with an AxioCam ERc
5 s and a 40× objective.
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